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ABSTRACT 
Background 
Neuroinflammation is detected by elevated white blood cells in the cerebral spinal fluid 
(CSF).  A variety of factors cause neuroinflammation including infection, autoimmunity, trauma, 
degenerative processes, toxins, malignancy, and in some cases factors of unknown origin.  The 
cause of neuroinflammation is unknown in approximately 60% of patients and there is a need for 
improved diagnostic strategies.   
Objective 
The goals of this research were to define the clinical characteristics, laboratory data, and 
outcomes of patients within diagnostic categories of central nervous system (CNS) disease and 
define the neuroinflammatory responses that may differentiate diagnostic categories of CNS 
disease.  We hypothesized that specific immune responses would be characteristic of specific 
diagnostic categories in the neuroinflammation population. 
Methods 
To investigate the research objectives, this study:  
1) collected data from a retrospective neuroinflammation cohort by the cause of 
neuroinflammation (infection, autoimmune, malignancy, inflammatory disorder, or unknown 
etiology) as well as the disease etiology and time to diagnosis;  
2) evaluated the data in terms of time to positive test results, proportion of patients with 
neuroinflammation of unknown etiology, and clinical and laboratory diagnostics and parameters;  
iv 
3) evaluated a novel flow cytometry-based assay in terms of narrowing the suspected 
etiology into diagnostic categories (bacterial infection, viral infection, malignancy, autoimmune, 
inflammatory disorder); and  
4) made recommendations regarding future research to facilitate standardization of a 
biomarker testing to be tested in clinical studies to complement routine care.   
Results 
This study observed that no clear diagnostic test exists for patients with 
neuroinflammation at presentation to medical care.  53% of patients in the retrospective cohort 
study had neuroinflammation of unknown etiology and there were 48 different etiologic causes 
of neuroinflammation in 244 patients.  Additionally, mean time to diagnosis was > 16 days in all 
diagnostic categories.   
Results from the pilot study show that immune-based biomarkers can be defined in the 
CSF and can differentiate between categories of diseases that cause neuroinflammation.  Our 
data suggest that CSF panels of cytokines and growth factors may function as biomarkers in the 
CSF.  VEG-F may be a relevant biomarker for metastases involving the CNS since it was 
significantly elevated in the malignancy group compared to all other groups.  IL-16 was 
significantly higher in bacterial infection compared to any other group and may be a relevant 
biomarker for bacterial infection in the CNS.  IFN-γ was significantly higher in viral infection 
and may be a relevant biomarker for viral infection in the CNS. 
Conclusion 
Our data provide information on the comprehensive diagnostic approaches for patients 
that present with CSF pleocytosis, provide diagnostic approaches for each category of disease, 
and provide important outcome data in each of these groups of disease.  Additionally, these data 
v 
show that immune-based biomarkers can be defined in the CSF and can differentiate between 
categories of diseases that cause neuroinflammation. 
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Neuroinflammation, inflammation in the central nervous system (CNS), is due to both 
local immune responses in the CNS and peripheral immune cells crossing the blood-brain barrier 
(BBB) to initiate an immune response to an antigen.1  The CNS was thought to be an 
immune-privileged site because the BBB regulates the entry of molecules and cells into the 
brain,2 separating neurons from blood vessels.3  However, this barrier may be altered during 
inflammatory processes and immune regulatory cells migrate into and out of the CNS as part of a 
homeostatic process.4  Biological interactions can increase the ability of a molecule, such as an 
antigen, to cross the BBB and enter the cerebral spinal fluid (CSF).5  Activation and proliferation 
of resident cells called microglia is associated with dysfunction of the BBB.4  This dysfunction, 
including increased permeability, pleocytosis, and encephalopathy, facilitates disease processes 
associated with neuroinflammation.  Once the BBB is breached by a pathogen, a localized 
inflammatory reaction is activated in the CNS by microglia resulting in immune signaling and 
recruitment of peripheral white blood cells (WBCs).6  Peripheral WBCs traffick to the CNS 
through a complex process that includes adherence to endothelial cells on capillaries, migration 
across fenestrated capillaries or regions where the BBB has broken down with subsequent 
additional activation and functional activity within the paryemchyma of the CNS tissue.7   
Cytokines are a group of proteins secreted by cells of the immune system to help regulate 
the immune response.  There are different types of cytokines that have different functions during 
an immune response, including chemokines, interferons (IFN), interleukins (IL), lymphokines 
and tumor necrosis factor (TNF).  Production of TNF-α and related pro-inflammatory cytokines 
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may result in enhanced permeability of the BBB and pro-inflammatory monocytes such as Ly6+ 
can contribute to neuroinflammation.7  The cytokine response varies depending on the specific 
cause of inflammation.  For instance, IFN responses are the primary, early responses required to 
control west nile virus (WNV) infection and prevent viral invasion of the CNS, while 
recruitment of NK cells, activated T cells, dendritic cells, and IL-6 support control of herpes 
simplex virus (HSV)-1 (HSV-1) infection in the CNS.7  As with WNV, toll like receptor 3 
(TLR3)-mediated immune signaling pathways result in microglial activation and may restrict 
HSV spread in the CNS..  Further, there is an increase in IL-1β in plasma during WNV infection 
to control the infection and secretion of IL-1β in the CNS promotes CXCR4-mediated T cell 
adhesion to microvasculature endothelial cells which supports neuroinflammation.7  These 
complex responses impact control of disease and plays a role in disease pathology. 
Neuroinflammation is most commonly detected by elevated WBCs (pleocytosis) in the 
CSF.  Patients with neuroinflammation present with CSF pleocytosis, defined as WBC count >5 
cells/mm3 in the CSF, which may arise from a variety of factors including infection, 
autoimmunity, trauma, degenerative processes, toxins, malignancy, and in some cases factors of 
unknown origin.8  There are several different mechanisms by which pathogens can cross into the 
CNS, and the immune response at a high level looks similar regardless of the antigen (e.g., 
malignancy, infection). 
Patients that present to medical care with a CSF pleocytosis face several barriers to both 
obtaining a diagnosis and receiving successful treatment for their underlying disease.  First, 
clinical presentations of different diseases look similar and can have significant overlap making 
them often indistinguishable.  Hence, there may not be a clear diagnostic test for the treating 
physician to order based on specific clinical presentations.  Second, and related, there are also 
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numerous causes of CSF pleocytosis and accurate diagnosis is dependent on ordering several, 
individual tests for different diseases.  These diagnostic tests may not be appropriate for the 
underlying cause of disease and the sensitivity and specificity  may be poor for some of the 
tests.9  Due to the barriers discussed above, there is no clinically validated diagnostic approach 
for patients that present with a CSF pleocytosis.  Given these factors, patients often experience 
delays in diagnosis and treatment for many treatable causes of neuroinflammation, or patients 
may receive no diagnosis at all.  Because of these substantial challenges, in many studies 
evaluating causes of CSF pleocytosis such as encephalitis, no underlying diagnosis is found in as 
many as 40-60% of patients.10-12  Most prior studies of diseases in the CNS have focused on 
diagnostic approaches and improvement for a single cause of disease in the CNS like multiple 
sclerosis or viral infections in the CNS and have not studied different causes taken together.  
Despite numerous studies, new diagnostic approaches for a specific diagnosis have been elusive.  
For example, several studies have used next generation sequencing to discover novel causes of 
encephalitis but these studies have not provided a major, previously undiagnosed group of 
organisms causing disease.6  
In these studies, I proposed a novel approach to diagnosis in the neuroinflammation 
patient population.  The previous approach has been to develop novel diagnostic tests for each 
unique pathogen that can cause neuroinflammation.  In the novel approach proposed here, I have 
considered common neuroinflammation diagnostic categories (ie, viral infection, bacterial 
infection, malignancy, autoimmune/inflammatory disorder) and characterized the unique 
inflammatory response and cell types associated with each category.  Such an approach will 
provide novel diagnostic pathways.  The goals of these clinical studies were to define the clinical 
characteristics, laboratory data, and outcomes of patients within diagnostic categories of CNS 
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disease and to define the neuroinflammatory responses that may differentiate diagnostic 
categories of CNS disease.  
Clinical Description of Etiologic Causes of Neuroinflammation 
Infectious Causes of CNS Disease 
Although several underlying etiologies can initiate neuroinflammation, the most common 
identified cause of CNS disease is infection.13  Altered permeability of the BBB during 
meningeal inflammation causes vasogenic edema and can contribute to pathogenesis of infection, 
however, this process also increases drug penetration into the brain and CSF with most 
antibiotics.14  Since the immune response has developed a sophisticated and complex response to 
inhibit infections in the CNS, organisms have developed several approaches to counteract the 
immune response.  For example, encapsulated bacteria avoid detection and destruction by the 
complement system, enabling them to cross the BBB and proliferate in the CNS15 where a low 
concentration of immunoglobulin and weak complement-mediated host defenses facilitate 
bacterial replication.16  Additionally, viruses such as WNV develops escape mutations to 
maintain replication during innate immune responses.7 
Viruses are the most common causes of CNS infection.13  There are >100 viruses that can 
cause viral encephalitis alone.17  Viral replication initially occurs outside the CNS and can then 
enter the CNS by free virus bypassing the BBB, by virus-infected immune cells trafficking into 
the CNS or by a mechanism called transneuronal spread.  For example, herpes simplex virus 
(HSV), rabies virus, and varicella zoster virus (VZV) can reach the CNS through a mechanism 
called transneuronal spread, a process by which the virus moves across nerve terminals to enter 
nerve bodies in the CNS.15  Pathogens may also enter the CNS during trauma or surgery which 
facilitate direct inoculation or through direct infection.15  Inflammation from organisms in the 
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CNS significantly contributes to the symptoms of CNS infection which include fever, headache, 
meningismus, focal neurologic deficits (FND), and altered mental status (AMS).15  
Non-Infectious Causes of CNS Disease 
In addition to the large number of infectious causes of meningitis and encephalitis (ME), 
approximately 20% of suspected neuroinflammation cases are due to non-infectious causes, 
which adds to the complexity in the diagnostic pathway.18  Non-infectious causes of 
neuroinflammation include malignancy, autoimmune responses, inflammatory diseases, and 
trauma.  Non-infectious-related CNS inflammation can have similar clinical presentations to 
infectious causes which may include fever, headache, meningismus, AMS, seizures, and FND, 
and these symptoms are non-specific for the diverse group of infectious and non-infectious 
causes of neuroinflammation.7,18  However, as noted above, many patients present for evaluation 
and no clear etiology associated with neuroinflammation is found.  In the past, we thought many 
of these cases were due to unknown or not yet described viral infections.  Now, with 
deep-sequencing technology and other advanced molecular diagnostic techniques, it has become 
clear that we are not missing new or undiscovered viruses or bacteria; more likely, a significant 
number of patients are presenting with a post-infectious, inflammatory, or autoimmune cause of 
neuroinflammation.6  
Clinical Evaluation of CNS Disease 
Regardless of heterogeneous presentation, neuroinflammation can only present clinically 
as a couple of defined syndromes including ME.  The Infectious Disease Society of America and 
American Academy of Neurology have published guidelines for the diagnosis and management 
of encephalitis.19,20  If a patient has inflammation of the brain parenchyma, then the patient is 
said to have encephalitis which is typically characterized by AMS and/or significant FND.  
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Inflammation of the membranes lining the brain (meninges) and spinal cord is called meningitis.  
Bacteria, viruses, fungi, and parasites can all cause ME, but non-infectious causes can be a cause 
of this clinical syndrome as well.  At times, the clinical presentation can be mixed, resulting in 
symptoms of meningoencephalitis or enchaphalomyelitis (inflammation of the brain and spinal 
cord) and often indicate a diffuse process of CNS inflammation and/or CNS infection.15  
The clinical impact and global economic burden of neuroinflammation, including CNS 
infections, is high due to significant morbidity and mortality including permanent neurological 
sequelae, despite the effectiveness of available antimicrobials.20-23  A combination of direct 
effects of an antigen and the immune responses to the antigen impacts clinical outcomes.7  
Further, neuroinflammation contributes to injury patterns in the CNS.24  It is expected that 
patients with neuroinflammation of unknown origin have worse outcomes, which supports the 
hypothesis that the burden can be lessened by improved diagnostic capacity.25  Specifically, 
rapid diagnosis and early administration of treatment are critical for favorable outcomes as 
documented across multiple clinical studies.19,25-28  Unfortunately, the etiology of encephalitis 
remains unknown in 32%-75% of cases,10,11,29,30 and even in studies with large diagnostic panels 
to evaluate underlying causes of neuroinflammation, still no underlying etiology is found in as 
many as 40-60% of patients.10-12  Improving diagnosis may also impact utilization of 
antimicrobials, particularly in the case of presumed diagnosis because many cases are treated per 
suspicion of CNS infection rather than confirmatory diagnosis.31   
While diagnostic tests for CNS infections are well developed and comprehensive for the 
major causes of disease, diagnostics for other important causes of CSF neuroinflammation are 
less well-defined, resulting in prolonged time to diagnosis.  Time to treatment and proportion of 
patients with unknown etiology may be reduced in patients presenting with CSF pleocytosis if 
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they are promptly tested and diagnosed with the specific cause of neuroinflammation.  Rapid 
diagnosis and timely treatment is critical for improving morbidity and mortality in CNS 
infections and other causes of neuroinflammatoin.16   
Currently, the diagnostic pathway, or routine testing strategy, to diagnose patients with 
neuroinflammation includes comprehensive evaluation of clinical and laboratory signs and 
symptoms.  Clinical symptoms are non-specific for the diverse group of infectious and non-
infectious causes of neuroinflammation.18  Overlap may also exist in CSF findings with early 
bacterial meningitis, partially treated bacterial meningitis, viral meningitis, viral encephalitis and 
many non-infectious causes of neuroinflammation.  For patients with suspected ME or 
neuroinflammation, the diagnostic pathway is broad and routine testing is not well standardized 
between facilities and clinicians.  Given the complexity of this syndrome, the diagnostic pathway 
is susceptible to human-factor variability due to the need for clinicians to order specific tests for 
suspected causative pathogens and autoimmune or non-infectious diseases. 
Etiologic identification of CNS infections is highly important, even if there is no 
definitive treatment for the causative pathogen.  Despite the lack of targeted treatment in many 
cases, identifying the cause of neuroinflammation will help with prognosis, counseling, and 
public health interventions.  Delayed diagnosis results in delayed administration of effective 
therapies and unnecessary administration of broad-spectrum antimicrobials.  Given the lack of 
targeted testing, slow turnaround time for standard diagnostics, and the potential severity of 
disease associated with neuroinflammation, more comprehensive diagnostic panels, novel 
biomarkers, and more standardization of the diagnostic pathway may improve clinical outcomes 
in patients with neuroinflammation.  Thus, new diagnostic pathways and approaches to deal with 
this complex and deadly clinical syndrome are urgently needed. 
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Background and Literature Review 
The purpose of this literature review is to define the variables in diagnosing etiologic 
causes of neuroinflammation from available information from valid scientific sources.  This 
literature review addresses the following:  
1. What causes neuroinflammation? 
2. How are the etiologic causes of neuroinflammation diagnosed?  
3. What diagnostic improvements may be indicated for this patient population?   
Citation sources including PubMed and Google scholar were used to identify relevant 
publications in recognized scientific journals.  The following search terms were used:  
neuroinflammation, neuroinfection, CNS inflammation, CNS infection, diagnosing CNS 
inflammation, multiplex diagnostics with CSF, flow cytometry with CSF.  Bibliographies of 
acceptable publications yielded additional results.   
Inflammation in the CNS may arise from a variety of factors including infection, 
autoimmunity, trauma, degenerative processes, toxins, malignancy, and in some cases factors of 
unknown origin.8  The diagnosis of each individual etiology is made using different tests and 
approaches.  For example, polymerase chain reaction (PCR) is a common test method for 
specific viral infections, yet, it must be ordered specifically for each individual pathogen.32  
Cases of ME are diagnosed using a combination of CSF direct staining, CSF culture, nucleic acid 
amplification tests (NAT), PCR, immunoassays, and neuroimaging.33,34  Cellular and chemistry 
parameters are routinely tested using CSF when ME is suspected, but this testing is non-specific 
(Table 1).35  If bacterial meningitis is suspected, bacterial culture is performed which takes 2-5 
days and may demonstrate poor sensitivity, particularly if antibiotics have been administered, 
sterile techniques were lacking, or the pathogen does not grow in conventional culture.18  
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Bacterial culture has 80% sensitivity in the CSF samples of patients with acute disease prior to 
initiation of antibiotic treatment.27  In a large study of bacterial meningitis in pediatric patients, 
only 7% of cases were positive by blood culture alone.36  Empiric antibiotic treatment prior to 
obtaining a lumbar puncture is common and an important part of the management of bacterial 
meningitis but can also decrease the sensitivity of CSF gram stain and culture.16  For all cases of 
ME, the clinician also must order the correct PCR, antigen detection, or antibody detection test to 
identify if a pathogen is present which can introduce operator error into the evaluation process.  
Due to the complex algorithms and management of these patient, diagnosis of an underlying 
cause of CSF inflammation can be delayed or missed entirely. 
Evaluation of Patients with Neuroinflammation 
Neuroimaging and lumbar puncture (LP) to obtain CSF for analysis is highly critical in 
the diagnostic pathway for CNS infection and clinical features may direct clinicians to test for 
specific etiological agents.16,37  However, delay is diagnosis due to the complex evaluation of 
these patients is common.  In Auburtin et al., a 3-hour delay in antibiotic administration for 
pneumococcal meningitis was independently associated with an increase in 3-month case-fatality 
rate (CFR).38  It has been shown that diagnostic capacity of treating hospitals determines early 
diagnosis and outcomes of patients with CNS infections.25,26,39  This is likely related to the 
volume of complex cases seen at these centers and subsequent development of standardized 
testing approaches for these complex patients.  
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Table 1: Clinical and Laboratory Characteristics for CNS Inflammation  
Parameter (normal) Bacterial Viral Malignancy Fungal Autoimmune 
CSF Opening Pressure (<170 mm) >300 200 200 300 <170 
CSF WBC (<5) >1000 <1000 <500 <500 <500 
CSF %PMNs (0) >80% 1-50% 1-50% 1-50% 1-5-% 
CFS Glucose (>40) <40 >40 <40 <40 >40 
CSF Protein (<50) >200 <200 >200 >200 <50 
CSF Gram Stain (-) + - - - - 
CSF Cytology (-) - - + + - 
Abbreviations:  PMN – Polymorphonuclear Leukocyte, WBC – White Blood Cell 
References15,32,40 
 
Even though laboratory characteristics of CSF are well understood to differentiate 
between common bacterial versus other causes of ME (Table 1), these characteristics overlap in 
the literature and the CFR is still high for many types of CNS infections.  The CSF analysis 
guide the diagnostic strategy, thus it is the main contributor in the final diagnosis; however, 
clinical and laboratory parameters fail to differentiate between CNS infection and non-infectious 
causes of neuroinflammation.9   
Improvements to the diagnostic pathway for CNS infections are critical to facilitate rapid 
and accurate diagnosis, timely treatment, and favorable outcomes as documented across multiple 
clinical studies in the literature.25-28   
Infectious Causes of Neuroinflammation 
Infection in the CNS is the leading known cause of neuroinflammation.13  The California 
Encephalitis Project was a large study of suspected encephalitis (n = 1570) over 7 years which 
aimed to identify the etiology of encephalitis cases; however, 63% of cases had unexplained 
etiology in the study.10,13  Patients were tested for herpesviruses, arboviruses, enteroviruses, 
measles, respiratory viruses, Chlamydia species, and Mycoplasma pneumoniae.  A causative 
pathogen was identified (confirmed or probable) in 16% of the cases in which 69% of these 
agents were viral, 20% were bacterial, 7% were prion, 3% were parasitic, and 1% were fungal.  
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While the study suffered from extensive referral bias, the results clearly indicated the 
heterogeneity and complexity of diagnosis for these infections. 
A large multinational study (n = 2583) revealed that Streptococcus pneumoniae, 
Mycobacterium tuberculosis, Listeria monocytogenes, and Staphylococcus aureus were the most 
fatal causative pathogens of CNS infection and HSV type I (HSV-1) had significantly high 
sequale.25  Of the 2583 patients included in the study, 27.3% experienced unfavorable outcomes 
and no causative pathogen was detected in 58.2% of patients.  Multiple etiological agents were 
detected in 3% of patients and immunosuppressive conditions were present in 23.3%.  Oddly, 
there was a higher frequency of adverse outcomes in patients with a proven causative pathogen 
versus patients without confirmed etiological diagnosis in this study.  Thus, outcomes in these 
groups of patients are not well understood. 
Streptococcus pneumoniae, Streptococcus agalactiae (Group B Streptococcus), Neisseria 
meningitidis, Haemophilus influenzae, Escherichia coli (particularly the K1 serotype), and 
Listeria monocytogenes are the most common pathogens which cause acute bacterial meningitis 
infections, accounting for over 80% of bacterial infections.18  Prophylactic antibiotics are 
recommended for exposure to Neisseria or Hib meningitis, but not for pneumococcal meningitis.  
Quinolone resistance has been reported for Neisseria meningitis.15,41   
Cryptococcal meningitis is a common fungal cause of meningitis and has a high mortality 
rate.42  One study (n = 51) aimed to identify risk factors associated with Cryptococcal 
meningitis.  Immunosuppressive factors such as human immunodeficiency virus (HIV) infection 
and positive serum cryptococcal antigen were associated with higher pretest probability of 
Cryptococcal meningitis infection in the CNS.42  In general, immunocompromised patients do 
not present with classic responses to infection, are more susceptible to CNS infection, and are 
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more challenging to accurately diagnose.15   
An initial publication for the California Encephalitis Project summarized data from 334 
patients over 2 years and reported that 62% of cases had unexplained etiology.10  In the 2-year 
data summary, the most frequently identified viral pathogens were HSV-1 (11 patients), 
enterovirus (5 patients), Varicella-zoster virus (VZV, 3 patients), and Epstein-Barr virus (EBV, 4 
patients).  The most common bacterial agents were of the Bartonella species which were 
identified in 7 patients.  Core infectious disease testing included Herpes and Enterovirus PCR; 
serological testing for IgG antibody for HSV, VZV, St. Louis encephalitis virus, Western equine 
encephalitis virus, measles virus, Human Herpesvirus type 6 (HHV-6), adenoviruses, 
Chlamydiaspecies, Mycobacterium pneumoniae, and influenza viruses; and additional tests 
requested by the treating physician which was dependent exposure, travel history, and clinical 
symptoms.  A virus was found in 31 cases (9%) of suspected encephalitis, bacteria in 9 cases 
(3%), and a parasite in 2 cases (1%).  It is important to note that there were no clinical or 
laboratory characteristics that distinguished patients whose diseases had infectious causes from 
the non-infectious or unknown etiology groups in the 2 year data summary, which is contrary to 
previously published data and the current position in clinical practice.10 
Over 7 years, a confirmed or probable infectious cause of encephalitis was identified in 
248 patients, of which the majority were viral pathogens (n = 170).13  The most commonly 
identified viruses were enteroviruses (25%) and HSV-1 (24%).  Of the 78 non-viral infectious 
cases, Mycobacterium tuberculosis (n = 19) and Bartonella species (n = 13) were the most 
common causative pathogens.  The CSF WBC count in patients with infection was higher than in 
patients without infection (median CSF WBC count, 53.5 vs. 9.5 cells/mm3; P < .001) which is 
similar to what is expected in clinical practice, though CSF protein levels did not differ between 
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groups (median level, 71.0 vs. 67.0 mg/dL).  There were limitations in this study, the most 
significant of which was enrollment bias.  Investigators referred more difficult cases to the study 
and did not include cases which were diagnosed rapidly at local sites.   
Encephalitis due HSV accounts for 10%-20% of viral encephalitis cases worldwide.  
Enterovirus was the most commonly identified pathogen for encephalitis caused by an infectious 
etiology in the California Encephalitis Project (approximately 5% of patients).  There are 
approximately 10 – 15 million cases of enterovirus in the United States each year, though not all 
cases cause neuroinvasive disease.43   
Viruses are the major cause of aseptic meningitis, which is more common but less severe 
than bacterial meningitis.  A variety of pathogens cause encephalitis, though non-infectious 
inflammatory processes can also cause encephalitis and the etiology is unknown in 
approximately 60% of encephalitis cases with current diagnostic approaches.12  Enteroviruses, 
arboviruses, HSV, cytomegalovirus (CMV), adenoviruses, and HIV are the most common causes 
of viral meningitis.15,44  Extreme ages are more susceptible to significant morbidity and mortality 
from viral encephalitis.15  Viral encephalitis and viral meningitis are often concurrent; viral 
encephalitis is distinguished by neurologic abnormalities.15   
Diagnosis of Infectious Causes of Neuroinflammation 
Data from previous studies suggest a multiplex diagnostic approach for ME causative 
pathogens may improve patient outcomes, decrease inaccurate and presumptive treatment, and 
will decrease the healthcare burden imposed by neuroinflammation.  Previous studies have tested 
multiplex diagnostic approaches to improve the diagnostic pathway for patients with CNS 
infection.18,19,31,32,45-49  In Huang et al., a panel of PCR assays for 11 viruses were tested for 3485 
patients over 6 years.48  The PCR panel could detect Eastern Equine Encephalitis (EEE) virus, 
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California-serogroup viruses (e.g., LaCrosse virus and Jamestown Canyon virus), Cache Valley 
virus, rabies virus, HSV (types 1 and 2), VZV, CMV, EBV, enteroviruses, St. Louis Encephalitis 
(SLE), Powassan virus (POW), and WNV.  Positive test results were detected in 14.3% of 
patients (n = 498) and enteroviruses were detected in 72.3% of these cases (n = 360).  There 
were also 76 HSV, 29 VZV, and 18 WNV cases.  PCR positive rates were 17.2% for specimens 
collected within 5 days of symptom onset, compared to 8.6% for specimens collected 6 days or 
more after symptom onset due to decrease in viral titers.  In Boaretti et al., 226 patients with 
suspected CNS viral infection were tested for HSV-1, HSV-2, EBV, VZV, CMV, polyoma virus 
JC (JCV), measles virus, mumps virus, and rubella virus over a 2-year period.32  Eighteen 
patients were positive by PCR (8%), of which 7 were positive for HSV and 5 were positive for 
enterovirus.  In Boving et al., 8-plex PCR including bacterial and viral pathogens was performed 
for 1187 CSF samples from patients with suspected of meningitis.45  Pathogens tested included 
Neisseria meningitidis, Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus, 
Listeria monocytogenes, Streptococcus agalactiae, HSV-1, HSV-2, and VZV and 55 samples 
were positive (4.6%).  In Zhou et al., 163 CSF specimens from patients with suspected CNS 
infection were tested for Mycobacterium tuberculosis, Cryptococcus neoformans, Streptococcus 
pneumoniae, HSV-1, and HSV-2.46  A total of 113 specimens were positive (69.3%), 50 of 
which were positive for Mycobacterium tuberculosis and 29 were positive for HSV-1.  This test 
was performed in 3.5 hours.   
It is noteworthy that each of these multiplex PCR diagnostic approaches tested for a 
different number and variety of pathogens which are common causes of ME.  All multiplex PCR 
methods demonstrated rapid and sensitive diagnosis of common etiologic agents in meningitis.  
The most common ME causative pathogens may vary by region, which may explain the variety 
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of pathogens on multiplex diagnostic platforms in previous studies.  Although a range of 
4.6-69.3% of cases were positive in these studies, this strategy decreases the time to diagnosis for 
positive cases and has the potential to influence clinical outcomes.  This multiplex approach 
provides consistency and reduces the risk of not ordering a specific test and subsequently 
missing the cause of the CNS infection, but increases the diagnostic burden if a patient has a 
non-infectious cause of neuroinflammation.   
A multiplex diagnostic approach for CNS infections focuses on a very small number of 
the potential causes of neuroinflammation.  To date, there is no data to suggest that multiplex 
diagnostic approaches for CNS infections have improved the proportion of patients diagnosed 
with neuroinflammation of unknown etiology and the impact to patient outcomes for CNS 
infection is unknown.  Much effort has gone into developing and evaluating diagnostics specific 
for CNS infections to improve time to diagnosis, minimize error, and improve treatment for this 
population.  However, there is variability in the number and types of pathogens tested on 
multiplex platforms in the literature.  There is also high variability in the number of positive 
cases identified with these platforms in the clinical setting, information regarding the clinical 
impact is lacking, and these platforms do not consider non-infectious causes of 
neuroinflammation.   
Outcomes Associated with Infectious Causes of Neuroinflammation 
Significant morbidity and mortality from CNS infections is demonstrated throughout the 
literature and is highly dependent on the etiology of neuroinflammation; further, CNS infections 
are associated with significant morbidity and mortality including permanent neurological 
sequelae.25  Some previous studies of CNS infections have reported low frequencies etiological 
confirmation (32-35%),50,51 while other studies have revealed that the etiology of encephalitis 
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remains unknown in 32-75% of cases.10,11,29,30  It is expected that disease of unknown etiology is 
associated with poor outcomes. 
The CFR for meningococcal disease can be as high as 70% without treatment.52  For 
bacterial meningitis, antimicrobial therapy provides the best outcomes with rapid initiation of 
treatment.  Thus, antimicrobial therapy almost always precedes identification of the causative 
pathogen due to the potential severity of immediate complications.27  Interestingly, initiation of 
antimicrobial therapy prior to CSF analysis increases the likelihood of false-negative test results; 
however, delay in initiation of therapy significantly contributes to poor outcomes.16,28  Since the 
introduction of cephalosporins, the overall CFR is <20%  in community-acquired gram-negative 
meningitis.15   
In a study of patients with herpetic meningoenchephalitis (HME, n = 501), 52.9% 
experienced unfavorable outcomes.26  The CFR for Japanese encephalitis virus (JEV) is 
20-30%,53 10-60% for Tick-born encephalitis virus (TBEV) depending on the strain,53,54 58-88% 
for Aspergillosis,55 20-50% for acute HSV,54 5-100% in viral encephalitis due to rabies,19,56 and 
100% for prion infections such as Creutzfeldt-Jakob disease (CJD) although prion infections are 
typically non-inflammatory.57  West Nile virus (WNV) is associated with neuroinvasive disease 
and initial neurologic illness does not necessarily correlate with outcomes.58  Some studies report 
that over half of WNV cases experience persistent post-infection neurologic dysfunction, 
including movement disorders, headaches, fatigue, and cognitive complaints up to a year after 
acute illness.53,59  
Non-Infectious Causes of Neuroinflammation 
There are numerous non-infectious causes of neuroinflammation including autoimmune 
disorders, inflammatory disorders, malignancy, and trauma.  Autoimmune disorders represent a 
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broad spectrum of conditions that have a similar clinical presentation to CNS infections and 
other causes of neurioinflammation.3  Antibody-associated immune disorders, multiple sclerosis, 
and other autoimmune disorders may differ in the pathogenesis, but as with other causes of 
neuroinflammation, when inflammatory cells are released in the CNS, innate and adaptive 
immunity is activated.3  It is crucial to include tests, such as tissue-based assays, to detect 
autoantibodies in the CSF to diagnose autoimmune disorders affecting the CNS.  Multiple 
sclerosis may or may not present with CNS involvement depending on disease progression and is 
a challenge to diagnose because the etiology for this disease is largely unknown.60,61  Presence of 
oligoclonal bands or intrathecal IgG production is the only diagnostic laboratory marker for 
multiple sclerosis and the presence of lesions on neuroimaging is critical for diagnosis.   
Activation and differentiation of CD4+ T cells into effector and regulatory immune 
subsets plays a role in the pathogenesis of autoimmunity and neuroinflammation.62  Specifically, 
studies have demonstrated that infiltration of CD4+ T cells into the CNS occurs in autoimmune 
diseases such as multiple sclerosis and autoimmune encephalomyelitis.  Subsets of CD4+ cells 
including Th9, Thf, Tr1, Th1, Th17, and Tregs are reported to contribute to the development of 
autoimmunity.62  Information about the pathogenesis of autoimmune disorders and other causes 
of neuroinflammation through immunophenotyping can provide detailed information to 
complement clinical symptoms and laboratory features currently available to clinicians during 
diagnostic work up of patients with CSF pleocytosis.   
Primary CNS lymphoma, defined as diffuse large B-cell lymphoma (DLBCL), and 
metastatic malignancies in the brain may cause inflammation in the CNS.  Primary CNS 
lymphoma accounts for 3% of primary CNS tumors.63  Secondary CNS involvement occurs in 
<5% of acute myeloid leukemia cases, 5% of patients with non-Hodgkin lymphoma, 3% of 
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indolent lymphomas, and 27% of high-grade lymphomas.  Cytology is the gold standard for 
diagnosing CNS lymphoma and hematologic malignancies with CNS involvement, but has 
document false-positive rates between 20-60%.64   
Neuroimaging in Patients with Neuroinflammation 
Neuroimaging is important in the diagnostic pathway for neuroinflammation to identify 
loss of cellular functions but has major limitations.  It does not provide information about disease 
etiology, is non-specific for the type of tissue change, and lacks sensitivity for damage to CNS 
tissue until substantial damage has accumulated; this is the case regardless of underlying disease 
etiology.65  Thus, a broad-spectrum approach to inform the diagnostic pathway may be 
appropriate to complement existing diagnostic tools to decrease time to diagnosis and increase 
the possibility of identifying the etiologic cause of neuroinflammation.  The suspected cause of 
neuroinflammation informs the diagnostic approach.  That is, a clinician will order specific 
diagnostic test depending on suspected cause of clinical symptoms.  This approach may vary 
greatly if the clinician suspects viral infection, bacterial infection, autoimmunity, trauma, 
degenerative processes, toxins, or malignancy.  The clinical manifestation is similar for the 
diseases that cause inflammation in the CNS; thus, understanding the inflammation mediators 
may better guide diagnosis of disease etiology.  Rapidly grouping a patient into a pre-specified 
diagnostic category will drastically reduce the possible tests a clinician needs to order to identify 
the etiology of the neuroinflammation.   
New Diagnostic Approaches for Patients with Neuroinflammation 
The Biofire FilmArray ME Panel was FDA cleared in 2015 for rapid, simultaneous, 
PCR-based detection of 14 pathogens which cause CNS infections using CSF.  This PCR panel 
detects Escheriachia coli K1, Haemophilus influenza, Listeria monocytogenes, Neisseria 
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meningitides (encapsulated), Streptococcus agalactiae, Streptococcus pneumonia, CMV, 
enterovirus, HSV-1, HSV-2, HHV-6, human parechovirus, VZV, Cryptococcus neoformans, and 
Coccioides immitus/gattii.  A multi-center diagnostic validation study was performed using 1560 
prospectively collected CSF specimens which were compared to a gold standard (culture for 
bacteria and PCR for all other pathogens).18  There were 141 positive results (9%) using the ME 
panel and 104 positive results using gold standard tests.  Test characteristics varied by pathogen, 
but acceptable sensitivity (>96%) was demonstrated for all pathogens except for Listeria 
monocytogenes and Neisseria meningitides, as they were not detected in this study.  
Additionally, HHV-6 had a lower sensitivity of 85.7%.  The specificity was >99% for all 
pathogens.  Preliminary data has revealed concerns regarding false-positive HHV-6 results.  The 
manufacturer of the test also claims that it cannot differentiate from latent and active CMV and 
HHV-6.  Further, HHV-6 from previous infections can integrate into chromosomes and cause 
false positives using the ME Panel.  This is a potential limitation of the ME Panel and of PCR 
testing for HHV-6 in general. 
The potential clinical impact of the Biofire ME Panel was also evaluated in a small 
number of children at Children’s Hospital Colorado.49  The ME Panel was compared to standard 
diagnostics in children with suspected CNS infections.  The panel had 96% agreement to 
standard diagnostics and facilitated improved time-to-diagnosis by 10.3 hours, with an estimated 
3-hour time-to-diagnosis for the ME Panel.  Time to diagnosis was defined as time from receipt 
of CSF by the laboratory to time of reporting the organism identification.  To date, there is no 
data to evaluate how this assay impacts patient outcomes or the health economic burden 
associated with adding this test to routine practice.  Further, this diagnostic approach is limited 
because it does not consider non-infectious cases of neuroinflammation which may present the 
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same or similar clinically although underlying immunology is functionally different.   
Cerebral spinal fluid inflammatory markers and immune cell subtypes present in patients 
with CSF pleocytosis may complement the current diagnostic approach and provide an approach 
to differentiate immune responses specific to broad diagnostic categories including both 
infectious and non-infectious causes of neuroinflammation.  Flow cytometry and other assays 
with multiplex configuration provide a platform to identify the subtypes of immune cells present 
in the CSF during neuroinflammation.  Clinical decisions guided by biomarkers specific for 
diseases may be more advantageous than the empirical approach.65,66   
Data exists for immune phenotypic subsets of WBCs in the CSF for some disorders but is 
lacking overall for the neuroinflammation population.  To date, there are no known biomarkers 
that are proven surrogates for clinical outcomes related to neuroinflammation.  It is well 
established that WBC >5 cells/mm3 in the CSF indicates inflammation in the CNS, but it is 
unlikely that a single biomarker will simplify the diagnostic pathway and help clinicians identify 
the etiologic cause of the neuroinflammation.  Immunophenotyping can capture multiple 
biomarkers to measure multiple immune processes contributing to neuroinflammation in a single 
CSF sample.  Patients with neuroinflammation will undergo an LP as part of routine care.  
Requesting flow cytometry with a panel of immune subsets may provide clinicians with much 
more detailed information about the immune processes in relation to the inflammation.  Because 
pathogenesis is dependent on disease etiology, immune subsets present during 
neuroinflammation may inform clinicians about the cause of neuroinflammation.   
Mechanisms of Neuroinflammation in Patients 
In a healthy individual, CSF is acellular and exhibits no inflammation. In patients with 
acute inflammation, CSF can often contain T-cells of which 70-75% are CD4+ T helper cells and 
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approximately 25% are CD8+ cytotoxic or suppressor T cells.65,67-69  There are other immune 
cells in healthy individuals which are important in immune responses in the brain including :  
natural killer-like T cells (NKT), natural killer (NK) cells, gamma/delta T cells, B cells (<1%), 
plasmablasts, plasma cells, and dendritic cells (DCs).65,67  There are multiple subsets of these 
immune cells.  The leukocyte profile in the CSF has been investigated for various causes of 
neuroinflammation.  These studies have focused on specific causes of neuroinflammation, such 
as multiple sclerosis.  In general, an increased proportion of B cells, plasmablasts, and NK cells 
are present in the CSF and monocytes are reduced during neuroinflammation although the 
pattern of abnormality differs between diseases.65,67  Plasmabasts are the predominant B cell 
subset in multiple sclerosis and are increased in NMO, while they are low or undetected in non-
inflammatory disorders.66,70  An increase in gamma/delta T cells, CD4+ T cells, and CD4:CD8 
ratio, and CD19+ B cells has also been reported in MS.65,70-72  Monocyte:B cell ratio is lower in 
relapsing-remitting multiple sclerosis, while NK cell CD56bright/CD56dim is increased in 
multiple sclerosis.73,74  NK cells have been reported as higher in bacterial and viral meningitis 
than in other diseases.67  Monocytes and NK cells have been reported as slightly elevated with 
CNS malignancies and viral meningitis, while monocytes may decrease with other causes of 
neuroinflammation such as multiple sclerosis.67,70  Further, an inverse correlation of monocytes 
to B cells and plasmablasts has been reported in some case series studies.67  Elevated CD8+ T 
cells, B cells, and plasmablasts have been observed in patients with multiple sclerosis and 
bacterial and viral meningitis.67  Little or no data exists on the leukocyte profile in neuromyelitis 
optica (NMO), anti-N-methyl D-aspartate receptor (anti-NMDAR) encephalitis, acute 
disseminated encephalomyelitis, neuropsychiatric system lupus erythermatosus, traumatic brain 
injury, or stroke.65 
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Several studies have been conducted to evaluate immune cell subsets in common 
neurological diseases.  A study of patients with relapsing-remitting multiple sclerosis concluded 
that CD4+CD8+ double-positive T cells are functional in multiple sclerosis.75  This study 
evaluated CD4+CD8+ double-positive T cells in patients with and without natalizumab therapy.  
This study demonstrated that CD4+CD8+ double-positive T cells are present in the CSF and may 
be of interest for immune surveillance, however there is a lack of accumulation of this T cell 
subset within active MS lesions. 
A study that analyzed CSF from 319 patients, included patients with neuroinflammation 
and symptomatic controls with normal routine CSF parameters, to describe CSF immune cell 
subsets in common neurological diseases with comparison to reference data from CSF without 
pleocytosis.67  The aim of this study was to investigate whether changes to underlying 
immunology is specific for the disease etiology.  Leading diagnoses in this study included 
multiple sclerosis (n = 70), HIV infection (n = 35), viral meningoencephalitis (n = 17), Lyme 
neuroborreliosis (n = 15), Guillain-Barre syndrome (n =13), idiopathic intracranial hypertension 
(n = 13), bacterial meningoencephalitis (n = 13), and metastasis (n = 12).  There was a 
correlation of CD4+ T cells with cell count and impaired blood-brain barrier in this study.  
Elevated B cells and plasma blasts were observed in patients with neuroinflammatory diseases, 
specifically in patients with bacterial CNS infections and autoimmune diseases such as multiple 
sclerosis, sarcoidosis, and lupus erythematosus.  Low monocytes were observed in patients with 
inflammatory diseases, particularly in cases with elevated B cells.  There were increased NK 
cells in viral and bacterial meningitis.  One major limitation to this study is that patients with 
multiple sclerosis and HIV, which were leading diagnoses in this study, showed a normal to 
slightly elevated CSF WBC count, which indicates these patients did not have inflammation in 
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the CNS at the time of CSF collection.  This contributed to the limited amount of CSF cells 
available for flow cytometry in this study.  No major recommendations are made from data in 
this study other than a recommendation for additional studies to differentiate CSF cells in more 
detail.   
Another study analyzed 230 CSF specimens from 145 patients with suspected 
hematologic neoplasms; no history of malignancy was reported for 71/145 patients of whom 35 
had reported neurologic symptoms.76  It has previously been recommended that flow cytometric 
immunophenotyping be used in conjunction with cytology for specimens with suspected 
hematologic neoplasms, thus this study evaluated flow cytology as a diagnostic tool for detection 
of hematologic malignancy in CSF specimens.77  There were 77 specimens collected for primary 
diagnosis and 153 specimens collected for follow-up known malignancy.  Flow cytometric 
immunophenotyping was positive in 4.8% of cases and indeterminate in 8.3% of cases.  Only 1 
specimen was positive for malignancy by cytology and negative by flow cytometry.  Samples 
that were positive by flow cytometry were characterized by the presence of a discrete population 
of phenotypically similar cells and an abnormal phenotype that could adequately distinguish 
neoplastic and non-neoplastic cell populations.  Of note, in this study flow cytometry was used 
for specimens from patients with low clinical suspicion of hematopoietic or lymphoid 
malignancy, which explains the low rate of positive cases.  This study documented value in the 
addition of flow cytometry in routine testing for suspected hematologic neoplasms.   
At some centers, flow cytometry is part of routine clinical testing for patients with altered 
mental status, even if risk factors are low, because multiple and simultaneous diagnostic tests 
facilitate a more timely determination of disease etiology.63  The National Comprehensive 
Cancer Network recommends both cytology and flow cytometry of CSF for patients with high 
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clinical suspicion of CNS lymphoma.78  A study of 373 patients with CSF evaluated for 
lymphoma screening by flow cytometry assessed the diagnostic accuracy of flow cytometry and 
cytology as a parallel testing strategy for patients with suspected CNS lymphoma.63  Neurologic 
symptoms were observed in 78% of patients, brain imaging was abnormal in 51% of patients, 
and the combined cytology and flow cytometry tests yielded a positive result in 4% of patients 
included in this study; 100% of these cases represented a B-cell malignancy.  The positive and 
negative predictive values of the parallel diagnostic approach was 92% and 89%, respectively.  
The CD19:CD3 ratio was higher in lymphoma cases compared to polytypic cases.  This study 
documents the added value of flow cytometry in complementing cytology for the detection of 
CNS lymphoma.   
A retrospective study of 369 patients (601 consecutive samples) with acute myeloid 
lymphoma or high-grade myelodysplastic syndrome demonstrated that flow cytometry had 
greater test sensitivity than morphological analysis due to false-negatives associated with current 
standard testing.79  Combined results from studies evaluating flow cytometry for hematological 
malignancies suggest that this approach may be valuable to aid in the diagnosis of patients with 
malignancies with CNS involvement.   
As represented throughout the literature, a broad diversity of disorders which cause 
inflammation in the CNS may present the same or similar clinically although underlying 
immunology is functionally different.  The Meso Scale Discovery (MDS) assay has been used in 
diagnostic discovery research due to the multiplexed design which measures 30 cytokines in the 
same sample at the same time which are relevant to inflammation response and immune system 
regulation.  So far cytokine profiles have not been used clinically as biomarkers for 
neurodegenerative diseases or other disorders which cause neuroinflammation.80  Multiple 
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biomarkers are likely needed to improve diagnostic strategies for patients with 
neuroinflammation since adding more disease-specific test methods to the list of options for 
clinicians has not demonstrated improvement in patients with disease of unknown etiology.  
Therefore, multiplexed assays such as the MDS which may describe the immune response in 
more detail may be more informative for clinicians to guide disease-specific testing.  To date, 
such assays have not been used in the neuroinflammation population, but have been used to 
study specific diseases such as Alzheimer’s Disease,81 multiple sclerosis,82 autoimmune 
disorders,83 and malignancies84 for drug discovery, diagnostic development, disease monitoring, 
and basic research.   
Taken together, data from these studies emphasize the need for improved diagnostic 
strategies for patients with inflammation in the CNS.  Further, these data confirm changes in the 
immune cell subtypes present in the CNS during neuroinflammation compared to healthy 
individuals and non-inflammatory disorders.  These changes appear to vary by cause of 
inflammation and may inform the differential diagnosis when neuroinflammation is detected. 
Problem Statement, Research Questions, Hypotheses 
Problem Statement 
Patients that present to medical care with inflammation in the CSF can be complex to 
evaluate due to the heterogeneity of causes that result in overlapping clinical and laboratory 
features.85  For these reasons, no clear diagnostic test exists for specific clinical presentations, 
and a high frequency of patients with no known cause of neuroinflammation present in medical 
practice.  Current standard practice utilizes CSF biomarkers such as WBC, protein, and glucose 
to guide diagnosis; however, routine testing strategies to identify disease etiology differ between 
facilities and clinicians, and patients often experience delays in diagnosis and treatment or 
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receive no diagnosis at all.   
There is a need for a clinical approach that rapidly provides a diagnosis in an unbiased 
manner and improves outcomes for patients presenting with neuroinflammation.  Research and 
development of multiplex diagnostic panels, novel biomarkers, and standardization of the 
diagnostic pathway for patients presenting with CSF pleocytosis is urgently needed to improve 
diagnosis and treatment of specific causes of neuroinflammation.  No data exists for the 
frequencies of various etiologic causes of CNS inflammation, associated clinical and laboratory 
parameter of this population, or proportion of patients with CNS inflammation for whom no 
etiology was identified at the University of Colorado Hospital (UCH).  Additionally, no studies 
to date have described the immune phenotypic subsets of WBCs in the CSF overall for the 
neuroinflammation population.  Further, no studies have investigated neuroinflammation in 
terms of pre-specified diagnostic categories to facilitate more efficient diagnostic testing in this 
population.  Research aimed at quickly narrowing the suspected etiology into diagnostic 
categories is needed; such studies may improve the time to diagnosis and minimize diagnostic 
burden.  This research aims to partly fulfil that gap. 
Purpose 
The goals of this research were to define the clinical characteristics, laboratory data, and 
outcomes of patients within diagnostic categories of CNS disease and define the 
neuroinflammatory responses that may differentiate diagnostic categories of CNS disease.  When 
a patient presents with neuroinflammation, clinicians need to know if the patient has an infection, 
which pathogen is causing the inflammation, and what will treat the infection.31  If a 
non-infectious antigen is the suspected cause of neuroinflammation, a different diagnostic and 
treatment approach is warranted.  
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This research suggests that to improve the diagnosis in this patient population, patients 
with neuroinflammation must be studied as a group (as opposed to studying single etiologies) 
with novel multiplexed diagnostic panels or arrays so that improved diagnostic algorithms can be 
developed.  Since clinicians evaluate patients with neuroinflammation and then recommend 
diagnostic testing based on clinical features, it is important to understand the underlying causes 
and outcomes of these patients as a group.  Additionally, since the underlying immunology for 
each of these categories should be functionally different, studies can be aimed at defining the 
immunology of the broader diagnostic categories to define immunologic biomarkers of disease 
categories.   
To guide the identification of biomarkers which may improve clinical outcomes, we 
group patients into pre-specified diagnostic categories that include diseases that have similar 
pathogenesis in the CNS.  For example, various diagnoses can be grouped into broad diagnostic 
categories including viral infection, bacterial infection, autoimmune/inflammatory disorder, 
malignancy, other, and unknown.  Immunophenotyping of CSF to provide insight into diagnostic 
categories to be tested may improve patient outcomes, decrease inaccurate and presumptive 
treatment, and decrease the healthcare burden imposed by neuroinflammation.  Further 
evaluation of immunophenotyping in inflamed CSF is warranted.18,49  Standardization of the 
appropriate panel of biomarkers which predict the diagnostic category was investigated in this 
research.  Information about patients with neuroinflammation at UCH was also defined in this 
research and the data supported the evaluation of a multiparameter assays specific for expected 
immune subtypes in this population.  Further exploration of cytokines relevant to inflammation 
response was also conducted in this research. 
This study suggests that multiplex assays measuring the immune response in the CSF 
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would complement the current diagnostic approach for patients presenting with 
neuroinflammation by narrowing the suspected etiology into diagnostic categories which will aid 
clinicians to target evaluations.  Since causes of neuroinflammation are heterogeneous, prior 
studies that have evaluated a single etiology of neuroinflammation have failed to identify 
improved diagnostic or treatment approaches due to small numbers.   
To improve the diagnostic pathway discussed above, this study:  
1) collected data from a retrospective neuroinflammation cohort by the cause of 
neuroinflammation (infection, autoimmune, malignancy, inflammatory disorder, or unknown 
etiology) as well as the disease etiology and time to diagnosis;  
2) evaluated the data in terms of time to positive test results, proportion of patients with 
neuroinflammation of unknown etiology, and clinical and laboratory diagnostics and parameters;  
3) evaluated a novel flow cytometry-based assay in terms of narrowing the suspected 
etiology into diagnostic categories (bacterial infection, viral infection, malignancy, autoimmune, 
inflammatory disorder); and  
4) made recommendations regarding future research to facilitate standardization of a 
biomarker testing to be tested in clinical studies to complement routine care.   
The study evaluated clinical and laboratory parameters in both a retrospective and pilot 
cohort, quantified the frequency of specific causative pathogens, and sought to understand the 
proportion of patients diagnosed with CNS inflammation of unknown origin.  This initial work 
has facilitated improvement in the diagnostic pathway by describing patients with 
neuroinflammation at UCH and by recommending future research to facilitate standardization of 
biomarker testing to evaluate immune differential patterns for patients who present with 
symptoms of neuroinflammation.  Further, evaluation of specific etiologic agents in this cohort 
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can guide future directions to develop additional multiplex diagnostic approaches, novel 
biomarkers, and more standardization of the diagnostic pathway, thus  
• minimizing the diagnostic burden,  
• improving the diagnostic pathway for patients with neuroinflammation,  
• improving the percentage of patients that receive a timely diagnosis,  
• improving time to appropriate treatment, and eventually, and 
• improving outcomes for these potentially devastating diseases. 
Specifically, this research aimed to accomplish two main objectives: 
1. To define the neuroinflammation patient population at UCH in a retrospective cohort 
over 1 year to understand where improvements may be made in the diagnostic pathway in 
the following ways: 
a. Identify if there was a difference in time to diagnosis between neuroinflammation 
patients in each pre-specified diagnostic category (infection, autoimmune, 
malignancy, inflammatory disorder, or unknown etiology) in a retrospective cohort in 
patients with CSF WBC >5 cells/mm3.   
b. Determine frequencies of all etiologic causes of neuroinflammation at UCH and the 
proportion of patients in each diagnostic category (infection, autoimmune, 
malignancy, inflammatory disorder, or unknown etiology) in the retrospective cohort.   
c. Evaluate clinical and laboratory parameters including CSF WBC count, glucose, and 
protein; neurologic deficit; and overall mortality between patients in each diagnostic 
category in the retrospective cohort.   
2. To define the role of a novel flow cytometry-based assay in the differentiation between 
pre-specified diagnostic categories (bacterial infection, viral infection, malignancy, 
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autoimmune, inflammatory). 
a. Describe the leukocyte profile by diagnostic category in terms of difference in 
proportions of 5 cell types (neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T 
cells, Th17 cells, and B cells) between the categories of disease.   
b. Establish the leukocyte profile that best characterizes each diagnostic category.  We 
expect the following 5 panels:  bacterial infection (CD15+/CD49- [neutrophils]); viral 
infection (CD3+/CD8+/PD1- [PD1- cytotoxic T cells]); malignancy 
(CD3+/CD8+/PD1+ [PD1+ cytotoxic T cells]); inflammatory (CD3+/CD4+/IL17+ 
[Th17 cells]); and autoimmune (CD19+/CD45+ [B cells]). 
c. Explore the immune differential patterns of samples in each diagnostic category in 





Since causes of neuroinflammation are heterogeneous, prior studies that have evaluated a 
single etiology of neuroinflammation have failed to identify improved diagnostic approaches.  
Clinicians evaluate patients with neurologic syndrome and CSF pleocytosis and then recommend 
diagnostic testing based on clinical features; thus, it is important to understand the underlying 
causes and outcomes of these patients as a group as opposed to only studying single etiologies, 
all of which present with inflammation in the CNS.  Further, clinicians are challenged with 
diverse underlying etiologies of disease and a high frequency of patients with no known cause of 
neuroinflammation.  Given that there are >100 viruses that can cause viral encephalitis alone, the 
list of possible diagnostic tests for patients who present with CSF pleocytosis is extensive.  
Moreover, standard diagnostic strategies are inconsistent and may result in missed on delayed 
diagnoses.  This research evaluated specific diseases which cause neuroinflammation at the 
University of Colorado Hospital and considered biomarkers in the CSF which may be indicators 
of a category of disease and explores differences in the immune response between different 
diagnostic categories which may be useful to guide more rapid diagnosis of etiologic causes of 
neuroinflammation.   
Study Design, Methods, and Statistical Approach 
Overall Purpose 
The overall purpose of this research was to improve the diagnostic pathway for patients 
who present with symptoms of neuroinflammation.  We hypothesized that immune markers of 
disease would complement the current diagnostic approach for patients presenting with 
neuroinflammation by narrowing the differential diagnosis.  We first characterized a 
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retrospective cohort to understand the current diagnostic approach, clinical presentation, and 
outcomes in the neuroinflammation population.  This work also helped to define categories of 
disease that could be utilized for biomarker development. Next, a pilot study evaluated immune 
biomarkers in the CSF for patients with CNS neuroinflammatory diseases.  To test our 
hypothesis, we developed a multiparametric flow cytometry panel that we propose can 
distinguish between patients that have neuroinflammation due to bacterial infection, viral 
infection, autoimmune inflammation, inflammatory disease, and malignancy.  Using CSF 
samples from these patient groups, we evaluated immune signatures using multiparametric flow 
cytometry and a multiplex ELISA test in a cohort of patients with known and unknown causes of 
neuroinflammation.   
To identify the diagnostic categories used in the pilot study, we first characterized the 
clinical characteristics of all patients presenting with a CSF pleocytosis at UCH to understand 
what clinical parameters needed to be targeted in the evaluation of patients with 
neuroinflammation.  Thus, improvement to the diagnostic pathway for patients with 
neuroinflammation was investigated in 2 ways:  1) by defining a retrospective cohort of patients 
who presented with CNS inflammation in terms of pre-specified diagnostic categories (infection, 
autoimmune, malignancy, inflammatory disorder, or unknown etiology); and 2) by evaluating 
immune cell markers to differentiate between immune responses in broad diagnostic groups 
(bacterial infection, viral infection, malignancy, autoimmune disease, and inflammatory disease). 
Research Hypotheses and Specific Aims 
The goals of this research were to characterize neuroinflammation at UCH and to define the 
immune profile of patients presenting with CSF pleocytosis.  We hypothesized that specific 
immune responses would be characteristic of specific diagnostic categories including bacterial 
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infection, viral infection, malignancy, autoimmune, inflammatory.  We tested this hypothesis in 
the following specific aims. 
Specific aim 1 
To define the neuroinflammation patient population at UCH in a retrospective cohort over 1 year 
to understand where improvements may be made in the diagnostic pathway in the following 
ways: 
a) Identify if there was a difference in time to diagnosis between neuroinflammation 
patients in each pre-specified diagnostic category (infection, autoimmune, malignancy, 
inflammatory disorder, or unknown etiology) in a retrospective cohort in patients with CSF 
WBC >5 cells/mm3.   
b) Determine frequencies of all etiologic causes of neuroinflammation at UCH and the 
proportion of patients in each diagnostic category (infection, autoimmune, malignancy, 
inflammatory disorder, or unknown etiology) in the retrospective cohort.   
c) Evaluate clinical and laboratory parameters including CSF WBC count, glucose, and 
protein; neurologic deficit; and overall mortality between patients in each diagnostic category in 
the retrospective cohort.   
Specific aim 2 
To define the role of a novel flow cytometry-based assay in the differentiation between 
pre-specified diagnostic categories (bacterial infection, viral infection, malignancy, autoimmune, 
inflammatory). 
a) Describe the leukocyte profile by diagnostic category in terms of difference in 
proportions of 5 cell types (neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 
cells, and B cells) between the categories of disease.   
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b) Establish the leukocyte profile that best characterizes each diagnostic category.  We 
expect the following 5 panels:  bacterial infection (CD15+/CD49- [neutrophils]); viral infection 
(CD3+/CD8+/PD1- [PD1- cytotoxic T cells]); malignancy (CD3+/CD8+/PD1+ [PD1+ cytotoxic 
T cells]); inflammatory (CD3+/CD4+/IL17+ [Th17 cells]); and autoimmune (CD19+/CD45+ 
[B cells]). 
c) Explore the immune differential patterns of samples in each diagnostic category in terms 
of measuring cytokine levels relevant to inflammation response. 
Both studies were descriptive studies that adds to the literature in the field of neurology in 
terms of improving diagnostic approaches for patients with neuroinflammation. 
Specific aim 1 (a-c) was evaluated in a retrospective cohort study.  Understanding differences 
in time to diagnosis, etiologic frequencies, and clinical and laboratory parameters between 
patients with autoimmune, infection, or origin unknown as primary causes of neuroinflammation 
is important to understand where improvements may be made to diagnose these patients and for 
informing further research in terms of evaluating the impact of a new diagnostics or novel 
biomarkers on confirmatory diagnoses.  It is expected that patients with neuroinflammation of 
unknown origin have worse outcomes; thus, identifying the proportion of patients presenting 
with CNS inflammation of unknown origin highlights a critical need for diagnostic 
improvement.  Additionally, understanding the frequencies of specific etiologies at UCH will 
inform future diagnostic development. 
Specific aim 2 (a-c) was evaluated in a pilot study.  A flow cytometry-based panel was 
utilized to define proportions of specific inflammatory cell types in the categories of 
neuroinflammatory disease.  It was expected that proportions of specific CSF leukocyte 
subpopulations would correlate with specific diagnostic categories.  Thus, evaluating this 
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information simultaneously with standard CSF analysis may inform the diagnostic pathway and 
guide clinicians to order the most appropriate tests for the suspected etiologic cause of 
neuroinflammation.  
This research team had infectious disease, neuroscience, clinical science, and statistical 
expertise and immediate access to patient charts from a CNS inflammation cohort.  Retrospective 
and pilot evaluation of this cohort was logistically feasible because the team had access to the 
appropriate laboratory resources as well as CSF samples needed to test this hypothesis. 
Research Methodology Overview 
The aims of this research were evaluated in 2 separate clinical studies:  a retrospective 
cohort study and a pilot study.  The retrospective cohort study evaluated comprehensive clinical 
and laboratory parameters for 244 patients with neuroinflammation.  The pilot study evaluated 
the leukocyte profile of CSF in 61 patients with neuroinflammation. 
Specific aim 1 (a-c) was evaluated in the following retrospective cohort study. 
Research Methodology:  Retrospective Neuroinflammation Cohort Study to Evaluate Outcome 
Predictors to Improve the Diagnostic Pathway 
Study design 
This was a retrospective chart review in a cohort of patients who presented to UCH with 
neuroinflammation.  Neuroinflammation is defined as CSF WBC count >5 cells/mm3.  
De-identified data was extracted from a patient log, from a patient list generated by the UCH 
microbiology laboratory, and from patient charts for this study.  Data were collected for patients 
who presented with neuroinflammation on July 1, 2015 through June 30, 2016 and were entered 
in a patient log by a neuroinfectious disease fellow for education purposes.  This patient log only 
contained suspected neuroinflammation patients; all patients with CSF samples drawn at UCH 
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and a CSF WBC count >5 cells/mm3 were selected for the study.  Additional patients who were 
suspected of neuroinflammation during this time period were also included in this study.  
Patients not included on the patient log were identified through the UCH microbiology 
laboratory as CSF samples received and cultured during this time period.  The patient list was 
provided by the UCH microbiology laboratory to the research team and data was extracted from 
patient charts by the research team.  The infectious disease patient log and patients for whom 
CSF was tested in the UCH microbiology laboratory was considered a comprehensive list of 
patients who presented to UCH from July 1, 2015 through June 30, 2016.  Identifiable data was 
not used on the research data collection worksheet.   
Clinical and laboratory parameters associated with CNS inflammation may include AMS, 
FND, headache; and/or altered CSF WBC, glucose, or protein; and/or positive neuroimaging.  
CNS inflammation is defined as CSF WBC >5 cells/mm3 and patients were grouped within 1 of 
the following diagnostic categories for purposes of this research:  infection, autoimmune, 
malignancy, inflammatory disorder, or unknown etiology.   
Research hypotheses for the retrospective cohort study 
Hypothesis1:  There is a difference in time to diagnosis between patients is each diagnostic 
category:  infection, autoimmune, malignancy, inflammatory disorder, or unknown etiology. 
Hypothesis 2:  There is a difference in CSF WBC count, glucose, protein, and overall mortality 
between patients for which the CNS inflammation etiology was confirmed versus patients for 
which the cause of CNS inflammation was unknown. 
Hypothesis 3:  There is a higher frequency of patients with CNS inflammation (CSF WBC >5 
cells/mm3) with CNS infection or unknown etiology.   
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Study procedures 
Broad diagnostic evaluation is necessary for patients with suspected or confirmed 
neuorinflammation including CSF cultures, blood bacterial and fungal cultures, CSF and blood 
serology and PCR, and neuroimmaging, thus the data collection worksheet for this retrospective 
cohort study was comprised of 70 data fields.  De-identified data was extracted from patient 
charts by the research team entered into a research spreadsheet to be used for primary and 
secondary endpoint analyses according to the study protocol (Appendix A).  The patient charts 
were considered the source data for this study.  Data was collected in this retrospective chart 
review from patients who presented with suspected CNS inflammation over a 1-year period.  A 
patient list was compiled by identifying patients with CSF WBC >5 cells/mm3 during the 
specified time range.  These patients were identified by an infectious disease fellow on a patient 
log and by the UCH microbiology laboratory.  The research team identified which patients had a 
CSF WBC count >5 cells/mm3 using data from patient charts.  De-identified data was extracted 
from the patient charts onto a data collection worksheet.    
To ensure quality control (QC) of the data, 5% of the patient charts were entered by 2 
members of the research team.  If major discrepancies were noted, the research team pre-
specified that 10% of the patient charts would be reviewed by 2 members of the research time.  If 
it was necessary to QC 10% of the patient charts and major discrepancies were still noted, there 
was a pre-specified plan to conduct 100% data verification.   
Confirmatory diagnostic tests are variable patient-to-patient, and there is no single gold 
standard test for this patient population; thus, tests performed vary depending on the suspected 
etiology by the treating physician.  Data was collected for a variety of diagnostic tests including 
blood and CSF serology, blood and CSF PCR, blood culture, CSF culture, serum WBC, serum 
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creatinine, CSF WBC, CSF glucose, CSF protein, neuroimaging, and biopsy.  Not all patients 
had data for every data field, but all patients had data on time to diagnosis, CSF WBC count, and 
diagnostic category which ensured no missing data for the primary endpoint of the retrospective 
study.   
Selection criteria 
Patients were enrolled in this study if they presented to UCH from July 1, 2015 through 
June 30, 2016 with suspected neuroinflammation and had CSF fluid cultures submitted to the 
laboratory with evidence of a WBC count in the CSF of >5 cells/mm3.  Any patients with CSF 
submitted to the laboratory following ventricular shunt placement or other neurological 
procedure within 3 months of the specimen collection were excluded from this study.  There 
were 244 patients who met these criteria and were selected for the study.   
Sample size determination 
No sample size calculation was conducted; all patients who met enrollment criteria were 
included in this retrospective cohort study.  Further, no power calculation was conducted.  
Though we know the final sample size, the desired power, the desired alpha, and can calculate 
the variance in this dataset, we did not have sufficient preliminary data in the literature to 
calculate the anticipated effect size.   
IRB approval and informed consent 
Informed consent was waived because this was a retrospective chart review study.  This 
study was approved by COMIRB (16-2728, Appendices A-D). 
Primary endpoint 
The primary endpoint was proportion of participants diagnosed with infection, 
autoimmune, malignancy, inflammatory disorder, or unknown etiology. 
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Proportions are presented by primary cause of neuroinflammation.  The denominator is 
the total number of participants.  No missing data was expected for the primary endpoint of this 
study. 
Secondary endpoints 
There were 5 secondary endpoints of interest in this study:   
1. The frequencies of all etiologic causes of neruoinflammation 
2. CSF laboratory parameters including leukocyte count and differential, glucose, and protein 
between participants diagnosed with infection, autoimmune, and unknown  
3. Time to diagnosis and treatment in participants diagnosed with infection, autoimmune, 
malignancy, inflammatory disorder, and unknown and overall time to diagnosis and 
treatment.  Time to diagnosis will be calculated from the time of presentation with symptoms 
of neuroinflammation to UCH to the time of positive diagnostic test results. 
4. Neurologic deficit at presentation and discharge in participants diagnosed with infection, 
autoimmune, malignancy, inflammatory disorder, and unknown  
5. Explore clinical and laboratory parameters between infection (bacterial, viral, fungal, and 
parasite), autoimmune, malignancy, inflammatory disorder, and unknown neuroinflammation 
etiology including the following: 
• Symptoms such as headaches, AMS, FND, and fever  
• Laboratory results including complete cell count, comprehensive metabolic panel, 
renal function, lumbar puncture opening pressure, serum cryptococcal antigen, 
CSF cryptococcal antigen, CSF culture, blood culture, CSF cell count, CSF 
glucose, and CSF protein 
Data was collected for a variety of diagnostic tests including blood and CSF serology, 
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blood and CSF PCR, blood culture, CSF culture, serum WBC, serum creatinine, CSF WBC, CSF 
glucose, CSF protein, neuroimaging, and biopsy.  Not all patients had data for every data field, 
but all patients had available data on time to diagnosis, CSF WBC count, and diagnostic category 
which ensured no missing data for the primary endpoint of the retrospective study.   
Statistical analysis plan 
Descriptive statistics were used to describe the primary endpoint of the proportion 
patients in each diagnostic category (autoimmune, infection, malignancy, inflammatory disorder, 
and unknown).  Chi-square was conducted to determine the difference in proportions between 
each category.  If the chi-square test revealed a significant difference in proportions between 
categories, t-tests were conducted to identify where the differences lie between groups.   
Descriptive statistics for each diagnosis are presented for the secondary endpoints as well 
including the frequencies of all etiologic causes of neuroinflammation.  After consideration of 
assumptions, an ANOVA test was used to test the secondary endpoint of time to diagnosis.  If 
time to diagnosis between diagnostic categories was statistically significant, post-hoc t-tests were 
conducted to determine whether there were significant differences between the etiology groups 
(infection, autoimmune, malignancy, inflammatory disorder, or unknown etiology) with regard 
to clinical and laboratory parameters, as appropriate.  A correction was used to adjust the p-value 
for multiple comparisons, when necessary. In the case of missing data for some of the clinical 
and laboratory parameters, these parameters were tested on a case-by-case basis; if the number of 
data points were small, non-parametric tests were considered.  No formal power calculation was 
conducted for this study; however, 95% confidence intervals were presented with each point 
estimate. 
Proportions in respect to diagnoses are reported the follow way: 
41 
Number of participants with diagnosis (eg, infection, autoimmne, malignancy, 
inflammatory disorder, or unknown)/Number of total neuroinflammation participants in 
the study = Proportion 
Frequency of headache, AMS, or FND and other non-specific clinical and laboratory 
parameters between patients in each diagnostic category were evaluated in post-hoc analyses.  
The chi-square or ANOVA test were used in post-hoc analyses.  T-tests were also conducted to 
identify differences.   
Research Methodology:  Evaluation of the Leukocyte Profile in Cerebral Spinal Fluid in 
Meningitis and Encephalitis to Improve the Diagnostic Pathway for Patients with 
Neuroinflammation 
Specific aim 2 (a-c) were evaluated in a pilot study.  Specific aim 2 was to evaluate the 
leukocyte profile of CSF in a cohort of patients with neuroinflammation in terms of 
characterizing the profile for pre-specified diagnostic categories.   
Study design 
The purpose of the pilot study was to evaluate immunophenotyping by flow cytometry to 
facilitate improvement in the diagnostic pathway for identifying etiologic causes of 
neuroinflammation.   
This study was conducted in a neuroinflammation cohort to describe the immune 
differential patterns of immune cell subtypes for confirmed etiologic causes of 
neuroinflammation.  Diagnoses were classified as bacterial infection, viral infection, 
autoimmune, inflammatory disorder, or malignancy based on confirmatory diagnostic tests from 
routine clinical testing.  Participants were included in this study if they presented to UCH with 
CSF WBC count >5 cells/mm3 and have a CSF specimen with adequate residual volume of 
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uncentrifuged CSF (≥500μL) left over from routine testing.  
Using CSF specimens left over from routine clinical testing was most feasible to evaluate 
the flow cytometry panel in a pilot study.  A large, prospective evaluation of the flow cytometry 
panel may be indicated if the results from the pilot study appear to differentiate patients based on 
the immune subsets used in this study.  A larger, prospective study should also evaluate the 
impact of the new test in terms of time to diagnosis and proportion of patients with 
neuroinflammation of unknown origin. 
Research hypothesis for the prospective pilot study 
Hypothesis 4:  5 immune cell subtypes will describe differential patterns of the pre-
specified diagnostic categories in the neuroinflammation cohort.  We anticipate the following 
dominate cell subtypes for each category:  bacterial infection (CD15+/CD49- [neutrophils]); 
viral infection (CD3+/CD8+/PD1- [PD1- cytotoxic T cells]); malignancy (CD3+/CD8+/PD1+ 
[PD1+ cytotoxic T cells]); inflammatory (CD3+/CD4+/IL17+ [Th17 cells]); and autoimmune 
(CD19+/CD45+ [B cells]) 
Study Procedures 
Cerebral spinal fluid specimens left over from routine testing in the clinical laboratory 
with a CSF WBC count >5 cells/mm3 were selected for this pilot study.  The research team 
coordinated with the central laboratory and reviewed patient charts to identify specimens that 
met selection criteria.  De-identified data was collected from respective patient charts and 
entered into a spreadsheet to be used for primary and secondary endpoint analyses.  Residual 
CSF specimens were de-identified and transferred to the infectious disease research laboratory.   
Fresh, residual clinical samples were collected and prepared within 3-4 days of collection 
to maintain sample integrity.  Samples were centrifuged, and the pellet was removed for flow 
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cytometry testing.  The supernatant fluid was used for multiplex ELISA.     
Flow cytometry: Immune cells present in the CSF were evaluated by flow cytometry in 3-
6 samples from each diagnostic category.  Previously frozen cells were first thawed and rested 
overnight in R10 (RPMI with glutamine (Thermo Fisher, Waltham, MA) + 10% FBS (Hyclone, 
Thermo Fisher) + 1% Penicillin/Streptomycin (Gibco, Thermo Fisher), 1% HEPES (Gibco), 1% 
non-essential amino acids (Gibco), and 1% sodium pyruvate (Gibco)) media in an incubator at 
37°C.  The cells were then washed twice with PBS (Gibco or Corning Cellgro) and incubated 
with Ghost violet 510 dye (Tonbo Biosciences, San Diego, CA) for 10 minutes.  Antibodies 
against surface antigens diluted in FACS buffer (PBS + 1% FBS) were then added to the cells for 
25 minutes. After washing, the cells were permeabilized for 20 minutes using 
Fixation/Permeabilization solution (BD Biosciences, San Jose, CA).  The cells were then 
washed, and intracellular antibodies diluted in Perm/Wash buffer (BD Biosciences) were added 
for 45 minutes.  The cells were washed once more and fixed with 1% paraformaldehyde (PFA, 
Fisher Scientific).  All antibody incubations were performed at 4°C in the dark.  The data were 
collected on a LSRII flow cytometer (BD Biosciences) and analyzed in FlowJo (FlowJo, LLC). 
The following antibodies were used: anti-IL17A BV421 (Biolegend, San Diego, CA), anti-
CD49d BV605 (Biolegend), anti-CD14 BV650 (BD Biosciences), anti-CD3 BV711 (Biolegend), 
anti-CD8 BV785 (Biolegend), anti-CD27 FITC (Biolegend), anti-perforin PE (Biolegend), anti-
CD15 PE-Cy7 (Biolegend), anti-CD4 PE-Cy5.5 (eBioscience, Thermo Fisher), anti-CD19 PE-
CF594 (BD Biosciences), anti-PD1 APC (Biolegend), anti-CD66b AF700 (Biolegend), and anti-
CD56 APC Fire 750 (Biolegend).  
Multiplex ELISA: 30 cytokines and chemokines were evaluated for 4-6 samples in each 
diagnostic category by multiplex ELISA (V-plex Human Cytokine 30-Plex Kit, Meso Scale 
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Discovery, Rockville, MA).  Previously frozen CSF fluid was thawed, centrifuged to remove any 
residual cells, and the assay was carried out according to the manufacturer’s instructions.  The 
plates were run on a MESO QuickPlex SQ 120 (Meso Scale Discovery).  
Patient classification and chart review: Additional clinical and laboratory data were 
collected from patient charts including diagnostic test results used to identify the cause of 
neuroinflammation.  Information from patient charts was used to classify patients into larger 
diagnostic categories including viral infection, bacterial infection, malignancy, 
autoimmune/inflammatory, ‘other’, or unknown etiology.   
Data were collected for a variety of diagnostic tests including blood and CSF serology, 
PCR diagnostics, blood culture, CSF culture, serum WBC, serum creatinine, CSF WBC, CSF 
glucose, CSF protein, neuroimaging, and pathology.  The treating physicians’ notes were the 
source to determine the diagnosis in combination with supportive diagnostic test results.   
Enrollment criteria 
Participants will be included in this study if they had a CSF specimen by LP with 
adequate residual volume of uncentrifuged CSF (≥ 500μL) left over from routine testing, WBC 
count in the CSF > 5 cells/mm3, and ≥ age 18.  Previous neurologic surgery did not exclude 
patients from this pilot study.  Enrollment criteria was assessed by the research team reviewing 
the patient charts. 
Sample size determination 
This was a descriptive study utilizing residual CSF samples left over from routine clinical 
testing.  All samples available through the clinical laboratory that meet enrollment criteria were 
included in this pilot study. 
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IRB and informed consent 
Informed consent was waived for the CSF specimens used in this study.  Samples were 
left over from routine clinical testing.  The research team selected residual clinical samples based 
on enrollment criteria (CSF WBC >5 cells/mm3).  De-identified samples were tested by flow 
cytometry by the infectious disease research team.  De-identified data from the flow cytometry 
testing and patient charts were entered into the research spreadsheet.  This study was approved 
by COMIRB (protocol number 17-1811, Appendix B). 
Primary endpoint 
1. Leukocyte profile by diagnostic category (bacterial infection, viral infection, malignancy, 
autoimmune, inflammatory) in terms of proportions of 5 cell types (neutrophils, PD1- 
cytotoxic T cells, PD1+ cytotoxic T cells, Th17 cells, and B cells) between the categories.   
Secondary endpoints 
1. Establish the leukocyte profile that best characterizes each diagnostic category 
2. Explore additional inflammatory cytokines using immunoassays 
3. Clinical and laboratory parameters by diagnostic category  
4. Explore the leukocyte profile of samples with a presumed diagnosis/unconfirmed 
etiology 
Statistical analysis plan 
For the primary analysis, difference in the average proportions of each of the 5 immune 
cell subtypes between 5 diagnostic categories was analyzed using ANOVA.  This was conducted 
as 5 separate test/5 separate graphs with the 1 cell type on the y-axis and 5 diagnostic categories 
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on the x-axis.  We tested for normal distribution of the data and used non-parametric test, when 
appropriate. 
Descriptive statistics and t-tests, as appropriate, were presented for clinical and laboratory 
parameters by diagnostic category including CSF WBC, glucose, protein and neurologic deficit 
using NIH stroke scale.  A correction was not used to adjust the p-value for multiple 
comparisons because this was a descriptive pilot study with small numbers.   
Potential Pitfalls and Alternative Approaches 
Preanalytical variation due to sample acquisition and processing (transport, preparation) 
was expected, but somewhat beyond our control in this pilot study.  We collected residual 
clinical samples from the clinical laboratory as fresh as possible, transported de-identified 
samples to the infectious disease laboratory in a cooler, and processed the samples within 48 
hours of receipt in the research lab. 
The biomarker life-cycle may introduce the risk of false-positives.  This risk may vary 
depending on when the LP is performed and at what disease stage the patient presents.  This risk 
could not be mitigated in this pilot study, but could be somewhat, but not totally, mitigated by a 
well designed, prospective, controlled study.   
We collected samples consecutively from the clinical laboratory to minimize selection 
bias.  However, there was not always adequate CSF remaining after routine clinical tests were 
performed and clinical laboratory staff discarded samples instead of saving them for the research 
team in some cases.  We coordinated with the clinical laboratory staff to maximize sample 
collection for this research and minimze impact to the clinical laboratory processes which was 
most feasible for this study. 
47 
Institutional Review Board 
Clinical studies conducted as part of this research were reviewed and approved by the COMIRB 








Define the etiologies, clinical features, time to diagnosis, and outcomes of patients that 
present with cerebral spinal fluid (CSF) pleocytosis. 
Patients and Methods  
This is retrospective cohort study of patients with CSF pleocytosis, defined as WBC 
count >5 cells/mm3 in the CSF, from July 2015 to June 2016 at a large tertiary care hospital.  The 
proportion of patients within specific diagnostic categories were analyzed for differences in 
diagnostic testing and outcomes.  
Results  
Fifty-three percent of patients had neuroinflammation in the CSF due to an unknown 
etiology. The leading known cause of neuroinflammation was CNS infection (n = 43/244, 18%), 
followed by malignancy (n = 28/244, 11%).  Mean time to diagnosis was 125 days in patients 
with autoimmune neuroinflammation and was 16 days in patients with an infection or 
malignancy.  Cerebral spinal fluid parameters and peripheral white blood cell counts did not 
distinguish between categories of disease.  Cerebral spinal fluid oligoclonal bands distinguished 
autoimmune causes from other causes of CSF pleocytosis, and biopsy results distinguished 
                                                 
1 I am the author of the following work published in Clinical Neurology and Neurosurgery: 
Brown B, Fidell A, Ingolia G, Murad E, Beckham JD. Defining diagnostic approaches and 
outcomes in patients with inflammatory CSF: A retrospective cohort study. Clin Neurol 
Neurosurg. 2018;172:105-111. 
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malignancy from other causes of neuroinflammatory disease.  Neuroimaging changes were 
present in only 44% of infections but were found in 80-90% of other categories of 
neuroinflammation.  Patients presenting with a severe neurologic deficit had 22.3 higher odds of 
a severe deficit at the last neurologic assessment, and mortality was highest (29%) in patients 
with malignancy-associated neuroinflammation.  
Conclusions 
This study to defines general diagnostic categories of neuroinflammatory disease in 
patients and provides new insight on the value of specific diagnostic testing, time to diagnosis, 
and outcomes in these patient populations.  
Introduction 
Inflammation in the central nervous system (CNS), or neuroinflammation, is most 
commonly detected by finding elevated white blood cells (pleocytosis) in the cerebral spinal 
fluid (CSF).  Neuroinflammation may arise from a variety of factors including infection, 
autoimmunity, trauma, degenerative processes, toxins, malignancy, and in many cases, unknown 
causes.8,86  Regardless of the heterogeneous causes, patients with neuroinflammation or CSF 
pleocytosis can present clinically with overlapping, nonspecific symptoms and nonspecific 
laboratory parameters upon analysis of the blood or CSF.7  
Multiple infectious organisms like bacteria, viruses, fungi, and parasites can cause 
meningitis and encephalitis resulting in significant burden of disease,85,87 but non-infectious 
causes of CNS inflammation can have similar clinical presentations to infectious causes and also 
cause significant disease burden.7  The clinical presentation in patients with neuroinflammation 
can be also be mixed resulting in meningoencephalitis or encephalomyelitis.15,88,89  Recent 
advances in next-generation sequencing for pathogen detection have not provided numerous, 
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previously undiscovered pathogens in unknown cases of neuroinflammation.90  So, new 
approaches for this patient population are required to improve diagnosis and treatment.  
Patients that present to medical care with inflammation in the CSF can be complex to 
evaluate and treat due to the heterogeneity of causes that result in overlapping clinical and 
laboratory features.85  There is no clear diagnostic test for specific clinical presentations, and 
even in studies with large diagnostic panels, no underlying etiology is found in as many as 40%-
60% of patients.10-12  Given these factors, patients often experience delays in diagnosis and 
treatment or receive no diagnosis. Improving time to diagnosis may also impact utilization of 
antimicrobials, particularly in the case of presumed diagnosis.31  Additionally, in a recent study 
over a 7-year period, 81 different diagnoses were identified in patients with CSF pleocytosis 
besides unknown causes, which is a reminder to clinicians of the broad spectrum impact of 
diseases in patients who present with CSF pleocytosis indicating inflammation in the CNS.91  
This also supports the approach of narrowing patients into suspected disease categories to 
improve diagnosis of disease etiology. 
We completed a retrospective study of all patients that had a lumbar puncture upon 
presenting to a tertiary care center for acute care evaluation over a 1-year time period.  The study 
objective was to evaluate all patients with CSF pleocytosis, defined as a CSF white blood cell 
[WBC] count >5 cells/mm3, and define the underlying etiologies, predictive diagnostic 
approaches, time to diagnosis, and outcomes for these patients over a 1-year period of time.  
Patients and Methods 
Selection Criteria  
All work was reviewed and approved by the Colorado Multiple Institutional Review 
Board prior to data capture. Data were collected for patients who presented with CSF pleocytosis 
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to University of Colorado Hospital (UCH) from July 1, 2015 through June 30, 2016.  
Neuroinflammation or CSF pleocytosis was defined as CSF WBC >5 cells/mm3, reviewed all 
lumbar puncture results within the times described above, and obtained clinical data from patient 
charts that met the inclusion criteria.  This study included both inpatient and outpatient lumbar 
punctures conducted at UCH.  Patients with ventricular shunt placement or other neurological 
surgery within 3 months prior to CSF specimen collection were excluded due to the confounder 
of iatrogenic injury-related CSF pleocytosis.  
Study Endpoints 
The primary endpoint of the study was to determine the proportion of participants 
diagnosed with infection, autoimmune, malignancy, inflammatory disorder, or unknown 
etiology.  Secondary endpoints included the frequency of all known causes of 
neuroinflammation, time to diagnosis by diagnostic category, laboratory parameters between 
diagnostic categories, and clinical outcomes as measured by mortality and neurologic deficit at 
presentation and discharge.  
Collection of Data 
Patients were grouped within 1 of the following diagnostic categories for purposes of this 
research: infection, autoimmune, malignancy, inflammatory disorder, or unknown etiology. 
Patients with a diagnosis of autoimmune disease included patients with diagnoses of multiple 
sclerosis and antibody-mediated encephalitis such as anti-N-methyl-D-asparate (NMDA) 
receptor encephalitis.  Patients diagnosed with an inflammatory disease included patients with 
primary inflammatory disorders such as optic pseudotumor cerebri, optic neuritis not multiple 
sclerosis, CNS sarcoid, and dementia. Patients diagnosed with an infection or malignancy 
received a diagnosis based on isolation of a malignancy or infection from the CNS.  An ‘other’ 
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category was created to include patients with miscellaneous diagnoses such as trauma, 
intracranial and subarachnoid hemorrhage, and stroke which do not fit into the prior diagnostic 
categories.  Data were collected for a variety of diagnostic tests including blood and CSF 
serology, PCR diagnostics, blood culture, CSF culture, serum WBC, serum creatinine, CSF 
WBC, CSF glucose, CSF protein, neuroimaging, and pathology.  Data for time to diagnosis, CSF 
WBC count, and diagnostic category was recorded for all patients in the study; some data for 
other tests were missing.  The treating physicians’ notes were the source to determine the 
diagnosis in combination with supportive diagnostic test results.  Mortality was obtained, if 
available, and neurologic deficit was determined at baseline and at the last documented 
neurologic assessment in the patient chart.  Neurologic deficit was classified as none, minor, or 
severe based on altered mental status and focal neurologic deficits.  During review of chart 
reviews, we utilized the NIH Stroke scale criteria to evaluate for level of consciousness, gaze 
palsy, visual changes, facial palsy, motor or sensory changes, ataxia, or speech changes to 
determine if the patient had minor or severe neurologic deficit.  A minor deficit was defined as 2 
or fewer minor impairments in the above and severe deficit was considered >2 or severe 
impairment in the above criteria. 
If there was a questionable diagnosis, an infectious disease physician was consulted to 
clarify.  Time to diagnosis was calculated from time of presentation to UCH to time of positive 
applicable diagnostic test results.  In the case of unknown etiology, time to diagnosis was from 
time of presentation to time of last unknown diagnosis.  In many cases, this was date of 
discharge from UCH with no confirmed diagnosis.  To ensure quality control of the data, 10% of 
the data from patient charts was entered by 2 members of the research team.  There was 100% 
correlation during the quality and integrity comparison between the two reviewers. 
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Statistical Methodology 
All data were analyzed using SAS software.  Descriptive statistics are reported for the 
primary endpoint. Descriptive statistics for each diagnosis are reported for the secondary 
endpoints as well including the frequencies of all etiologic causes of neuroinflammation.  A chi-
square test was performed to evaluate the primary endpoint.  The ANOVA test was used to 
determine if there was a difference in time to diagnosis between groups.  Time to diagnosis was 
log transformed to better fit the data.  Regression was used to produce diagnostic plots and there 
were no violations of assumptions.  Additionally, t-tests were performed to identify where the 
significant differences were between each group. 
Ninety-five percent confidence intervals (CIs) were calculated for each point estimate.  
Neurologic deficit and other non-specific clinical and laboratory parameters between patients in 
each diagnostic category were evaluated in post-hoc analyses.  Neurologic deficit was classified 
as none, minor, or severe; the variable was dichotomized as none or minor/severe for analysis.  
Logistic regression was used to test the final neurologic deficit given the baseline degree of 
neurologic deficit.  
Results 
There were 1309 patients reviewed for this study who had a lumbar puncture and CSF 
analysis during the study period.  Of the 1309 patients with a CSF analysis, 306 had 
neuroinflammation.  An additional 62 patients were excluded from the study for ventricular 
shunt placement or other neurological procedure within 3 months of specimen collection.  Thus, 
a total of 244 patients were included in the primary endpoint analysis (Table 2).  
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Diagnostic Categories 
The proportion of patients in all diagnostic categories was significantly different 
(p<.0001), and over half of the patients (n = 130/244, 53%, Table 3) had CSF 
neuroinflammation due to an unknown etiology.  
The most common known cause of neuroinflammation was CNS infection (n = 43/244, 
18%).  Herpes simplex virus 2 (HSV-2) infection was the most common infection (n = 10/43, 
23% of infections) in the cohort followed by Varicella zoster virus (VZV, n = 5/43, 12%), West 
Nile virus (WNV, n = 3/43, 7%), Cryptococcus (n = 3/43, 7%), and Streptococcus pneumoniae 
(n = 3/43, 7%). 
The second most common cause of CSF neuroinflammation was malignancy (n = 28/244, 
11%), followed by other (n = 22/244, 9%), inflammatory (n = 12/244, 5%), and autoimmune 
(n = 9/244, 4%).  The leading cause of autoimmune neuroinflammatory disease was multiple 
sclerosis (n = 5) and the most common malignancy in the cohort was diffuse large B-cell 
lymphoma (n = 11) followed by metatstatic melanoma (n = 4).  The ‘other’ category diagnoses 
most commonly included stroke, trauma, and intracranial hemorrhage.  
Of the patients with CSF neuroinflammation due to an unknown etiology (n = 130/244), 
60% of cases were treated for a presumptive diagnosis without diagnostic confirmation (Table 
3).  In many cases of CSF neuroinflammation (n = 51/130, 39%) with an unknown cause, a 
presumptive diagnosis could not be obtained.  A total of 79 cases had a presumptive diagnosis 
and the majority (n = 51) were suspected infection (28 viral infection, 12 bacterial infection, and 
11 unknown infection).  
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Time to Diagnosis 
We next evaluated time to diagnosis in each diagnostic group and found that the mean 
(standard deviation [SD]; 95% CI) time to diagnosis was longest in patients with autoimmune-
associated neuroinflammation (125 days [274(SD);(CI)0, 336], Table 4).  Patients diagnosed 
with an inflammatory disease of the CNS had a mean time to diagnosis of 71 days ([111; 1, 
142]).  Mean (SD) time to diagnosis in both the infection and malignancy groups was 16 days 
(56(SD) and 32(SD) days, respectively)).  Time to diagnosis was significantly different between 
all diagnostic categories of neuroinflammation (p<.0001).  
Clinical Presentation 
There was significant overlap in clinical symptoms at presentation including headache, 
fever, altered mental status, focal neurologic deficit, and meningismus.  The most common 
symptom at presentation in the bacterial infection group was altered mental status (75%), 
whereas this symptom was less common in patients with viral infections (32%), fungal infections 
(17%), malignancy (30%), and autoimmune or inflammatory disorder (14%). Headache was the 
most common symptom at presentation in patients with a viral infection (68%) and fungal 
infection (60%); and 58% of patients with a bacterial infection, 33% of patients with a 
malignancy, and 35% of patients with an autoimmune or inflammatory disorder presented with a 
headache.  Fever was present in 45% of patients with a viral infection, 43% of patients with a 
bacterial infection, 17% of patients with a fungal infection, and 18% of patients with a 
malignancy.  Focal neurologic deficits were present in 23-42% of patients and meningismus was 
present in 15-20% of patients in all types of CNS infections.  Focal neurologic deficits were the 
most common symptom for patients with an autoimmune or inflammatory disorder (76%) and a 
malignancy (46%), while meningismus was not present in any patients in these groups. 
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Clinical Laboratory Data 
Laboratory parameters were compared by diagnostic category including peripheral white 
blood cell count (WBC), CSF WBC, CSF glucose, and CSF protein.  The infection diagnostic 
group was further characterized as viral, bacterial, fungal, or parasite.  Mean values for 
peripheral WBC were not significantly different between diagnostic groups (Figure 1).  Mean 
values from the CSF analysis are consistent with previous reports,15,32,40 and there was no 
significant difference in major CSF parameters between categories (Figure 1).  The mean CSF 
WBC count (SD) was 14 (17) in the autoimmune group, 37 (61) in the malignancy group, 2976 
(615) for patients with bacterial infections, 198 (238) for patients with viral infections, and 169 
(177) for patients with fungal infections.  The mean (SD) CSF glucose was 59 (7) for the 
autoimmune group, 63 (24) for the malignancy group, 43 (34) for patients with bacterial 
infections, 65 (47) for patients with viral infections, and 42 (32) for patients with fungal 
infections.  The mean (SD) CSF protein was 104 (159) for the autoimmune group, 166 (284) for 
the malignancy group, 451 (546) for patients with bacterial infections, 121 (80) for patients with 
viral infections, and 176 (57) for patients with fungal infections.  A significant percentage of 
cases in each diagnostic category presented with a lymphocytic predominance in the CSF 
(Figure 1).  A predominance of lymphocytes was most sensitive for autoimmune diseases 
(100%) as no autoimmune diseases in the CNS were associated with another predominant cell 
type upon CSF analysis.  CSF neutrophil predominance was common in infectious causes 
(48.4%) of disease including bacterial, fungal, and viral causes such as West Nile virus and a 
case of enterovirus CNS disease.  77.8% and 59.1% of inflammatory cases and malignancy 
cases, respectively, were associated with a lymphocytic predominance. Monocyte/macrophage 
predominance in the CSF occurred in the highest frequency of malignancy cases of 
57 
neuroinflammation (22.7%).  Unknown causes of neuroinflammation exhibited a mix of 
predominant cell types in the CSF including neutrophils (40.2%), lymphocytes (48.3%), and 
monocytes/macrophages (11.5%). 
Diagnostic Laboratory Testing Results   
When patients present with CSF pleocytosis, testing requirements for limited CSF can be 
extensive.  We next determined which diagnostic tests best distinguished between diagnostic 
groups of disease.  Serum serological testing provided a diagnosis or supported a diagnosis of 
neuroinflammation in 50% of cases due to an infection but was less sensitive in cases of 
autoimmune disease, inflammatory diseases, and malignancy (Table 5).  
In the CSF, serology and antigen testing was positive in 30% of infections, largely due to 
West Nile virus IgM testing, fungal antigen testing for Cryptococcus, or serology testing for 
Coccidioidies infection (Table 5).  In contrast, positive oligoclonal bands in the CSF were 
significantly (p=0.022) associated with distinguishing autoimmune causes of neuroinflammatory 
disease from other causes (Table 6). 85% of autoimmune causes of neuroinflammatory disease 
expressed oligoclonal bands, largely due to the diagnosis of multiple sclerosis in this cohort.   
CNS biopsy was a significant (p<0.0001) diagnostic tool in this cohort to distinguish 
malignancy as an underlying cause of neuroinflammation in 89.5% of cases from other causes of 
neuroinflammation (Table 6).  In other cases of neuroinflammation in which a biopsy was 
completed, it was positive in 27% of cases with neuroinflammtion due to an infection and only 
17.9% of unknown causes of neuroinflammation. In these cases of unknown neuroinflammation 
with a positive biopsy, nonspecific inflammatory changes were found in the meninges or nerve 
root, granulation tissue in the sella, and glial tissue with macrophages was found one case.  
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Neuroimaging Results 
In patients with CSF pleocytosis, neuroimaging is commonly obtained and interpreted in 
the diagnostic work up.  In the cohort of patients with known causes of neuroinflammation, 
neuroimaging studies, most commonly MRI, were obtained in 96 cases of neuroinflammation 
during the initial evaluation.  Of these cases, neuroimaging was most commonly abnormal in 
patients with underlying malignancy in 90.5% (n=19 positive results) of malignancy cases.  
Neuroimaging changes in cases of malignancy was more common than neuroimaging 
abnormalities in patients with infection-related CSF pleocytosis (43.9%, n=18, p=0.0002).  
Neuroimaging was also positive in the majority of cases of autoimmune disease (83.3%, n=5) 
and inflammatory disease in the CNS (88.9%, n=8).  The diversity of neuroimaging 
abnormalities was broad in this neuroinflammatory cohort supporting the need for MRI studies 
with and without contrast (Figure 2) to appropriately evaluate this patient population.  
Outcomes 
Mortality was highest in the malignancy group at 29%, 7% in the infection group and 5% 
in the unknown group (Table 7).  
Overall, patients with severe neurologic deficits at presentation had 22.29 (95% CI: 7.65, 
64.98) higher odds of a severe deficit at the last neurologic assessment (p<0.0001).  Severe 
neurologic deficits were noted in 28 patients at presentation and 23 patients at the last neurologic 
assessment.  Seventeen percent of patients with CNS infection had a severe neurologic deficit at 
presentation which decreased to 3% with a severe deficit at the last neurologic assessment.  
Eleven percent of patients with neuroinflammation from malignancy had a severe neurologic 
deficit at presentation that increased to 19% at the last neurologic assessment (Table 7).  
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Discussion 
This study further highlights that patients that present to medical care with inflammation 
in the CSF can be complex to evaluate due to the heterogeneity of causes that result in 
overlapping clinical and laboratory features.  In our cohort of patients, over half of the patients 
had disease from an unknown etiology (53%) causing neuroinflammation in the CNS, and about 
60% of those patients received a presumptive diagnosis.  This is consistent with previous reports 
in which approximately 60% of encephalitis cases were undiagnosied.10-12,29,30  The California 
Encephalitis Project was a large study of suspected encephalitis (n = 1570) over 7 years which 
aimed to identify the etiology of encephalitis cases; however, 63% of cases had unexplained 
etiology in the study despite a large panel of studies to identify an underlying cause.10,13  Our 
study adds to the existing literature since we evaluated all patients with neuroinflammation, 
defined distinguishing diagnostic testing, and defined outcomes related to underlying diagnostic 
grouping.  Since clinicians evaluate patients with neuroinflammation and then recommend 
diagnostic testing based on clinical features, it is important to understand the underlying causes, 
diagnostic testing, and outcomes of these patients as a group.  
Infection was the most common confirmed underlying etiology of neuroinflammation.  
Virus infection was the leading infectious cause of neuroinflammatory disease (n = 22, 51% of 
infections) followed by bacterial infections (n = 14, 33%).  This is similar to prior studies that 
found a causative pathogen in 16% of cases and 69% were viral while 20% were bacterial.10,13  
Encephalitis due HSV type 1 accounts for 10% to 20% of cases of viral encephalitis cases 
worldwide,92 and mortality from acute HSV encephalitis is 20-50%.54  However, HSV type 2 
most commonly causes meningitis in adults,85 and we found that HSV-2 was the most commonly 
identified pathogen (n = 10, 23%) in our cohort. 
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This study observed that no clear diagnostic test exists for specific clinical presentations, 
and a high frequency of patients with no known cause of neuroinflammation present in medical 
practice.  Current standard practice utilizes various laboratory results to place patients into 
diagnostic categories.  We extend these data by identifying the utility of specific tests in their 
ability to differentiate between causes of neuroinflammation.  In our cohort, peripheral testing 
such as serum WBC or serum serology did not significantly differentiate between diagnostic 
groups.  While CSF analysis of patients in this cohort was consistent with prior studies,15,32,40 
there was significant overlap in the CSF parameters which implies that routine use of CSF 
parameters alone may not aide clinicians in defining categories of diagnosis (Figure 1).  A recent 
study evaluated categories of CNS disease in patients with CSF pleocytosis in a large cohort of 
patients with known infection and other causes.91  The study describes characteristics of CSF 
pleocytosis in different categories of neuroinflammation which agree with our findings, but the 
study did not evaluate diagnostic approaches in these cases.  Additionally, clinical symptoms at 
presentation were nonspecific for infection type.  Our data provide a picture of comprehensive 
diagnostic approaches for patients with neuroinflammation and provide data on the usefulness of 
specific testing in these cases.  
For example, CSF testing for oligoclonal bands was significantly predictive of 
autoimmune disease in patients presenting with CSF pleocytosis.  While these results may have 
been biased towards multiple sclerosis in our small cross-section of autoimmune disease, these 
data suggest that CSF testing for oligoclonal bands can help to differentiate autoimmune diseases 
from other causes of CSF pleocytosis.  Similarly, CSF PCR testing for viral infections was very 
sensitive and specific.  Given that neuroimaging was positive in a minority of CNS infection 
cases, it is important to keep a large differential diagnosis for possible underlying viral causes of 
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disease.  This highlights the importance of recent multiplexed CSF PCR assays93 to improve 
consistent evaluation of a core set of viruses that commonly cause CNS disease.  Additionally, 
CNS biopsy provided significant differentiation between malignancy and other causes of CNS 
pleocytosis.  These data support the use of CNS biopsy in the evaluation of neuroinflammation 
cases, especially in cases where malignancy is in the differential.  
These data also support the importance of neuroimaging during an initial evaluation in 
patients with CSF pleocytosis.  Major causes of neuroinflammation including autoimmune 
etiologies, inflammatory etiologies, and malignancy commonly have significant abnormalities on 
neuroimaging.  However, infectious causes of CSF pleocytosis exhibited neuroimaging changes 
in only 44% of cases. Additionally, neuroimaging results provide vital data on CNS lesion 
architecture, complications, and location (Figure 2) which can guide diagnostic testing.   
This study also highlights variability in time to diagnosis for specific groups of patients 
with neuroinflammation.  While diagnostic tests for infections are well developed and 
comprehensive for the major causes of disease, diagnostics for other important causes of CSF 
neuroinflammation are less well-defined resulting in prolonged time to diagnosis.  For example, 
patients with autoimmune causes of CSF neuroinflammation have similar clinical presentations 
and CSF parameters to some patients with virus infection.  In many clinical cases, physicians 
wait for a variety of clinical tests to “rule out” infection as well.  This common approach along 
with non-standardized ordering of tests for CSF pleocytosis resulted in a mean time to diagnosis 
of 125 days in the patients with autoimmune causes of CSF neuroinflammation.  
There were 48 different diagnoses besides unknown and ‘other’ causes in the 244 patients 
with CSF pleocytosis in this study.  The diversity of etiologic causes of inflammation in the CNS 
observed in this study is consistent with previous studies in this patient population which have 
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also reported a large number of different diagnoses and high frequency of patients receiving no 
diagnosis at all.10,13,91  There is a need for diagnostic pathways that rapidly provide a diagnosis in 
an unbiased manner and improve outcomes for patients presenting with neuroinflammation.  
Specifically, research including multiplex diagnostic panels, novel biomarkers, and more 
standardization of the diagnostic pathway is urgently needed to improve diagnosis and treatment 
of specific causes of neuroinflammation.  
This is a retrospective, single-center cohort study, thus only existing data for patients 
could be collected and overall numbers analyzed are limited.  All patients did not have the same 
routine tests performed for comparison and there were no samples to test in the event of an 
unclear diagnosis.  The amount of red blood cells in the CSF sample was not included in the 
dataset; thus, CSF WBC count was not corrected for blood contaminated samples.  Additionally, 
data for erythrocytes sedimentation rate and C-reactive protein was not collected. 
There also may be overlap in mechanisms of neuroinflammation between the 
autoimmune and inflammatory groups.  Thus, these groups may be difficult to differentiate 
without using more advanced immune phenotyping testing.  Considerations should be made 
about leading causes of disease at each institution because the causes of CSF pleocytosis may 
vary by region. 
Conclusions 
Clinicians that evaluate patients with a neurologic syndrome and neuroinflammation are 
challenged with diverse underlying etiologies of disease and a high frequency of patients with no 
known cause of neuroinflammation.  The poorly developed diagnostic pathway for these 
complex patients resulted in a prolonged mean time to diagnosis of >16 days in all categories of 
disease, except the other category of disease with a mean time to diagnosis of 6 days.  Specific 
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testing including oligoclonal bands, CSF PCR testing for viral infections, neuroimaging, and 
CNS biopsy provided important diagnostic information in many of the cases of 
neuroinflammation.  Despite aggressive work up, a significant number of patients receive no 
diagnosis and the mortality rate in this group is 5%.  Further research including multiplex 
diagnostic panels, novel biomarkers, and more standardization of the diagnostic pathway is 
urgently needed to improve diagnosis and treatment of specific causes of neuroinflammation.  
Table 2: Demographics (age, sex, ethnicity) by Diagnostic Category 
Category Age: Mean(SD) Sex: N (%) Ethnicity: N (%) 
Autoimmune 44.8 (23.95) F- 7 (78 %) 
M- 2 (22%) 
Hispanic: 1 (11%) 
NonHispanic: 8 (89%) 
Infection  47.1 (20.32) F- 19 (44%) 
M- 24 (56%) 
Hispanic: 8 (19%) 
NonHispanic: 34 (79%) 
Unknown: 1 (2%) 
Inflammatory  44 (14.43) F- 6 (50%) 
M- 6 (50%) 
Hispanic: 4 (33%) 
NonHispanic: 8 (67%) 
Malignancy 55.3 (13.37) F- 10 (36%) 
M- 18 (64%) 
Hispanic: 3 (11%) 
NonHispanic: 24 (86%) 
Unknown: 1 (4%) 
Other  41.3 (21.17) F- 8 (36%) 
M- 14 (64%) 
Hispanic: 7 (32%) 
NonHispanic: 15 (68) 
Unknown  44.6 (22.61) F- 66 (51%) 
M-64 (49%) 
Hispanic: 24 (19%) 
NonHispanic: 103 (80%)  
Unknown: 2 (2%) 
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Table 3: Disease Etiology by Diagnostic Category 
Category of Diagnosis Frequency (n) Percent (%) 
 
Autoimmune 9 4 
Infection - Total 
    Infection – Viral 
    Infection – Bacterial 
    Infection – Fungal 











Inflammatory 12 5 
Malignancy 28 11 
Other 22 9 
Unknown 130 53 
 Unknown/Presumptive 
Category of Diagnosis 
Frequency (n) Percent (%) 
Infection – Total 
    Infection – Viral 
    Infection – Bacterial 









Autoimmune 10 8 
Malignancy 4 3 
Inflammatory 3 2 
Other 10 8 
Unknown 51 40 
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Lower 95% CL  Upper 95% CL N 
Autoimmune 125.3 274.2 0 336.1 9 
Infection 15.6 55.7 0 32. 8 43 
Inflammatory 71.5 111.0 1.0 142.0 12 
Malignancy 16.3 31.8 4.0 28.7 28 
Other 6.3 23.6 0 16.8 22 
Unknown 30.3 83.2 15.8 44.7 130 
 
Table 5: Positive Serology & Antigen Testing  
Serum Testing Frequency of Positive (n) Percent (%) 
Autoimmune 1 16.7 
Infection 16 50 
Inflammatory 2 25 
Malignancy 4 28.6 
CSF Testing Frequency of Positive (n) Percent (%) 
Autoimmune 1 25 
Infection 6 30 
Inflammatory 0 0 
Malignancy 0 0 
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Table 6: Positive CSF Testing for Oligoclonal Bands and CNS Biopsy Results 
Positive CSF Oligoclonal 
Bands 
Frequency of Positive (n) Percent (%) 
Autoimmune 6 85.7 
Infection 2 16.7 
Inflammatory 4 50 
Malignancy 1 25 
Positive CNS Biopsy 
Results 
Frequency of Positive (n) Percent (%) 
Autoimmune 0 0 
Infection 3 27.3 
Inflammatory 0 0 
Malignancy 17 89.5 
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Table 7: Neurologic Deficit and Case Fatality Rate 
 Frequency of Death (n) Percent (%) 
Autoimmune 0 0 
Infection 3 7 
Inflammatory 1 8.3 
Malignancy 8 28.6 
Other 1 5 
Unknown 7 5.4 
 
 
Neurologic deficit at presentation (n) 
 Autoimmune Infection Inflammatory Malignancy Other Unknown  
None 2 23 4 13 11 60 
Minor 6 11 6 11 4 55 
Severe 1 7 2 3 3 12 
Neurologic deficit at final assessment (n) 
None 2 30 4 15 8 90 
Minor 6 9 6 7 4 27 





Figure 1. Mean Peripheral WBC and CSF Parameters for Each Diagnostic Category. 
Results from A) Peripheral white blood cell counts, B) CSF WBC, C) CSF protein and D) CSF 
glucose in each diagnostic category.  E) Percent of cases in each diagnostic category exhibiting a 




Figure 2. Neuroimaging Results. 
Neuroimaging Results in each diagnostic group.  A) MRI image of T2, hyperintense lesions in 
white matter consistent with multiple sclerosis.  White arrow indicates lesion.  B) MRI image 
showing a T1 post-gadolinium contrast ring-enhancing lesion with surrounding edema consistent 
with the diagnosis of toxoplasmosis.  C) MRI image showing T2 hyperintense lesions within 
bilateral optic nerves most pronounced in orbital apices and optic canals consistent with the 
diagnosis of isolated bilateral optic neuritis.  D) Dominant focal MRI T2 FLAIR signal 
abnormality in the right parietal cortex consistent with the diagnosis of CNS lymphoma.  
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CHAPTER IV 
INFECTIOUS CAUSES AND OUTCOMES IN PATIENTS WITH CEREBRAL SPINAL 
FLUID PLEOCYTOSIS 
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Abstract 
Objective  
Evaluate the infectious etiologies, clinical features, and outcomes of patients with CNS 
infections at a tertiary care center. 
Methods 
Patients with neuroinflammation or CSF pleocytosis, defined as WBC count >5 
cells/mm3 in the CSF, from July 2015 to June 2016 at a large tertiary care hospital were 
analyzed for this report.  Data from patients with confirmed (n = 43) and presumed (n=51) CNS 
infections were analyzed.  
Results 
CNS infection was the leading known cause of CSF pleocytosis (n = 43, 18% of all 
patients with CSF pleocytosis) and HSV-2 was identified as the leading causative pathogen 
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(n = 10) followed by VZV (n = 5).  CNS infection was presumed in 51 patients (21% of patients 
with CSF pleocytosis).  Mean time to diagnosis for patients with confirmed CNS infection was 
16 days but was highly variable depending on the causative pathogen.  Common pathogens were 
detected in the CSF in an average of 5 days, whereas less common pathogens took an average of 
30 days to detect.  There was significant overlap in CSF parameters and peripheral white blood 
cell counts for viral, bacterial, fungal and parasite infections.  Neuroimaging changes were 
present in only 44% of CNS infections.  Overall mortality was 7% for CNS infections and 17% 
of patients with CNS infection had a severe neurologic deficit at presentation while only 3% had 
a severe deficit at the last neurologic assessment.  
Conclusions 
This study quantifies the frequency of infectious causes of disease in the CNS in a cohort 
of patients as well as the laboratory features and outcomes of CNS infections and serves as a 
reminder to clinicians of what to expect for patients who present with CSF pleocytosis indicating 
inflammation in the CNS. 
Introduction 
Infection is the leading cause of inflammation in the central nervous system (CNS) 
leading to patients presenting with cerebral spinal fluid (CSF) pleocytosis or 
neuroinflammation.13  Many different organisms can cause CNS infection that can result in 
meningitis, encephalitis, or myelitis.  In some studies, approximately 20% of suspected cases 
were found to have a non-infectious cause and in all cases of suspected encephalitis, the etiology 
was unknown in approximately 60% of cases.10  Notably, recent advances in next-generation 
sequencing for pathogen detection have not provided numerous, previously undiscovered 
pathogens in unknown cases of neuroinflammation.  Infection in the CNS is commonly 
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suspected with elevated white blood cells (pleocytosis) in the cerebral spinal fluid (CSF).  
Neuroimaging and lumbar puncture (LP) to obtain CSF for analysis is important in the diagnostic 
pathway for CNS infections and clinical features may direct clinicians to test for specific 
etiological agents.16,37  When patients present with a possible CNS infection, a specific diagnosis 
can be critical to improve outcomes.  In studies of bacterial meningitis, a 3-hour delay in 
antibiotic administration for pneumococcal meningitis was independently associated with an 
increase in 3-month case fatality rate.38  Other studies have shown that diagnostic capacity of the 
treating hospitals determines early diagnosis and outcomes of patients with CNS infections.25,26,37 
Multiple infectious organisms like bacteria, viruses, fungi, and parasites can cause 
meningitis or encephalitis and can contribute to a significant burden of disease.85,87  Viral 
infections in the CNS are the major cause of aseptic meningitis which is more common but often 
less severe than bacterial meningitis.  The CFR for meningococcal disease can be as high as 70% 
without treatment but death from viral meningitis is rare.52  For bacterial meningitis, rapid 
initiation of antimicrobial therapy provides the best outcomes and current guidelines recommend 
initiation of antimicrobial therapy prior to specific identification of the causative pathogen to 
prevent complications.27  However, initiation of antimicrobial therapy prior to CSF analysis can 
increase the likelihood of false-negative CSF culture results as well.16,28 
Patients that present to medical care with CSF pleocytosis can be complex to evaluate 
and treat due to the heterogeneity of causes that result in overlapping clinical and laboratory 
features.85  Due to significant overlap in clinical presentations, there is no clear diagnostic test 
for specific clinical presentations of CSF pleocytosis.  Additionally, immunocompromised 
patients may not present with classic clinical symptoms from infection, are more susceptible to 
CNS infection, and can be more challenging to evaluate due to the broad differential diagnosis.15  
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Despite large testing panels in several studies evaluating causes of encephalitis, no underlying 
etiology is found in as many as 40%-60% of patients.10-12  These studies imply that additional 
pathogen specific diagnostic approaches may not result in additional progress in diagnosing 
causes of CSF pleocytosis in patients. Instead, rapid diagnosis of common infections using 
multiplex CSF testing platforms may improve time to diagnosis of common infections. In order 
to develop rapid, multiplex tests, studies evaluating the frequency, time to diagnosis and 
outcomes of infectious causes of pleocytosis need to be completed in adults. 
We evaluated a cohort of patients who presented with a CSF pleocytosis which was 
defined as a CSF white blood cell (WBC) count >5 cells/mm3 and had a LP upon presenting to a 
tertiary care center for initial evaluation over 1-year period.  The aim of the study was to define 
the frequency of specific infectious causes of CSF pleocytosis, time to diagnosis, and outcome of 
infection.  We also compared clinical and laboratory parameters between infection type for 
confirmed infectious causes of neuroinflammation.  In patients with CSF pleocytosis, we found 
that viral and bacterial causes of CNS infection are the most common causes of disease and that 
diagnostic delays were significant even for common pathogens of the CNS.  Mortality was less 
than 10% in all diagnostic groups and neurologic deficits significantly improved from 
presentation in all diagnostic groups.  Taken together, these data provide important insight into 
common and uncommon pathogens that cause disease in patient presenting with a CSF 
pleocytosis and highlight the need for improved rapid tests that shorten time to diagnosis. 
Methods 
Selection Criteria  
This is a retrospective clinical trial that evaluated all patients that presented to the 
University of Colorado Hospital (UCH) with CSF pleocytosis.  All work was reviewed and 
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approved by the Colorado Multiple Institutional Review Board prior to data capture.  Data were 
collected for patients who presented to UCH from July 1, 2015 through June 30, 2016 with CSF 
pleocytosis, defined as CSF WBC >5 cells/mm3.  We reviewed all LP results within the times 
described above and obtained clinical data from patient charts that were diagnosed with an 
infection in the CNS.  Patients with ventricular shunt placement or other neurological surgery 
within 3 months prior to CSF specimen collection were excluded due to the confounder of 
iatrogenic injury-related CSF pleocytosis and opportunity for direct inoculation.   
Collection of Data 
A definitive diagnosis of a CNS infection was based on isolation of a pathogen from the 
CSF or a positive diagnostic test in the CSF for a specific pathogen.  Data were collected for a 
variety of diagnostic tests including serum and CSF serology, PCR diagnostics, blood and CSF 
culture, serum and CSF WBC, serum creatinine, CSF glucose, CSF protein, neuroimaging, and 
pathology.  The treating physicians’ notes were the source to determine the diagnosis in 
combination with supportive diagnostic test results.  Mortality was obtained, if available, and 
neurologic deficit was determined at baseline and at the last documented neurologic assessment 
in the patient chart.  Neurologic deficit was classified as none, minor, or severe based on altered 
mental status and focal neurologic deficits.  During review of chart reviews, we utilized the NIH 
Stroke scale criteria to evaluate for level of consciousness, gaze palsy, visual changes, facial 
palsy, motor or sensory changes, ataxia, or speech changes to determine if the patient had minor 
or severe neurologic deficit.  A minor deficit was defined as 2 or fewer minor impairments in the 
above and severe deficit was considered >2 or severe impairment in the above criteria. 
If there was a questionable diagnosis, for example if multiple pathogens were detected in 
the CSF and the primary causative pathogen was not clearly documented in the patient chart, a 
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neurology or infectious disease physician was consulted to confirm the diagnosis.  Time to 
diagnosis was calculated from time of presentation to UCH to time of positive diagnostic test 
results.   
Statistical Methodology 
All data were analyzed using SAS software.  Descriptive statistics are reported for 
clinical and laboratory parameters associated with confirmed CNS infections in this cohort of 
patients.  A t-test was performed to evaluate the difference in time to diagnosis between common 
and uncommon confirmed causes of CNS infection.  Neurologic deficit was classified as none, 
minor, or severe; the variable was dichotomized as none or minor/severe for analysis.  Logistic 
regression was used to test the final neurologic deficit given the baseline degree of neurologic 
deficit between confirmed CNS infection type.   
Results 
There were 1309 patients reviewed in the cohort who had a LP and CSF analysis over 1 
year.  Of the 1309 patients with a CSF analysis, 306 patients had CSF pleocytosis.  Sixty-two 
patients were not evaluated because they had ventricular shunt placement or other neurological 
procedure within 3 months of specimen collection.  Thus, a total of 94 patients met inclusion 
criteria and had a confirmed or presumptive diagnosis of CNS infection (Figure 3); 43 had 
confirmed CNS infection, and 51 had presumed CNS infection.  All fungal infections occurred in 
males, while 43% of bacterial and 55% of viral infections were in males.  The mean age ranged 
from 33 (parasite infection) to 50 (viral infections) and the majority of all patients with CNS 
infection were non-Hispanic (Table 8).   
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Confirmed and Presumptive CNS Infections 
There were 43 confirmed CNS infections over 1 year.  Viruses were the leading cause of 
CNS infection (n = 22), followed by bacterial (n = 14), fungal (n = 6), and parasitic (n = 1) 
causes of disease.  Herpes simplex virus 2 (HSV-2) was the most common infection (n = 10/43, 
23% of infections) followed by infections due to Varicella zoster virus (VZV, n = 5/43, 12%), 
West Nile virus (WNV, n = 3/43, 7%), Cryptococcus neoformans (n = 3/43, 7%), and 
Streptococcus pneumoniae (n = 3/43, 7%) (Table 9).   
A total of 51 CSF pleocytosis cases of unknown etiology were treated presumptively as a 
CNS infection (28 viral infections, 12 bacterial infections, and 11 unknown infections).  Of note, 
the specific etiology was not identified in cases with a presumptive diagnosis; rather, patients 
were presumed to have a diagnosis such as aseptic meningitis based on clinical and laboratory 
data such as CSF parameters.   
Clinical Laboratory Data 
Laboratory parameters were reviewed including peripheral WBC, CSF WBC, CSF 
glucose, and CSF protein (Table 10).  CNS infections were grouped by categories of disease 
including viral, bacterial, fungal, or parasitic organisms.  Mean values from the CSF analysis are 
consistent with previous reports.15,32,40  The mean CSF WBC count (SD) was 2976 (615) for 
patients with bacterial infections, 198 (238) for patients with viral infections, and 169 (177) for 
patients with fungal infections.  The mean (SD) CSF glucose was 43 (34) for patients with 
bacterial infections, 65 (47) for patients with viral infections, and 42 (32) for patients with fungal 
infections.  The mean (SD) CSF protein was 451 (546) for patients with bacterial infections, 121 
(80) for patients with viral infections, and 176 (57) for patients with fungal infections.  The 
differential of WBCs in the CSF was variable between infections.  Lymphocytes predominated in 
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all cases of HSV-2 infection, neutrophils predominated in all cases of Streptococcus pneumonia 
and Methicillin-resistant Staphylococcus aureus (MRSA) infection, and lymphocytes 
predominated in the 2 cases of Cryptococcus infection.  In the single case of Cryptococcus 
infection, neutrophils were the predominant cell type (Table 14). 
Other Diagnostic Testing Results   
Serum serological testing provided a diagnosis or supported a diagnosis of 
neuroinflammation in 50% of cases due to an infection.  In the CSF, serology or antigen testing 
were positive in 30% of infections, largely due to WNV IgM testing and fungal antigen testing 
for Cryptococcus or serology testing for Coccidioidies immitis infection.  
For cases in which a biopsy was completed (11/43, 26%), it was positive in 27% (n = 3) 
of cases with CSF pleocytosis due to an infection.  One case with WNV infection had ulcerated 
skin lesions with underlying deep tissue necrosis and acute inflammation revealed by biopsy, and 
one case had invasive fungal sinusitis with associated acute inflammation and necrosis caused by 
aspergillus fumigatus and biopsy revealed diagnostic information.  Generally, biopsy of patients 
with a CNS infection revealed pathologic evidence of necrosis and was non-specific. 
Neuroimaging Results 
In patients with CSF pleocytosis, neuroimaging is commonly obtained and interpreted in 
the diagnostic work up.  In this cohort of patients, neuroimaging was obtained in 38/43 patients 
with confirmed CNS infections and abnormalities were detected in 37% of patients with 
infection (n=14).  When obtained, neuroimaging was abnormal in 6/13 bacterial infections, 4/5 
fungal infections, 3/19 viral infections, and 1/1 parasite infection.  The diversity of neuroimaging 
abnormalities was broad.  In the case of toxoplasmosis infection, MRI and positive IgG serology 
for toxoplasmosis in the serum were suggestive of the infection in the CNS and the patient 
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responded to anti-toxoplasmosis therapy.  In the case of toxoplasmosis, neuroimaging revealed 2 
dominant ring enhancing lesions in the right parietal and left frontal lobes with significant edema 
and 2 bilateral temporal lobe punctate enhancing lesions in the case of toxoplasmosis infection in 
the CNS.  In most cases of CNS viral infection, neuroimaging was often not diagnostic and did 
not contribute to the diagnosis in the cases of meningitis.   
Time to Diagnosis and Outcomes 
Mean (SD) time to diagnosis in patients with confirmed CNS infections was 16 days (32 
days). Time to diagnosis was shorter in patients with more common CNS infections (p = 0.019, 
Table 11).  We grouped patients in Panel A or Panel B to evaluate the time to diagnosis for 
common versus less common causative pathogens, respectively.  Patients with Haemophilus 
influenzae, Streptococcus pneumonia, cytomegalovirus (CMV), Enterovirus, HSV-2, 
Cryptococcus, Coccidioides immitis, or VZV (Panel A) were diagnosed in an average of 5 days; 
whereas, it took an average of 30 days to diagnose patients with neurosyphilis, MRSA, WNV, 
Enterobacter cloacae, Propionibacterium acnes, Streptococcus anginosus, Toxoplasma, 
Aspergillus Fumigatus, Coxiella burnetti, Streptococcus agalactiae (Group B Streptococcus), 
Ebstein-barr virus (EBV), or Candida albicans (Panel B). While common pathogens were 
diagnosed significantly more rapidly than uncommon pathogens, the mean time to diagnosis was 
5 days. Indicating that rapid, multiplex diagnostic approaches for common pathogens may 
improve time to diagnosis and improve initiation of appropriate therapy. 
Seventeen percent of patients with CNS infection had a severe neurologic deficit at 
presentation while only 3% had a severe deficit at the last neurologic assessment (Table 12).  
Seven patients with CNS infections presented with severe neurologic deficits at baseline.  In 5 of 
these 7 cases, bacterial meningitis was the cause of CNS infection.  The other 2 cases with severe 
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neurologic deficits were in patients with a parasitic (Toxoplasmosis) and viral cause of disease 
(encephalitis).  Neurologic deficits completely resolved in 3 of these 7 patients (MRSA, 
Streptococcus pneumoniae, and toxoplasmosis), minor deficits were present at the last 
neurologic assessment in 2 patients (Haemophilus influenzae and Streptococcus pneumoniae) 
and 2 patients died prior to discharge (Enterobacter cloacae and EBV with subsequent 
lymphoma).  All-cause mortality was 7% for patients with a CNS infection (Table 13).   
Discussion 
These data provide important information on diagnostic approaches and outcomes for 
patients that present with a CSF pleocytosis caused by an infection.  Importantly, there were 21 
different diagnoses of CNS infection.  Herpes virus infections, HSV-2 and VZV, were major 
causes of disease in this study, representing 35% of total infectious causes.  Interestingly, 
enteroviruses were not a major cause of disease in this cohort of patients with only two cases 
over a one-year period but this may represent a referral bias since many of the patients in tertiary 
care centers are referred in due to complex disease.  A previous 7-year encephalitis study 
identified EBV as the leading infectious causes of disease, so referral patterns likely play a role 
in a specific center’s common causes of CSF pleocytosis.13  In our study, viral infection was the 
leading cause of CNS infection (n = 22, 51% of infections) followed by bacterial infections (n = 
14, 33%).  This is similar to prior encephalitis and CNS infection studies that found a causative 
pathogen in 16% of cases and 69% were viral while 20% were bacterial.10,13  Encephalitis due 
HSV- 1 accounts for 10% to 20% of cases of viral encephalitis cases worldwide,92 and mortality 
of acute HSV encephalitis is 20-50%,54 while HSV- 2 most commonly causes meningitis in 
adults.85  We found that HSV-2 was the most commonly identified pathogen (n = 10, 23%) in 
this cohort of patients.  We also had 2 additional cases of EBV PCR positive CSF and both cases 
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were eventually diagnosed with lymphoma.  These data are consistent with prior reports that 
EBV encephalitis in adults is relatively rare, while lymphoma is common.  Thus, a detectable 
EBV PCR in the CSF should initiate an intensive evaluation for lymphoma or related 
malignancies prior to making a diagnosis of EBV encephalitis.  
Over the one-year study, there were 5 cases of VZV disease and all were diagnosed using 
CSF PCR.  Prior data suggest that CSF IgG synthesis is a sensitive marker of VZV infection in 
the CSF.94  In our cohort, VZV PCR of the CSF identified the pathogen causing CSF pleocytosis 
but most of the cases were likely meningitis cases since neuroimaging was negative in 4 of the 5 
cases.  Thus, CSF IgG synthesis studies may provide increased sensitivity for VZV encephalitis, 
which is more consistent with the vasculopathy-related lesions commonly noted in this 
infection.94 
In this cohort of patients, pneumococcus and Staphylococcus aureus were equally 
represented.  While the numbers are small in this cohort, the data support the increasing 
importance of staphylococcus as a cause of acute bacterial meningitis in adults.  A recent study 
in Denmark of infectious meningitis found that Staphylococcus aureus was the second most 
common cause of community acquired bacterial meningitis in adults after Streptococcus 
pneumoniae infections.95  
In this study, laboratory parameters from serum and CSF tests exhibited significant 
overlap.  Current standard practice utilizes CSF parameters such as WBC, protein, and glucose to 
guide diagnosis.  CSF analysis of patients in this cohort was consistent with prior studies;15,32,40 
however, there was significant overlap in the CSF parameters between patients with CNS 
infections which implies that routine use of CSF parameters alone may not aide clinicians in 
defining categories of diagnosis (Table 10).  Prior studies suggest that a CSF WBC count >1,000 
81 
cells/mm3 is consistent with bacterial infections in the CNS, and this cohort of patients with 
bacterial infection in the CNS exhibited an average (SD) CSF WBC count of 2,976 cells/mm3. 
Typically, a CSF WBC count <1,000 cells/mm3 is thought to be suggestive of viral infections 
and <500 cells/mm3 is suggestive of a malignancy, autoimmune disease, or a fungal infection in 
the CNS.  The average observed CSF WBC count for viral and fungal infections were all <200 
cells/mm3 and all exhibited lymphocyte predominant CSF WBC differentials.  While classic CSF 
parameters such as WBC count and differential help with focused diagnostic testing, relying on 
these tests to rule out use of specific diagnostic testing may lead to a missed diagnosis.  In 
patients that present with a possible infection of the CSF and a pleocytosis, the major clinical 
challenge remains the large number of etiologic causes and diagnostic testing for infectious and 
non-infectious causes as well as lack of clear clinical parameters to guide complex diagnostic 
ordering.   
Recent and important work in the development of multiplex CSF arrays have been 
reported to help standardize testing and decrease turnaround time for test results.18  In this study, 
we evaluated time to diagnosis of common organisms included in a commercially available rapid 
testing CSF array (Panel A, Table 11) and found a mean time to diagnosis of 5 days for 
organisms not included in the CSF array panel compared to 30 days for uncommon organisms 
included in this diagnostic array (Panel B, Table 11).  The PCR array was not used in this study; 
thus, it did not influence time to diagnosis.  While challenges remain regarding diagnostic 
sensitivity and specificity of multiplex PCR platforms, development and use of a panel that is 
more specific for common adult pathogens may have a significant impact on time to diagnosis 
for common pathogens.  
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In this cohort, we also evaluated outcomes in patients with CNS infections.  Seventy-four 
percent of patients with bacterial meningitis presented with minor or severe neurologic deficits.  
At the final recorded assessment, 41% of patients with a diagnosis of bacterial meningitis still 
met criteria for a minor or severe neurologic deficit implying that long term morbidity is still a 
problem for these patients despite a relatively low mortality rate of 7% in this cohort.  In the case 
of viral CNS infections, 63% of patients had no neurologic deficit upon initial evaluation and 
76% exhibited no deficit at the final evaluation.  The viral cases of CNS infection associated 
with neurologic deficits and mortality were all consistent with encephalitis cases. A recent study 
evaluated outcomes in adults with HSV and VZV-related CNS disease and found that 16% of 
patients with encephalitis had an adverse clinical outcome and also found that patients with HSV 
meningitis had positive outcomes.96  
The strengths of this study include the longitudinal, unbiased selection and analysis of a 
cohort of patients at a large tertiary care center with a large catchment area in the Rocky 
Mountain region.  The data were collected at 1 hospital over 1 year and capture all patients who 
had CSF pleocytosis during the time period to minimize selection bias.  The breadth of data 
collected allow for a complete analysis of infections in the CNS and related outcomes.  The 
limitations of the study include the single-center, retrospective design.  Also, the data may 
include referral bias of complex cases since more routine care of CNS infections may occur in 
the community without referral, while more complex cases in the community often get referred 
early to the study site.  Thus, the data may be biased toward more complex disease and some 
more common community-acquired cases like enterovirus CNS infection may be 
underrepresented in this cohort.  There are also regional differences in the presentation of cases 
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like WNV, Lyme disease, or endemic mycosis that may limit the generalizable nature of the 
diagnostic patters found in this cohort.  
Conclusions 
Clinicians that evaluate patients with a neurologic syndrome and CSF pleocytosis are 
challenged with diverse underlying etiologies of disease and a high frequency of patients with no 
known cause of neuroinflammation.  Considerations should be made about leading causes of 
disease at each institution because the causes may vary by region.   Additional development of 
multiplex diagnostic CSF testing may improve time to diagnosis in these cases and decrease the 
number of missed diagnoses because a test is not submitted for analysis. 










Age 46 (23.8%)  42 (21.1%) 33 50 (18.6) 
Sex 
M- 6 (42.9%) 
F- 8 (57.1%) 
M- 6 (100%) F- 1 (100%) 
M- 12 (54.6%) 
F- 10 (45.5%) 
Ethnicity 
Hispanic- 3 (21.4%) 
Non-Hispanic- 11 
(78.6%) 
Hispanic- 2 (33.3%) 
Non-Hispanic- 4 
(66.7%)   
Non-Hispanic- 1 
(100%) 
Hispanic- 3 (13.6%) 
Non-Hispanic- 18 
(81.8%) 
Refused – 1 (4.6%) 
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Table 9: All Confirmed Infections in the Central Nervous System 
Diagnosis Count Percentage Confirmatory Diagnostic Test(s) 
Herpes Simplex type-2 10 23% 
HSV-2 was detected in the CSF by PCR in all 
confirmed cases 
Varicella Zoster virus 5 12% 
VZV was detected in the CSF by PCR in all confirmed 
cases 
West Nile virus 3 7% WNV IgM was detected in the CSF in all cases 
Ebstein-barr virus 2 5% 
Two cases confirmed by PCR detection of EBV in the 
CSF 
Enterovirus 1 2% Confirmed by CSF PCR 
Cytomegalovirus 1 2% CMV was detected in the CSF by PCR 
Total Viral Causes 22 51%  
Streptococcus pneumonia 3 7% 
Two cases were confirmed by CSF and blood cultures 
and 1 case was confirmed by a combination of blood 
culture, neuroimaging, and CSF profile 
Methicillin-resistant 
Staphylococcus aureus 
3 7% Three cases of MRSA were confirmed by CSF culture 
Propionibacterium acnes 2 5% Both cases of P acnes were confirmed by CSF culture 
Neurosyphilis 1 2% 
Confirmed by positive Treponema pallidum antibodies 
in the CSF 
Enterobacter cloacae 1 2% Confirmed by positive CSF culture 
Streptococcus anginosus 1 2% 
MRI showed multiple ring enhancing lesions consistent 
with multifocal brain abscesses and a left upper lobe 
aspirate confirmed strep anginosus 
Coxiella burnetii 1 2% 
Confirmed by identification of Q-fever phase I & II in 
the serum  
Group B Streptococcus 1 2% Confirmed by blood culture and CSF profile 
Haemophilus influenzae 1 2% Confirmed by blood culture and CSF profile 
Total Bacterial Causes 14 31%  
Cryptococcus species 3 7% 
Three cases of Cryptococcus were confirmed by CSF 
culture (positive in 2 cases) and/or CSF antigen 
detection (positive in 2 cases); neuroimaging was 
abnormal with leptomeningeal involvement in 2 cases 
Coccidioides immitis 1 2% Confirmed by CSF serology 
Aspergillus fumigatus 1 2% Confirmed by fungus culture and neuroimaging 
Candida albicans 1 2% Confirmed by blood culture and CSF profile  
Toxoplasma gondii 1 2% Confirmed by neuroimaging and serology 
Total Other Causes 7 15%  
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A total of 51 cases of unknown etiology were treated 




Table 10: Laboratory Parameters by Infection Types 








WBC, mean (SD) 2975.86 (61.4) 169 (176.8) 10 198.32 (237.8) 
Protein, mean (SD) 450.57 (546.1) 175.67 (57.2) 119 121.74 (79.7) 
Glucose, mean (SD) 42.71 (34.3) 41.83 (31.5) 46 64.62 (46.9) 
SD – Standard deviation 
 
Table 11: Time to Diagnosis 
 Mean* SD N 
Panel A (common) 5.3 7.9 25 
Panel B (uncommon) 30.0 84.9 18 
Overall 15.6 55.7  
Panel A: Haemophilus influenza, streptococcus pneumonia, CMV, Enterovirus, HSV-2, Cryptococcus, 
Coccidioides immitis, VZV 
Panel B: Syphilis, MSSA, WNV, Enterobacter cloacae, Proprionobacterium acnes, MRSA, Streptococcus 
anginosus, Toxoplasma gondii, Aspergillus fumigatus, Coxiella burnetti, Group B Streptococcus, EBV, Candida 
albicans. *p=0.019 
  
Table 12: Neurologic Deficit by Infection Type 
 Bacterial  Fungal Parasite Viral 
Baseline  
 





N Missing = 2 
None- 6 (100%) 
Severe- 1 
(100%) 
None- 14 (64%) 
Minor- 7 (32%)  








N Missing =2 
None- 6 (100%) None- 1 (100%) 
None- 16 (76%) 
Minor- 5 (24) 
N Missing =1 
 
86 
Table 13: All-cause Mortality  
Infection Type Total N Number of Deaths (%) 
Bacteria 14 1 (7%) 
Viral 22 2 (9%) 
Fungal 6 0 (0%) 















All cases presented 
with headache, and/or 
fever, and/or 
meningismus.  One 
patient presented 
with AMS which was 
most likely due to 
dementia. 
• Average CSF WBC 
count was 341, with 
CSF WBC count 
>600 in 2 cases.   
• Average CSF protein 
level was 125 (range: 
26-348) and average 





• Negative in 
all cases 
• Not ordered 
in 1 case 
• HSV-2 was detected in the 
CSF by PCR in all cases 
(100%). 
• HSV IgM was detected in the 
serum in 1 case. 
 
• Time to 
diagnosis was 
<2 days in 
more than half 
of the cases. 
• Time to 
diagnosis was 
between 3 and 
8 days in 4 
cases.    
The average 
age was 44 




Four of the 5 patients 
with confirmed VZV 
infection in the CNS 
were 
immunocompromised
; 2 patients had 
transplants, 1 patient 
had HIV, and 1 
patient was on 
immunosuppressant 
therapy for ulcerative 
colitis.   
The average CSF WBC 
count was 147 (range: 
37 – 256), average CSF 
protein level was 123 
(range: 96 – 200), and 
average CSF glucose 
was 64 (range: 40 – 
115).   
Neuroimaging 
was negative 
in 4 cases and 
was not 
ordered in 1 
case 
• VZV and/or antibodies were 
detected in the serum and/or 
CSF in 14 patients. 
• One additional unconfirmed 
case was presumed VZV 
meningitis in which VZV IgG 
and IgM were detected in the 
serum, but VZV was not 
detected in the CSF by PCR. 
• In 2 additional patients, VZV 
IgG was detected in the CSF.  
One of these cases had WNV 
in the CSF which was the 
primary cause of 
neuroinflammation.  The 
second case had 
neuroinflammation of 
unknown etiology, had a 
WBC count >500, and 
streptobacillus moniliformis 
was considered in the 
differential diagnosis.   
Three of the 5 
cases took 3 days 
to diagnose; the 
remaining 2 cases 
took 1 day and 5 
days to diagnose.   
The average 
age was 60 
(range: 29 – 










Neuroimaging Diagnostic Test Results Time to 
Diagnosis 
Age 
West Nile virus 




and sacral decubitus 
ulcers.   
In the 3 confirmed 
cases of WNV 
encephalitis, the CSF 
WBC count ranged 
from 25 to 162, CSF 
protein ranged from 79 
to 144, and CSF 
glucose ranged from 33 
to 92.   
Neuroimaging 
was negative is 
2 of the 3 
cases and 1 
case had 
oligoclonal 
bands.   
• Antibodies to WNV were
detected in serum and/or CSF
in 8 patients; however, WNV
was determined to be the
cause of neuroinflammation in
3 patients.  A fourth case was
confirmed after the patient
was discharged.
• Both IgM and IgG anti-WNV
antibodies were detected in
the CSF in 2/3 cases, while
only anti-WNV IgM
antibodies were detected in
the CSF in 1/3 case.
• Serum anti-WNV IgG and
IgM was reported in 1 case
(33%).
• In 2 cases of
neuroinflammation of
unconfirmed etiology, WNV
antibodies were detected in
the serum, but CSF WNV
serology was not ordered.
Time to diagnosis 
ranged from 5 to 
11 days.   
The ages 
ranged from 
52 to 78 
Streptococcus 
pneumonia 
• There were no
significant
comorbidities to












in all 3 cases (92-
98%) and CSF WBC
count was > 5000 in
2 cases.
• In one case, CSF
WBC count was 41,
CSF protein was
623, and glucose was
10; neuroimaging




in 2 cases.  
Two cases were confirmed by 
CSF and blood cultures (67%) 
and 1 case was confirmed by 
blood culture, neuroimaging, and 










between 3 to 11
days after
presentation.


















pneumonia in the 
urine. 
• The CSF protein was 
> 500 and CSF 
glucose was < 14 in 




• The patient was 
immunocompromis
ed in all cases (n 
=3). 
• Two patients had a 
history of transplant 
and 1 patient had 
HIV.   
• Lymphocytes were 
predominant in 2 
cases and neutrophils 
were predominant in 
1 case.   
• The CSF WBC count 
ranged from 7 to 
160, CSF protein 
ranged from 115 to 
182, and CSF 
glucose ranged from 






in 2 cases.   
• Three cases of Cryptococcus 
were confirmed by CSF culture 
(positive in 2 cases) and/or 
CSF antigen detection (positive 
in 2 cases). 
• The antigen was present in the 
blood in 2 of 3 cases.   
• Diagnosis took 
> 1 month in 1 
case and 
approximately 1 
week in another 
case.   
• The patient with 






within 1 day. 
Mean age 51 








one patient had HIV 
and AIDS.   
• Both cases 
presented with 
altered mental status 




• In 1 patient, the CSF 
WBC count was 8 
with 94% 
lymphocytes, CSF 
protein was 98, and 
CSF glucose was 43.   
• In 1 patient, the CSF 
WBC count was 129, 
CSF protein was 192, 
and CSF glucose was 
38.   
Neuroimaging 
was ordered in 
1 case and 
detected a 
probable 
lesion on the 
right side of 
the spinal cord 
at T3 with 
nonspecific 
appearance.   
• Antibodies against EBV were 
detected in the serum in 9 
patients and the virus was 
detected in the serum in 2 
cases.   
• EBV was confirmed as the 
cause of neuroinflammation in 
2 cases by detection of the 
virus in the CSF.   
• There were 2 cases of EBV 
with subsequent lymphoma.  
One of these cases had 
neuroinflammation caused by 
the EBV infection which was 
• The virus was 
detected 3 days 
after 
presentation in 
1 case.   




1 case and the 
patient died 15 
days after 
presentation. 









Neuroimaging Diagnostic Test Results Time to 
Diagnosis 
Age 
confirmed by PCR detection of 
EBV in the CSF; this patient 
had subsequent lymphoma.  
The second case had 
neuroinflammation caused by 
the lymphoma and EBV was 
detected in the blood; the final 
diagnosis was EBV-driven 
lymphoma. 
• One additional case had 
neuroinflammation of 
unknown etiology with 
positive results from CSF PCR 
for EBV and VZV IgG after 





1 patient was a 
premature infant. 
A 65-year-old patient 
presented with severe 
altered mental status 
fever, headache, 
altered mental status, 
and meningismus 
Neuroimpairment 
resolved at the time 
of the last neurologic 
assessment.   
• CSF WBC count was 
>1000 in 1 case 
(WBC 2,303), 785 in 
1 case, and 11 in 1 
case.  
• CSF protein was 
>200 in 2 cases and 
was 133 in 1 case.  
• CSF glucose was 
<40 in 1 case.   
• WBC differential 
was available in 2 
cases and revealed 




ordered in 2 








cases.   







ar ischemia.   
• Three cases of MRSA were 
confirmed by CSF culture.   
• Blood culture was ordered for 
2 patients and Staphylococcus 
aureus was detected in both 
cases. 
• In 1 case, P acnes was also 
detected in the CSF, but 
MRSA was determined to be 
the cause of 
neuroinflammation. 
• MRSA was 
detected 16 days 
after birth in 1 
case. 
• MRSA was 
detected in the 
blood 3-4 days 
after 







both cases.   
Ages 0, 48, 
and 65 
Propionibacteri • Although patients The CSF WBC count Neuroimaging • CSF culture confirmed P. Confirmed by Ages 31 and 
9
0





Neuroimaging Diagnostic Test Results Time to 
Diagnosis 
Age 
um acnes with any neurologic 
procedure within 3 
months of CSF 
specimen collection 
are not reviewed in 
this report, there 
were 2 confirmed 
cases of P Acnes as 
the cause of 
neuroinflammation.   
• One patient has had 




symptoms related to 
pseudotumor 
cerebri.  Headache 
was the only 
clinical symptom.   
• One patient had a 







months prior to CSF 
specimen collection.   
was 33, CSF protein 
was 39, and CSF 
glucose was 68. 
The CSF WBC count 
was 5857 with 70% 
neutrophils, CSF 
protein was 593, and 
CSF glucose was 10. 
was negative 
in both cases. 
Acnes in both cases. 
• In 1 case, CSF culture grew 
lactobacillus sakei and P acnes; 
P acnes grew approximately 14 
days after presentation.  Shunt 
infection with P acnes was 
determined to be the cause of 
neuroinflammation.   
• In 1 patient, pathology was 
positive for trichilemmoma. 
CSF culture 10 – 
14 days after 
presentation 
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Neurosyphilis  • Presented with HIV, 




The CSF WBC count 
was 32, CSF protein 
was 62, and CSF 
glucose was 53.   
Neuroimaging 
was negative. 
Positive Treponema pallidum 
antibodies in the CSF and serum 
rapid plasma regain test was 
positive.   
 Age:  33 
9
1










Presented with fever, 
headache, and 
meningismus.   
The CSF WBC count 
was 31 with 79% 
neutrophils, CSF 
protein was 30 and CSF 
glucose was 65.   
Neuroimaging 
was negative. 
• Positive CSF PCR. 
• Serum was positive for 
varicella zoster IgG. 
Positive test 
results within 1 
day of 
presentation. 
Age:  26 
Enterobacter 
cloacae 
Presented with focal 
neurologic deficits, 
altered mental status, 
oral thrush, and 
history of 
estesioneuroblastoma
.   
The CSF WBC count 
was 44, CSF protein 
was 373, and CSF 






margins of the 
right frontal 







increase.   
Blood culture was positive for K 
pneumoniae and CSF culture 
was positive for Enterobacter 
cloacae complex 
CSF culture was 
positive 4 days 
after presentation. 
The patient died 
11 days after 
presentation. 
Age:  71 
Coccidioides 
immitis 
The patient presented 
with headache, focal 
neurologic deficits, 
and meningismus, 
was HIV positive, 
and had a VP shunt 
placed during 
admission.   
The CSF WBC count 
was 513 with 68% 
lymphocytes, CSF 
protein was 261, and 






Serum and CSF serology 
detected cocci. 
Positive CSF 







headache and altered 
mental status. 
Neuroimpairment 




CSF WBC count 24 
with 60% neutrophils, 
CSF protein of 71, and 









A left upper lobe aspirate 
confirmed strep anginosus 
Positive test 











Neuroimaging Diagnostic Test Results Time to 
Diagnosis 
Age 
Toxoplasma This case presented 
with headache and 
altered mental status.   
This patient 
presented with severe 
neuroimpairment that 
completely resolved 
by discharge.   
The CSF WBC count 
was 10 with 66% 
neutrophils, the CSF 
protein was 119 and 
CSF glucose was 46.   
2 dominant 
ring enhancing 
lesions of the 
right parietal 
and left frontal 
lobes with 
significant 







neuroimaging.   
• In addition to toxoplasmosis, 
this patient tested positive for 
P. Acnes and HIV (new HIV 
diagnosis).   
• Neuroimaging and serology 
confirmed toxoplasma as the 
cause for neuroinflammation.  
Toxoplasma antibodies were 
detected in the serum.   
The diagnosis 
was made within 
1 day.   
Age:  33 
Aspergillus 
fumigatus 
History of liver and 
kidney transplant 
secondary to hepatitis 
C 
The CSF WBC count 
was 138 with 90% 
neutrophils, CSF 
protein was 140, and 
















Aspergillus fumigatus confirmed 




presentation.   
Age:  55 
Coxiella 
burnetii 
The patient presented 
with fever, headache, 
focal neurologic 
deficits, and altered 
mental status; had no 
known comorbidities; 
The CSF WBC count 
was 12 with 72% 
neutrophils, CSF 
protein was 54, and 
CSF glucose was 74.   
Neuroimaging 
was negative 
Confirmed by identification of 
Q-fever phase I & II in the 
serum. 
CMV IgG was also identified in 
the serum.   
This case took 
approximately 14 
days to diagnose.   
Age:  61 
9
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Neuroimaging Diagnostic Test Results Time to 
Diagnosis 
Age 
and was immune 
competent.   







 The CSF WBC count 
was 15 with 81% 
monocytes, CSF protein 
was 153, and CSF 
glucose was 41.   
Neuroimaging 
was not 
ordered.   
Confirmed beta hemolytic 
streptococcus by blood culture.  





The patient presented 
with focal neurologic 
deficits and had a 
history of rheumatoid 
arthritis and Sjogren 
syndrome.   
The CSF WBC count 
was 33 with 40% 
monocytes, CSF protein 
was 108 and CSF 
glucose was 40. 
Neuroimaging 
was negative, 
CMV was detected in the CSF 
and serum by PCR. 
The patient tested positive for 
oligoclonal bands.   
approximately 18 
days 
Age:  63 
Candida 
albicans 
 The CSF WBC count 
was 81 with 20% 
neutrophils, CSF 
protein was 223, and 




Candida albicans was detected 
by blood culture.  CSF culture 





• This patient 
presented with 




was severe upon 
presentation and 
minor at discharge. 
The CSF WBC count 
was 4505 with 84% 
neutrophils, CSF 
protein was 168, and 
CSF glucose was 10.   
The patient 




• Haemophilus influenza was 
detected by blood culture. 
• Positive for hepatitis C 
antibodies in the serum. 
The patient was 
diagnosed within 
2 days.   


















Figure 3: Disease Etiology. 
A total of 43 patients had confirmed CNS infections in this cohort.   
 
Patients with lumbar puncture over 1 year 
Excluded (n =1235) 
CSF WBC < 5 (n = 1003) 
ventricular shunt placement or other neurological 
procedure within 3 months of specimen collection (n = 62) 
Other confirmed diagnosis or unknown disease etiology  
(n = 232) 
Met inclusion criteria (n = 94) 
Confirmed CNS Infection (n = 43) 
Viral (n = 22) 
Bacterial (n = 14) 
Fungal (n = 6) 
Parasite (n = 1) 
Presumed CNS Infection (n = 51) 
Viral (n = 28) 
Bacterial (n = 12) 




EVALUATING IMMUNE PARAMETERS IN PATIENTS WITH CEREBRAL SPINAL 
FLUID PLEOCYTOSIS INDICATES POTENTIAL BIOMARKERS OF 
NEUROINFLAMMATORY DISEASE 
Author Contributions: 
 Authors contributed in the following ways:  J. David Beckham, study concept, design, 
interpretation of data, funding, manuscript writing and editing; Bethany L Brown, study concept, 
design, acquisition and interpretation of data, manuscript writing; Kelsey Lesteberg, acquisition 
of data, assay development and testing, analysis of data, manuscript writing; and Andrea Fidell, 
analysis of data.  
Beckham is supported by grant funding: VA Merit I01BX003863, DOD PRMRP 
PR160117 Medical Investigator Initiated Research Award. Brown is supported in part by 
NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. 
Abstract 
Objective 
This prospective study was aimed at defining the immune responses in patients with CSF 
pleocytosis in pre-specified diagnostic categories to define immunologic biomarkers of 
neuroinflammatory disease. 
Methods  
Patients with CSF pleocytosis, defined as WBC count >5 cells/mm3 with available 
residual CSF samples at a large tertiary care hospital were prospectively analyzed for immune 
responses.  Data from 68 patients was evaluated in this study and 29 patients were included for 
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evaluation of immune differential patterns were explored by flow cytometry and multiplex 
ELISA.  
Results 
VEGF-A levels in the CSF were significantly higher in the malignancy group compared 
to the bacterial infection and ‘other’ groups (p = 0.03), CSF IL-16 levels were significantly 
higher in the bacterial infection group (p = 0.05), and CSF IFN-γ levels were higher in the viral 
infection group compared to all other groups (p = 0.001).  Upon analysis of immune cell 
phenotypes, the proportion of neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 
cells, and B cells exhibited differences between diagnostic categories, although the proportion of 
these cell types were not statistically different likely due to small numbers of patients included in 
the analysis.   
Conclusions 
These data suggest that CSF VEGF, IL-16, and IFN-γ may be relevant biomarkers of 
disease for malignancies, bacterial infections, and viral infections, respectively, in the CSF.  
Proportions of neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 cells, and B 
cells may differ between diagnostic categories and should be further explored. 
Introduction 
Inflammation in the central nervous system (CNS) may arise from a variety of factors 
including infection, autoimmunity, trauma, degenerative processes, toxins, malignancy, and in 
some cases factors of unknown origin.8  Cellular and chemistry parameters are routinely tested 
using cerebral spinal fluid (CSF) when CNS involvement is suspected, but this testing is non-
specific.35  The diagnosis of each individual etiology is made using different approaches and 
tests including CSF direct staining, CSF culture, nucleic acid amplification tests (NAT), 
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polymerase chain reaction (PCR), immunoassays, and neuroimaging.33,34  For example, CSF 
PCR and serology are common diagnostic tests submitted for specific viral infections, yet, 
current diagnostic approaches require that each individual test must be ordered specifically for 
each individual pathogen.32  Bacterial culture is performed if bacterial meningitis is suspected, 
but this process takes 2-5 days and may demonstrate low sensitivity; particularly if antibiotics 
have been administered or the pathogen does not grow in conventional culture.18  Neuroimaging 
and lumbar puncture (LP) to obtain CSF for analysis is critical in the diagnostic pathway for 
patients with potential inflammation in the CSF, and clinical features may direct clinicians to test 
for specific etiological agents.16,37  However, the complex algorithms to evaluate patients with 
CSF pleocytosis results in missed or delayed diagnosis in many cases.   
Thus, patients that present with CSF pleocytosis can be difficult to evaluate and treat due 
to the heterogeneity of causes that result in overlapping clinical and laboratory features.85  Due to 
significant overlap in clinical presentations, there is no clear diagnostic test for specific clinical 
presentations of CSF pleocytosis and as a result, many patients never receive a specific 
diagnosis.  Even in studies with large diagnostic panels to evaluate underlying causes of 
encephalitis, no underlying etiology is found in as many as 40%-60% of patients.10-12   
In a healthy individual, CSF is acellular and exhibits no inflammation.  In patients with 
acute inflammation, CSF can often contain T cells of which 70-75% are CD4+ T helper cells and 
approximately 25% are CD8+ cytotoxic or suppressor T cells.65,67-69  Other immune cells 
involved in CNS disease include:  natural killer-like T cells (NKT), natural killer (NK) cells, 
gamma/delta T cells, B cells (<1%), plasmablasts, plasma cells, and dendritic cells (DCs).65,67  
The leukocyte profile in the CSF has been investigated for various causes of neuroinflammation, 
but immune differential patterns have not previously been described for the neuroinflammation 
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cohort as a whole.  Likewise, few comparisons have been made between immune profiles for 
different underlying etiologies of neuroinflammation.  Immune cell subtypes each have 
distinctive roles and are differentially represented in different diseases and disease stages.82,97,98  
For example, elevated CD8+ T cells, B cells, and plasmablasts have been observed in patients 
with multiple sclerosis, as well as bacterial and viral meningitis.67  Additionally, subsets of 
CD4+ T cells including T helper 9 (Th9), T follicular helper (Tfh),  type 1 regulatory T cells 
(Tr1), T helper type 1 (Th1), T helper 17 (Th17), and T regulatory cells (Tregs) are reported to 
contribute to the pathogenesis of autoimmunity.62   
Previous studies have focused on specific causes of neuroinflammation, such as multiple 
sclerosis.  In this study, we hypothesized that to improve the diagnosis in this patient population, 
patients with neuroinflammation must be studied as a group (as opposed to studying single 
etiologies) with novel diagnostic panels or arrays so that improved diagnostic algorithms can be 
developed.  The diversity in etiologies of neuroinflammation and the broad diagnostic 
approaches for these patients significantly contribute to the difficulty of diagnosis, management, 
and treatment.  We hypothesized that evaluating spinal fluid inflammatory markers and immune 
cell subtypes present in patients with CSF pleocytosis would complement the current diagnostic 
approach and provide an approach to differentiate diagnostic categories including viral infection, 
bacterial infection, malignancy, and autoimmune/inflammatory disorders.  Since the underlying 
immunology for each of these categories should be functionally different, this study was aimed 
at defining the immunology of the broader diagnostic categories to define immunologic 
biomarkers of disease categories. 
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Methods 
Selection Criteria  
This is a prospective pilot clinical study that evaluated consecutive residual clinical CSF 
samples at the University of Colorado Hospital (UCH).  All work was reviewed and approved by 
the Colorado Multiple Institutional Review Board prior to data capture.  Consecutive residual 
clinical CSF specimens were identified over 8 months and screened using clinical data from 
patient charts to determine eligibility for this study.  Participants were included in this study if 
they had a CSF specimen by LP with adequate residual volume of uncentrifuged CSF (≥ 500μL) 
left over from routine testing and white blood cell (WBC) count in the CSF > 5 cells/mm3.  Data 
from patient charts was used to classify patients into larger diagnostic categories including CNS 
viral infection, CNS bacterial infection, malignancy, autoimmune/inflammatory, ‘other’ 
(diagnosis of subarachnoid hemorrhage, stroke, or other etiologies which did not fit into the 
defined diagnostic categories), or unknown etiology.  Only one CSF specimen per patient was 
included in the study.  There were 3-6 samples tested from each diagnostic category. 
Study Endpoints 
 The primary endpoint of the study was to describe the leukocyte profile by diagnostic 
category (bacterial infection, viral infection, malignancy, autoimmune/inflammatory disorder, 
and ‘other’) in terms of proportions of 5 cell types (neutrophils, PD1- cytotoxic T cells, PD1+ 
cytotoxic T cells, Th17 cells, and B cells) between the categories.  We expected that 5 immune 
cell subtypes would describe differential patterns of the pre-specified diagnostic categories in the 
neuroinflammation cohort.  We anticipated the following dominant cell subtypes for each 
category:  bacterial infection (CD15+/CD49- [neutrophils]); viral infection (CD3+/CD8+/PD1- 
[PD1- cytotoxic T cells]); malignancy (CD3+/CD8+/PD1+ [PD1+ cytotoxic T cells]); 
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inflammatory (CD3+/CD4+/IL17+ [Th17 cells]); and autoimmune (CD3+/CD19+ [B cells]).  
Proportions of these cell types were tested by flow cytometry using 4-6 samples from each 
diagnostic category.  Due to sample availability, autoimmune and inflammatory disorders were 
studied as a single diagnostic category and viral and bacterial infections were studied as a single 
diagnostic category for the primary endpoint analysis.  Additionally, we suspected that immune 
profiles would be similar between individuals with autoimmune and inflammatory diseases.  
Secondary study endpoints included evaluation of additional cell markers by flow 
cytometry and multiplex ELISA (Meso Scale Discovery [MSD]) assay, as well as additional 
clinical and laboratory parameters available in the patient charts.  We explored 8 additional cell 
markers including monocytes, total CD4 T cells (all CD3+ CD4+), total CD8 T cells (all CD3+ 
CD8+), NK cells (CD56+), Naïve B cells (CD19+ CD27-), Memory B cells (CD19+ CD27+), 
Perforin+ CD8 T cells (CD3+ CD8+ Perforin+) and activated neutrophils (CD15+ CD49d- 
CD66b+) using flow cytometry.  We also measured a panel of 30 human cytokines and 
chemokines via multiplex ELISA and evaluated clinical and laboratory parameters by diagnostic 
category.  The following pro- and anti-inflammatory cytokines and chemokines were measured 
by multi-plex ELISA: granulocyte-macrophage colony stimulating factor (GM-CSF), 
interleukin(IL)-1alpha (IL-1α), IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, tumor 
necrosis factor beta (TNF-β), vascular endothelial growth factor (VEG-f), eotaxin (CCL11), 
MIP-1β (CCL4), eotaxin-3 (CCL26), TARC (CCL17), IP-10 (CXCL10), MIP-1α (CCL3), IL-8 
(CXCL8), MCP-1 (CCL2), MDC (CCL22), MCP-4 (CCL13), interferon-gamma (IFN-γ), IL-1β, 
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor alpha (TNF-α). 
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Collection of Data 
We identified prospective CSF specimens left over from routine testing in the central 
clinical laboratory at UCH and reviewed patient charts to identify specimens that met selection 
criteria.  Fresh, residual clinical samples were collected and prepared within 3-4 days of 
collection to maintain sample integrity.  Samples were centrifuged, and the pellet was removed 
for flow cytometry testing.  The supernatant fluid was used for multiplex ELISA.     
Flow cytometry  
Based on the existing literature, we expected that the CSF fluid from each of our distinct 
diagnostic categories would be dominated by particular immune cell phenotypes.  To examine 
whether the immune cell types present in the CSF differed between our diagnostic categories, a 
total of 13 cell subtypes were evaluated by flow cytometry including neutrophils, PD1- cytotoxic 
T cells, PD1+ cytotoxic T cells, Th17 cells, total B cells, monocytes, total CD4 T cells, total 
CD8 T cells, NK cells, Naïve B cells, Memory B cells, Perforin+ CD8 T cells, and activated 
neutrophils (CD66b+) in 14 CSF specimens.   
Immune cells present in the CSF were evaluated by flow cytometry in 3-6 samples from 
each diagnostic category.  Previously frozen cells were first thawed and rested overnight in R10 
(RPMI with glutamine (Thermo Fisher, Waltham, MA) + 10% FBS (Hyclone, Thermo Fisher) + 
1% Penicillin/Streptomycin (Gibco, Thermo Fisher), 1% HEPES (Gibco), 1% non-essential 
amino acids (Gibco), and 1% sodium pyruvate (Gibco)) media in an incubator at 37°C.  The cells 
were then washed twice with PBS (Gibco or Corning Cellgro) and incubated with Ghost violet 
510 dye (Tonbo Biosciences, San Diego, CA) for 10 minutes.  Antibodies against surface 
antigens diluted in FACS buffer (PBS + 1% FBS) were then added to the cells for 25 minutes. 
After washing, the cells were permeabilized for 20 minutes using Fixation/Permeabilization 
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solution (BD Biosciences, San Jose, CA).  The cells were then washed, and intracellular 
antibodies diluted in Perm/Wash buffer (BD Biosciences) were added for 45 minutes.  The cells 
were washed once more and fixed with 1% paraformaldehyde (PFA, Fisher Scientific).  All 
antibody incubations were performed at 4°C in the dark.  The data were collected on a LSRII 
flow cytometer (BD Biosciences) and analyzed in FlowJo (FlowJo, LLC). The following 
antibodies were used: anti-IL17A BV421 (Biolegend, San Diego, CA), anti-CD49d BV605 
(Biolegend), anti-CD14 BV650 (BD Biosciences), anti-CD3 BV711 (Biolegend), anti-CD8 
BV785 (Biolegend), anti-CD27 FITC (Biolegend), anti-perforin PE (Biolegend), anti-CD15 PE-
Cy7 (Biolegend), anti-CD4 PE-Cy5.5 (eBioscience, Thermo Fisher), anti-CD19 PE-CF594 (BD 
Biosciences), anti-PD1 APC (Biolegend), anti-CD66b AF700 (Biolegend), and anti-CD56 APC 
Fire 750 (Biolegend).  
Multiplex ELISA 
30 cytokines and chemokines were evaluated for 4-6 samples in each diagnostic category 
by multiplex ELISA (V-plex Human Cytokine 30-Plex Kit, Meso Scale Discovery, Rockville, 
MA).  Previously frozen CSF fluid was thawed, centrifuged to remove any residual cells, and the 
assay was carried out according to the manufacturer’s instructions.  The plates were run on a 
MESO QuickPlex SQ 120 (Meso Scale Discovery).  
Patient classification and chart review 
Additional clinical and laboratory data were collected from patient charts including 
diagnostic test results used to identify the cause of neuroinflammation.  Information from patient 
charts was used to classify patients into larger diagnostic categories including viral infection, 
bacterial infection, malignancy, autoimmune/inflammatory, ‘other’, or unknown etiology.  
Patients with a diagnosis of autoimmune disease included patients with diagnoses including 
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multiple sclerosis and antibody-mediated encephalitis such as anti-N-methyl-D-aspartate 
(NMDA) receptor encephalitis.  Patients diagnosed with an inflammatory disease included 
patients with primary inflammatory disorders such as optic Pseudotumor cerebri, optic neuritis, 
CNS sarcoid, and dementia.  An ‘other’ category was created to include patients with 
miscellaneous diagnoses such as trauma, intracranial and subarachnoid hemorrhage, and stroke 
which do not fit into the prior diagnostic categories.  Patients diagnosed with an infection or 
malignancy received a diagnosis based on isolation of a malignancy or infection from the CNS.  
Data were collected for a variety of diagnostic tests including blood and CSF serology, 
PCR diagnostics, blood culture, CSF culture, serum WBC, serum creatinine, CSF WBC, CSF 
glucose, CSF protein, neuroimaging, and pathology.  The treating physicians’ notes were the 
source to determine the diagnosis in combination with supportive diagnostic test results.  If there 
was a questionable diagnosis, for example if multiple pathogens were detected in the CSF and 
the primary causative pathogen was not clearly documented in the patient chart, a neurology or 
infectious disease physician was consulted to confirm the diagnosis.   
Statistical Methodology 
All data were analyzed and graphed using SAS software and Graph Pad Prism.  This was 
a descriptive study in which 3-6 samples tested from each diagnostic category.  The primary 
hypothesis was that there was a difference in the average proportion of 5 biomarkers between the 
diagnostic categories.  To test this hypothesis, we conducted five one-way ANOVA’s, one for 
each biomarker tested by flow cytometry.  Given the small sample size, non-parametric tests 
were conducted which removed the distributional assumption.  Kruskal-Wallis uses Wilcoxon 
rank-sum scores to determine if there is a difference in the distribution of a specific biomarker 
under each etiology with respect to the mean.  Scores for each biomarker were ranked by 
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increasing order (smallest value receives a “one”, etc.) and summed across each etiology.  
Transformations on the data were considered including log transformation.  However, zero 
values existed in the dataset which were replaced as missing values when performing a log 
transformation.  Transformation by replacing zeros in the raw data with half the value of the 
smallest data point was also considered.  However, once performed, the patterns observed in the 
raw data were lost and there was no impact to statistical significance; thus, and the 
transformations misrepresented the data and analyses were conducted with data on the original 
scale.  The effect size, which is the amount of variance in the cell type proportions explained by 
the diagnosis, was evaluated and was medium to large for 4 of the 5 cell types evaluated in this 
study.  Additionally, a bootstrapping simulation was conducted using unrestricted random 
sampling with replacement to select units with equal probability and create a large number of 
bootstrap samples.  This simulation exercise was conducted to further explore observed patterns 
in this study and to determine what our study might have looked like if we had a larger sample 
size, based on what was observed. 
An ANOVA test was conducted to evaluate the difference in cytokine levels between 
diagnostic categories.  Additionally, t tests were performed to evaluate the differences between 
each diagnostic category, as applicable.  All t tests were corrected for multiple comparisons 
using the Tukey correction.  
Descriptive statistics were used to report demographics, neurologic deficit, and additional 
clinical and laboratory data.   
Results 
There were 271 patients reviewed in the cohort who had available residual CSF over 8 
months.  Of these 271 patients, 68 had CSF WBC >5 cells/mm3.  The majority of patients with a 
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diagnosis of an autoimmune/inflammatory disorder were female and the majority of patients with 
an infection were male (Table 15).  Most patients in all diagnostic categories were non-hispanic 
white.   
Flow cytometric immunophenotyping was conducted on 23 CSF samples and cytokine 
levels were measured in 23 CSF samples via multiplex ELISA, and most of the samples were 
evaluated using both test methods.  Thus, immune cell markers were evaluated in 29 patients 
using one or both methods (Figure 4).  Of the 23 samples tested by flow cytometry 
immunophenotyping, 7 had a CNS infection (5 bacterial and 2 viral), 3 had a malignancy, 4 had 
an autoimmune or inflammatory disorder, 3 had an ‘other’ diagnosis, and 6 have unknown 
disease etiology.  Of the 23 samples tested with a multiplex ELISA array, 9 had a CNS infection 
(3 viral and 6 bacterial), 4 had malignancy, 5 had an autoimmune or inflammatory disorder, and 
5 had an ‘other’ diagnosis.   
Sixteen different diagnoses were made in the 29 patients evaluated, including multiple 
sclerosis, Hashimoto’s encephalopathy, amyloid beta-related angiopathy, anti-neutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis, Streptococcal pneumonia, neurosyphilis, 
West Nile virus (WNV), Propionibacterium acnes, Enterobacter cloacae, metastatic breast 
cancer, glioblastoma, acute lymphoblastic leukemia (ALL), subarachnoid hemorrhage, human 
immunodeficiency virus (HIV), herpes simplex virus-1 (HSV-1), and pseudotumor cerebri.   
Flow Cytometry Immunophenotyping Reveals Patterns Amongst Diagnostic Categories 
Five cell subtypes were evaluated by flow cytometry for the primary study endpoint of 
this study (neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 cells, and B cells).  
There were no significant differences in the proportion of the 5 cell subtypes between diagnostic 
categories (neutrophils, p = 0.78; PD1- cytotoxic T cells, p = 0.46; PD1+ cytotoxic T cells, p = 
107 
0.91; Th17 cells, p = 0.71; and B cells, p = 0.66; Table 16, Figure 5).  Additionally, no 
significant differences in proportion of cells were observed between the diagnostic categories for 
any of the 13 cell subtypes measured by flow cytometry.   
Interesting patterns were observed in the descriptive statistics (Table 17), although none 
of our primary or secondary endpoints reached significance.  Specifically, the average proportion 
for each biomarker was similar in 2 groups and different in a third.  For example, the average 
proportion of Th17 cells were quite similar in the autoimmune/inflammatory disorder and 
infection categories but different in the malignancy category.  The pattern in the proportion of 
PD1+ cytotoxic T cells was minute in magnitude compared to the other biomarkers.  No 
significance differences were observed in the omnibus F-test, but effect size was observed.  In 
particular, PD1- cytotoxic T cells had a large effect size which means that the variance in PD1- 
cells could be largely explained by the category of diagnosis (Table 16).  A medium effect size 
was observed for Th17 CD4 T cells, total B cells, and neutrophils, and a large effect size was 
observed for total CD4 T cells and perforin+ CD8 cells.  The patterns observed motivated an 
informal post-hoc test, although no statistical significance was demonstrated.  According to each 
pattern, groups with similar group means were combined and compared to the other group.  For 
example, for Th17 the autoimmune/inflammatory and infection groups were collapsed and 
compared to the malignancy group.  There was no statistical significance demonstrated in these 
post-hoc tests, but when data was simulated using the bootstrapping method, significance was in 
each omnibus F test which confirms the patterns observed with descriptive statistics.  These data 
imply that a larger study with more patients included would provide enough power to define 
novel immunophenotypic biomarkers. 
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Multiplex ELISA Reveals Potential CSF Biomarkers 
To search for potential protein biomarkers of each diagnostic category in the CSF, we 
utilized a 30-plex ELISA assay (Meso Scale Discovery).  This assay combines 3 different panels: 
a panel of 10 cytokines important in inflammation of regulation of the inflammatory response 
(IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, the p70 unit of IL-12 (IL-12 p70), IL-13, and TNFα), 
10 additional cytokines which are important regulators of the immune response (GM-CSF, IL-
12/23 p40 subunit, IL-15, IL-16, IL-17A, IL-1α, IL-5, IL-7, TNFβ, and VEGF-A), and 10 
chemokines (Eotaxin, Eotaxin-3, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, and 
TARC).  We found that VEGF levels were significantly (p = 0.0278) higher in the malignancy 
group compared to any other group (Figure 6).  Similarly, IL-16 levels were significantly (p = 
0.0448) higher in the bacterial infection group compared to other diagnostic categories (Figure 
7), and IFN-γ was significantly (p = 0.0012) increased in the viral infection group compared to 
other diagnostic categories (Figure 8).  No significant differences in chemokine levels were 
observed between diagnostic categories. These results indicate that VEGF, IL-16, and IFNγ, are 
potential CSF biomarkers for malignancy, bacterial infection, and viral infection, respectively. 
Clinical Laboratory Data 
Laboratory parameters were reviewed including CSF WBC and differential (Table 18).  
Mean values from the CSF analysis are consistent with previous reports.15,32,40  The WBC count 
and lymphocytes were significantly different between diagnostic categories (p = 0.0386 and 
p = 0.0402, respectively).  There was no significant difference in proportion of neutrophils or 
monocytes between diagnostic categories.  The mean CSF WBC count (SD) was 765.0 (1264.53) 
for patients with bacterial infections, 143.25 (62.97) for patients with viral infections, 44.27 
(63.48) for patients with an autoimmune or inflammatory disorder, and 81.0 (57.83) for patients 
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with a malignancy. The mean proportion (SD) CSF lymphocytes was 0.30 (0.35) for patients 
with bacterial infections, 0.93 (0.05) for patients with viral infections, 0.66 (0.32) for patients 
with an autoimmune or inflammatory disorder, and 0.62 (0.33) for patients with a malignancy.  
Lymphocytes predominated in viral infections.   
Forty percent of patients with an autoimmune/inflammatory disorder or CNS infection 
presented with minor or severe neurologic deficits (Table 19).  At the final recorded assessment, 
70% of patients with an autoimmune/inflammatory disorder and 60% of patients with a CNS 
infection met criteria for a minor or severe neurologic deficit.  All patients with a malignancy 
and 80% of patients with an ‘other’ diagnosis exhibited minor or severe deficits at the final 
evaluation   
Discussion 
Patients that present to medical care with inflammation in the CSF can be complex to 
evaluate due to the heterogeneity of causes that result in overlapping clinical and laboratory 
features.85  For these reasons, no clear diagnostic test exists for specific clinical presentations, 
and a high frequency of patients with no known cause of neuroinflammation present in medical 
practice.  Time to diagnosis may be delayed due to lack of standardization in the diagnostic 
strategy for this patient population.  We have previously shown that mean time to diagnosis for 
patients with CSF pleocytosis is 16 days in patients with an infection and malignancy and 125 
days in patients with an autoimmune disorder.99  In other studies, approximately 60% of patients 
with pleocytosis in the CSF have disease of unknown etiology.10,13,99  Although previous studies 
have found significant differences in the cytokine status of the CSF of the patients with bacterial 
and viral meningitis, malignancies, and neurodegenerative disorders,100-104 there have been no 
previous studies describing immune differential patterns in patients that present with a CSF 
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pleocytosis. 
Data from this study provide important information on diagnostic approaches for patients 
that present with inflammation in the CNS.  Patterns were observed in proportion of neutrophils, 
PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 cells, and B cells between diagnostic 
categories in this study.  Additionally, data from this study suggest that VEGF may be a relevant 
biomarker for malignancy involving the CNS.  IL-16 and IFN-γ may be relevant biomarkers for 
bacterial and viral infections in the CNS, respectively.   
A higher proportion of neutrophils was seen in the infection group compared to other 
groups, although the difference was not statistically significant.  Neutrophils are important 
components of the innate cell-mediated immune response during bacterial infections of the CNS, 
which may explain the higher proportion of neutrophils observed in this group.105  CD8+ 
cytotoxic T lymphocytes are the main effector cell involved in clearing virus from the CNS.106  
However, we observed a higher proportion of PD1-cytotoxic T cells in the malignancy group 
compared to the other groups, although not statistically significant.  The contribution of different 
immune cells to the pathogenicity of CNS autoimmune diseases remains under intense debate; 
however, two major arms of CD4+ T lymphocytes are understood to mediate these diseases.  
These two cell types are characterized by the production of IFNγ (“Th1” type) or IL-17 (“Th17” 
type).107-113  Interestingly, the proportion of Th17 cells was not elevated in the 
autoimmune/inflammatory group in this study.  B cells were higher in the 
autoimmune/inflammatory group compared to the malignancy group, but not compared to the 
infection group.  Many cancers inhibit T cell responses by upregulating the ligands for CTLA-4 
or PD-1, which are expressed on T cells and result in downregulation of T cell responses when 
triggered.114,115  A slightly increased proportion of PD1+ cytotoxic T cells were observed in the 
111 
malignancy group compared to the autoimmune/inflammatory group, but the proportion was the 
same in the infection group.  Although there were no statistically significant differences observed 
in the immune cell subtypes measured by flow cytometry, these observed patterns warrant 
further exploration. 
Breast cancer, lung cancer and melanoma metastasize to the meninges in 5-15% of 
patients, causing inflammation in the CNS.101  CNS lymphoma, glioblastomas, 
oligodendrogliomas, choriocarcinomas, chondrosarcoma, and other types of malignancies may 
also cause inflammation in the CNS.99  Previous studies of CSF biomarkers in metastatic 
melanoma, breast cancer, and lung cancer demonstrated that VEGF was elevated (>20 pg/mL) in 
68% of patients with positive CSF cytology and normal (<20 pg/mL) in 97% of patients with 
negative CSF cytology.102,103  Interestingly, previous studies have also indicated that VEGF may 
be neuroprotective in Alzheimer’s disease.102,104  Lower levels of VEGF in CSF have 
distinguished Alzheimer’s disease from healthy controls with 76% sensitivity and a 84% 
specificity in previous reports.116  In this study, patients with a malignancy had an average VEGF 
level of 1129 pg/mL.  Patients in the autoimmune/inflammatory disorder group had an average 
level of 3 pg/mL, patients in the ‘other’ group had an average level of 8 pg/mL, and patients in 
the infection group had an average of 100 pg/mL.  The VEGF levels in the malignancy group 
were significantly higher compared to other diagnostic categories, suggesting this may be an 
appropriate biomarker to aid in the diagnosis of malignancies in the CNS.  Although patients 
with Alzheimer’s disease were not studied in this cohort, patients with 
autoimmune/inflammatory disorders had lower levels of VEGF, which warrants further 
investigation given previous claims that VEGF may be neuroprotective.   
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IL-16 expression was significantly higher in the bacterial infection group compared to 
other diagnostic categories.  One study reported higher IL-16 levels in the CSF of both bacterial 
(939 ng/L) and aseptic meningitis (341 ng/L) when meningeal symptoms existed compared to 
non-meningitis controls (29 ng/L) and levels were lower after meningeal symptoms 
disappeared.117  In this study, IL-16 levels in the CSF were higher in the infection group (223 
ng/L) compared to the autoimmune/inflammatory group (25 ng/L), malignancy group (33 ng/L), 
and ‘other’ group (33 ng/L), although disease stage was not evaluated.  Furthermore, IL-16 
levels were significantly higher in the bacterial infection group (302 ng/L) compared to other 
diagnostic categories, which is consistent with previous reports.117   
IFN-γ was also significantly increased in the viral infection group compared to other 
diagnostic categories.  One previous study reported elevated IFN-γ in relapsing multiple 
sclerosis.118  Another study reported that CSF IFN-γ did not distinguish between viral and 
bacterial meningitis although levels were increased in patients with CNS infections (n = 45).119  
However, in this study, there was a difference in the average IFN-γ in patients with viral 
infection (158 pg/mL) and bacterial infection (14 pg/mL).  The average IFN-γ level in patients 
with any CNS infection was 62 pg/mL, the average level in the autoimmune/inflammatory 
disorder group was 9 pg/mL, and the average level in both the malignancy and ‘other’ groups 
was 3 pg/mL.  IFN-γ levels were significantly higher in the viral infection group compared to 
other diagnostic categories.   
In this study, laboratory parameters from serum and CSF studies exhibited significant 
overlap.  Current standard practice utilizes CSF parameters such as WBC, protein, and glucose to 
guide diagnosis.  CSF analysis of patients in this cohort was consistent with prior studies.15,32,40  
However, there was significant overlap in the CSF parameters between diagnostic categories, 
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which implies that routine use of CSF parameters alone may not aide clinicians in defining 
categories of diagnosis to rapidly focus the diagnostic strategy.  Prior studies suggest that a CSF 
WBC count >1,000 cells/mm3 indicates bacterial infections in the CNS, and this cohort of 
patients with bacterial infection in the CNS exhibited an average (SD) CSF WBC count of 765.0 
(1264.53) cells/mm3.  Typically, a CSF WBC count <1,000 cells/mm3 is thought to be suggestive 
of viral infections and <500 cells/mm3 is suggestive of a malignancy, autoimmune disease, or a 
fungal infection in the CNS.  The average (standard deviation) observed CSF WBC count for 
viral infections was 143.25 (62.97) cells/mm3, 44.27 (63.48) cells/mm3 in the 
autoimmune/inflammatory disorder group, and 81.0 (57.83) cells/mm3 in the malignancy group.  
Additionally, patients with viral infections exhibited lymphocyte predominant differentials in the 
CSF.  While classic CSF parameters like WBC and differential help with focused diagnostic 
testing, relying on these studies to rule out use of specific diagnostic testing may lead to a missed 
diagnosis.  Approximately 49% of all patients in this study had minor or severe neurologic 
deficits at presentation and 60% had minor or severe neurologic deficits at the last assessment 
demonstrating that long term morbidity is still a problem for these patients.  This supports 
previous evidence of the high clinical impact and global economic burden associated with 
neuroinflammation due to significant morbidity and mortality including permanent neurological 
sequelae.20-23  In patients that present with a possible infection of the CSF and pleocytosis, the 
major clinical challenge remains the large number of diagnostic testing assays for infectious and 
non-infectious causes and lack of clear clinical parameters to guide complex diagnostic ordering.   
Data from this study support exploring immune differential patterns within diagnostic 
groups of diseases that cause CSF pleocytosis to guide clinicians to place patients in a category 
of underlying disease and guide specific diagnostic testing for specific causes.  By grouping 
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infrequent diagnoses into larger categories of disease, it is possible to define the immunology 
and genetics of inflammation, develop diagnostics, and target evaluations to improve time to 
diagnosis and outcomes.  Future studies to evaluate these biomarkers and this approach are vital 
for much needed progress to improve diagnostic approaches in patients that present with CSF 
pleocytosis.   
Limitations of this study include low sample size, sample volume, and low cell viability.  
The average cell viability was <45% in all groups for our flow cytometry studies.  The low cell 
viability was due to the use of CSF left over from routine clinical testing, which resulted in 
delays between obtaining the CSF sample and sample analysis.  Larger, prospective studies 
should focus on maintaining cell viability to better explore patterns between diagnostic 
categories.  Additionally, the autoimmune and inflammatory disorders were studied together due 
to low sample availability, although we expect the immune response may be different between 
diagnoses in these categories.  These data may also include referral bias of complex cases since 
more routine care of CNS infections may occur in the community without referral, while more 
complex cases in the community often get referred early to the study site.  Furthermore, residual 
CSF was not available for all patients that presented to UCH with CSF pleocytosis because there 
was no remaining sample, or the remaining sample was not saved by laboratory personnel due to 
logistical constraints.  The strengths of this study include the prospective, consecutive, un-biased 
selection and analysis of a cohort of patients at a large tertiary care center with a large catchment 
area in the Rocky Mountain region.   
Conclusions 
Patterns emerged which suggest that immune profiling of CSF from neuroinflammation 
patients may aid more rapid diagnosis of the underlying etiology.  Results from this study 
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confirm that there is a need to explore this area with a more comprehensive study.  Higher levels 
of Th17 and PD1- cytotoxic T cells and lower levels of B cells may be an indicator of 
malignancy.  Lower levels of PD1+ cytotoxic T cells may be an indicator of 
autoimmune/inflammation and higher levels of neutrophils may be an indicator of infection.  The 
data also suggests that VEGF may be a relevant biomarker for metastases involving the CNS and 
IL-16 and IFN-γ may be a relevant biomarker for bacterial and viral infection in the CNS, 
respectively.   
Clinicians that evaluate patients with a neurologic syndrome and CSF pleocytosis are 
challenged with diverse underlying etiologies of disease and a high frequency of patients with no 
known cause of neuroinflammation.  Moreover, standard diagnostic strategies are inconsistent 
and may result in missed or delayed diagnoses.  Considerations should be made about 
biomarkers in the CSF which may be early indicators of disease.  Further investigation of 
differences in the immune response between different diagnostic categories may also be useful to 
guide more rapid diagnosis of etiologic causes of neuroinflammation.  Future studies should 
focus on VEGF, IFN-γ, and IL-16.  Larger, prospective studies should also focus on maintaining 
cell viability to explore patterns observed in proportion of neutrophils, PD1- cytotoxic T cells, 
PD1+ cytotoxic T cells, Th17 cells, and B cells between diagnostic categories in this study. 
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Autoimmune/Inflammatory 49.7 (21.2) F: 7 (64%) 
M: 4 (36%) 
Hispanic: 3 (27%) 
NHO: 2 (18%) 
NHW: 6 (545%) 
11 
Infection 48.4 (17.2) F: 4 (29 %) 
M: 10 (71%) 
Hispanic: 1 (7%) 
NHO: 2 (14%) 
NHW: 11 (79%) 
14 
Malignancy 54.3 (11.2) F: 3 (75%) 
M: 1 (25%) 
NHB: 1 (25%) 
NHO: 1 (25%) 
NHW: 3 (50%) 
4 
Other 63.7 (14.5) F: 6 (60%) 
M: 4 (40%) 
Hispanic: 2 (20%) 
NHB: 1 (10%) 
NHO: 1 (10%) 
NHW: 6 (60%) 
10 
Unknown 50.0 (17.7) F: 11 (39%) 
M: 17 (61%) 
Hispanic: 5 (19%) 
NHB: 8 (30%) 
NHO: 2 (7%) 
NHW: 12 (44%) 
29 
Note: NHO= Non-Hispanic Other (Includes Non-Hispanic unknown and Non-Hispanic unknown); NHW= Non-
Hispanic White; NHB= Non-Hispanic Black 
Table 16: Difference in Proportion of Cell Markers Detected by Flow Cytometry  
Biomarker ANOVA  
(p-value) 
η2 95% CI Effect Size Kruskal-Wallis  
(p-value) 
PD1- 0.46 0.14 (0.00, 0.42) Large 0.86 
PD1+ 0.91 0.02 (0.00, 0.18) Small 0.98 
TH17  0.71 0.07 (0.00, 0.31) Medium 0.37 
B Cells 0.66 0.07 (0.00, 0.32) Medium 0.87 
Neutrophils 0.78 0.06 (0.00, 0.25) Medium 0.99 
Note: Effect size (η2) is defined as the amount of variance in the response variable (biomarker) explained by 
the explanatory variable (diagnosis). Threshold for effect size is as follows; 0.01 = small, 0.06 = medium, 
0.14 = large 
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Table 17: Mean and Viability for Biomarkers Across Categories of Diagnosis  
Biomarker AutoImmune/Inflammatory 
(N=4)  
Mean Percent (SD) 
Infection 
(N=7) 
Mean Percent (SD) 
Malignancy  
(N=3) 
Mean Percent (SD) 
PD1-  0.16 (0.18) 0.16 (0.25) 0.58 (1.00) 
PD1+ 0.343 (0.40) 0.56 (0.94) 0.56 (0.96) 
TH17 0.21 (0.23) 0.20 (0.49) 0.43 (0.45) 
B Cells 0.74 (0.95) 0.99 (1.11) 0.37 (0.44) 
Neutrophils 7.50 (10.82) 18.13 (31.97) 6.27 (5.91) 
    
Viability 42.13 % (21.85%) 22.69% (30.84%) 41.23% (29.91%) 
 
Table 18: Laboratory Parameters by Diagnostic Category 
Diagnosis WBC Mean (SD) Lymphocytes Mean (SD) N 
Autoimmune/Inflammatory 44.27 (63.48) 0.66 (0.32) 11 
Bacterial  765.0 (1264.53) 0.30 (0.35) 7 
Fungal 42.0 (13.45) 0.82 (0.15) 3 
Viral  143.25 (62.97) 0.93 (0.05) 4 
Malignancy  81.0 (57.83) 0.62 (0.33) 4 
Other 46.2 (96.01) 0.50 (0.31) 10 
Unknown 159.17 (301.79) 0.45 (0.34) 29 

































Figure 4. Flow of CSF Samples Tested 
 
Patients with residual CSF (n = 271) 
Excluded due to CSF WBC < 5 (n = 203) 
Met inclusion criteria (n = 68) 
Infection (n = 14) 
Autoimmune/Inflammatory Disorder (n =11) 
Malignancy (n = 4) 
Other (n = 10) 
    
Flow Cytometry (n = 23) 
Viral Infection (n = 2) 
Bacterial Infection (n = 5) 
Autoimmune/Inflammatory (n = 4) 
Malignancy (n = 3) 
Other (n = 3) 
MSD Assay (n = 23) 
Viral Infection (n = 3) 
Bacterial Infection (n = 6) 
Autoimmune/Inflammatory (n = 5) 
Malignancy (n = 4) 
Other (n = 5) 
Immune cell markers evaluated (n = 29) 
Viral Infection (n = 3) 
Bacterial Infection (n = 6) 
Autoimmune/Inflammatory Disorder (n = 5) 
Malignancy (n = 4) 
Other (n = 5) 
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Figure 5. Proportion of immune cell types present in the CNS by diagnostic category. 
The proportions of B cells, neutrophils, PD1+ CD8 T cells (PD1+), PD1- T cells (PD1-), and 
Th17 CD4 T cells (TH17) were analyzed by flow cytometry.  Cell viability:  
autoimmune/inflammatory – 42%; Infection – 23%; Malignancy – 41%. 
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Figure 6. VEGF Levels are Higher in Patients with CNS Malignancies.  
VEGF levels in the CSF were measured by multi-plex ELISA in 23 patients (5 patients had 





Figure 7. IL-16 Levels are Higher in Patients with Bacterial Infection.  
IL-16 levels in the CSF were measured by multi-plex ELISA in 23 patients (2 patients had levels 




Figure 8. IFNγ Levels are Higher in Patients with Viral Infections of the CNS. 
IFNγ levels in the CSF were measured by multi-plex ELISA in 23 patients. **p<0.01, t test 







DISCUSSION AND CONCLUSIONS 
Summary of Research Field and Gaps 
Neuroinflammation is detected by elevated white blood cells in the CSF.  A variety of 
factors cause neuroinflammation including infection, autoimmunity, trauma, degenerative 
processes, toxins, malignancy, and in some cases factors of unknown origin.   
Clinicians who evaluate patients with a neurologic syndrome and neuroinflammation are 
challenged with diverse underlying etiologies of disease that result in overlapping clinical and 
laboratory features.85  Although patients in this population have similar clinical presentation, the 
diagnostic strategy is drastically different depending on the suspected etiologic cause of disease.  
There are also numerous causes of neuroinflammation and accurate diagnosis is dependent on 
ordering several, individual tests for different diseases.  Further, no clear diagnostic test exists 
for specific clinical presentations, and a high frequency of patients with no known cause of 
neuroinflammation continue to present in medical practice.  Additionally, time to diagnosis and 
treatment may be delayed for many treatable causes of neuroinflammation due to lack of 
standardization in the diagnostic strategy for this patient population,  
Standard diagnostic strategies are inconsistent and may result in missed or delayed 
diagnoses and many patients that present with a CSF pleocytosis never receive a diagnosis.  
Because of these substantial challenges, in many studies evaluating causes of CSF pleocytosis 
such as encephalitis, no underlying diagnosis is found in as many as 40-60% of patients.10-12   
In general, prior work has focused on discovering new pathogens that cause CSF 
pleocytosis of unknown cause or evaluating better diagnostic approaches to a single etiology of 
disease.  Additionally, most prior studies of diseases in the CNS have focused on a single cause 
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of disease in the CNS like multiple sclerosis or viral infections in the CNS and have not studied 
neuroinflammation as a group.  Despite numerous studies, new diagnostic approaches for a 
specific diagnosis have been elusive.  For example, several studies have used next generation 
sequencing to discover novel causes of encephalitis, but these studies have not provided a major, 
previously undiagnosed group of organisms causing disease.6  
Summary of Importance and Purpose 
Over half of patients in this research had neuroinflammation of unknown etiology.  
Approximately 49% of all patients in this study had minor or severe neurologic deficits at 
presentation and 60% had minor or severe neurologic deficits at the last assessment 
demonstrating that long term morbidity is still a problem for these patients.  This supports 
previous evidence of the high clinical impact and global economic burden associated with 
neuroinflammation due to significant morbidity and mortality including permanent neurological 
sequelae.20-23   
Given that there are >100 viruses that can cause viral encephalitis alone, the list of 
possible diagnostic tests for patients who present with CSF pleocytosis is extensive; thus, 
improvement to the diagnostic pathway to more quickly diagnose the etiologic cause of disease 
is urgently needed.17  Specifically, there is a need for a clinical approach that rapidly provides a 
diagnosis in an unbiased manner and improves outcomes for patients presenting with 
neuroinflammation.   
Since clinicians evaluate patients with CSF pleocytosis that have protean clinical 
presentations, we hypothesized that immune responses would be specific for large categories of 
disease in the CNS and would be able to distinguish between causes such as viral infection and 
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malignancy.  If immune signatures could be developed for categories of disease, then focused 
diagnostic testing or second-tier multiplex platforms could then provide a specific diagnosis. 
To accomplish this work, we first completed 2 clinical studies to define categories of 
disease, clinical features, and outcomes of disease and to measure the immune response for 
categories of CNS disease.   
Research Hypotheses 
Hypothesis 1 
We hypothesized that there was a difference in time to diagnosis between patients is each 
diagnostic category:  infection, autoimmune, malignancy, inflammatory disorder, or unknown 
etiology. 
We found that there was a difference in time to diagnosis between patients between all 
diagnostic categories in the retrospective neuroinflammation cohort:  infection (16 days), 
autoimmune (125 days), malignancy (16 days), inflammatory disorder (72 days), or unknown 
etiology.   
Hypothesis 2 
We hypothesized that there was a difference in CSF WBC count, glucose, protein, and 
overall mortality between patients in each diagnostic category:  infection, autoimmune, 
malignancy, inflammatory disorder, or unknown etiology. 
 We found that there was no significant different in CSF WBC count, glucose, and protein 
between all diagnostic categories.  However, there was a significant difference in CSF WBC 
count, glucose and protein between CNS infection type (eg, bacterial, viral, fungal, and parasitic 
infections), although there was significant overlap for these parameters between infection type. 
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Hypothesis 3  
We hypothesized that there was a higher frequency of patients with CNS inflammation 
(CSF WBC >5 cells/mm3) with CNS infection or unknown etiology.   
 We found that there a higher frequency of patients with CNS inflammation (CSF WBC 
>5 cells/mm3) with CNS infection or unknown etiology and a significant difference in proportion 
of patients in each diagnostic category.  Specifically, the highest frequency of patients had 
disease of unknown etiology (53%) and the leading known cause of neuroinflammation was 
CNS infection (18%). 
Hypothesis 4  
We hypothesized that 5 immune cell subtypes will describe differential patterns of the 
pre-specified diagnostic categories in the neuroinflammation cohort.  We anticipated the 
following dominate cell subtypes for each category:  bacterial infection (CD15+/CD49- 
[neutrophils]); viral infection (CD3+/CD8+/PD1- [PD1- cytotoxic T cells]); malignancy 
(CD3+/CD8+/PD1+ [PD1+ cytotoxic T cells]); inflammatory (CD3+/CD4+/IL17+ [Th17 cells]); 
and autoimmune (CD19+/CD45+ [B cells]). 
 We found that the proportion of neutrophils, PD1 cytotoxic T cells, PD1+ cytotoxic T 
cells, Th17 cells, and B cells exhibited differences between diagnostic categories, although the 
proportion of these cell types were not statistically different. 
 We found that select cytokines were significantly different between diagnostic categories.  
VEGF-A levels in the CSF were significantly higher in the malignancy group compared to the 
bacterial infection and ‘other’ groups, CSF IL-16 levels were significantly higher in the bacterial 
infection group, and CSF IFN-γ levels were higher in the viral infection group compared to all 
other groups. 
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Summary of Contributions to the Field of Neurology 
Data from this study provide important information on diagnostic approaches for patients 
that present with inflammation in the CNS.   
Lengthy time to diagnosis and high frequency of patients with disease of unknown 
etiology represents a major concern for patients with neuroinflammation.  Time to diagnosis was 
an average of 16 days in patients with an infection and a malignancy with CNS involvement and 
125 days in patients with an autoimmune disorder presenting with pleocytosis in the CSF in the 
retrospective cohort studied.99  Over half of the patients had disease from an unknown etiology 
causing neuroinflammation in the CNS.   
In order to decrease time to diagnosis and improve accurate diagnosis for patients with 
neuroinflammation, this research proposed to standardize the diagnostic approach for the 
neuroinflammation cohort.  Standardization of the diagnostic approach will aid clinicians to 
more quickly narrow the possible etiologic causes of disease to consistently guide the diagnostic 
strategy for patients who present with CSF pleocytosis and associated, non-specific clinical 
symptoms. 
In these studies, I proposed a novel approach to standardize the diagnostic approach of 
patients with neuroinflammation.  The previous approach has been to develop new diagnostic 
tests for each unique pathogen that can cause neuroinflammation.  In the approach proposed in 
this research, I have considered broad neuroinflammation diagnostic categories (ie, viral 
infection, bacterial infection, malignancy, autoimmune/inflammatory) and characterized the 
unique inflammatory response and cell types associated with each category.  Such an approach 
will provide novel diagnostic pathways resulting in faster time to diagnosis and improved patient 
outcomes.   
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This research observed inconsistent diagnostic strategies, lengthy time to diagnosis, and a 
high frequency of patients with no known cause of neuroinflammation present in medical 
practice.  Current standard practice utilizes various laboratory results to narrow the diagnostic 
strategy.  We extended these data by identifying the utility of specific tests in their ability to 
differentiate between causes of neuroinflammation.  In our cohort, there was not a specific 
diagnostic test which could differentiate between diagnostic groups.  An extensive list of testing 
was conducted in most cases to identify the etiologic cause of disease.  While CSF analysis of 
patients in this cohort was consistent with prior studies,15,32,40 there was significant overlap in the 
CSF parameters between patients with different diagnoses which implies that routine use of CSF 
parameters alone may not aide clinicians in defining categories of diagnosis.  While classic CSF 
parameters such as WBC count and differential help with focused diagnostic testing, relying on 
these tests to rule out use of specific diagnostic testing may lead to a delayed or missed 
diagnosis.   
This research also highlights variability in time to diagnosis for specific groups of 
patients with neuroinflammation.  While diagnostic tests for infections are well developed and 
comprehensive for the major causes of disease, diagnostics for other important causes of CSF 
neuroinflammation are less well-defined resulting in prolonged time to diagnosis.  For example, 
patients with autoimmune causes of CSF neuroinflammation have similar clinical presentations 
and CSF parameters to some patients with virus infection.  In many clinical cases, physicians 
wait for a variety of clinical tests to “rule out” infection as well.  This common approach along 
with non-standardized ordering of tests for CSF pleocytosis resulted in a mean time to diagnosis 
of 125 days in the patients with autoimmune causes of CSF neuroinflammation in this research.99   
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There were 48 different diagnoses besides unknown and ‘other’ causes and 21 different 
infectious diagnoses in the 244 patients with CSF pleocytosis in the retrospective cohort 
studied.99  The diversity of etiologic causes of inflammation in the CNS observed in this research 
is consistent with previous studies in this patient population which have also reported a large 
number of different diagnoses and high frequency of patients receiving no diagnosis at all.10,13,91  
Specifically, in a recent study over a 7-year period, 81 different diagnoses were identified in 
patients with CSF pleocytosis besides unknown causes, which is a reminder to clinicians of the 
broad spectrum impact of diseases in patients who present with CSF pleocytosis indicating 
inflammation in the CNS.91  Thus, the major clinical challenge remains the large number of 
etiologic causes and diagnostic testing for infectious and non-infectious causes and lack of clear 
clinical parameters to guide complex diagnostic ordering.   
In addition to studying the neuroinflammation cohort as a whole and applying diagnostic 
category labels to patients in this cohort, this research provides valuable information about the 
immune differential patterns in patients who present with neuroinflammation which may be 
useful to the differential diagnosis for this patient population.  Given the observations in the 
retrospective neuroinflammation study, a prospective pilot study was conducted as part of this 
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research to further investigate immune differential patterns to inform the diagnostic category for 
patients with neuroinflammation.   
Overall, data from this study support exploring immune differential patterns within 
diagnostic groups of diseases that cause CSF pleocytosis to guide clinicians to place patients in a 
category of underlying disease and guide specific diagnostic testing for specific causes.   
Key Finding #1:  Over Half of Patients with Neuroinflammation have No Diagnosis 
We found that the current diagnostic pathway for these complex patients resulted in a 
prolonged mean time to diagnosis of >16 days in all categories of disease, except the ‘other’ 
category of disease with a mean time to diagnosis of 6 days.  Patients who presented with 
neuroinflammation were significantly more likely not to receive a diagnosis at all when they 
present with CSF pleocytosis.  In the retrospective cohort of patients studied, despite aggressive 
work up, over half of the patients had disease from an unknown etiology (53%) causing 
neuroinflammation in the CNS, and about 60% of those patients received a presumptive 
diagnosis.  This is consistent with previous reports in which approximately 60% of encephalitis 
cases were undiagnosied.10-12,29,30  The California Encephalitis Project was a large study of 
suspected encephalitis (n = 1570) over 7 years which aimed to identify the etiology of 
encephalitis cases; however, 63% of cases had unexplained etiology in the study despite a large 
panel of studies to identify an underlying cause.10,13  The retrospective study in this research adds 
to the existing literature since we evaluated all patients with neuroinflammation, defined 
distinguishing diagnostic testing, defined broad diagnostic categories to advance diagnostic 
strategies, and defined outcomes related to underlying diagnostic grouping.   
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Key Finding #2:  Value in Evaluating Neuroinflammation Cohort 
There were 48 different known causes of neuroinflammation in a cohort of 244 patients.  
Infections in the CNS were the most common diagnosed cause of neuroinflammation, and 
viruses represented the 3 most common causes of disease.  The second most common known 
cause of neuroinflammation was malignancy, followed by other causes, inflammatory, and 
autoimmune.   
Our data provide information on the comprehensive diagnostic approaches for patients 
that present with CSF pleocytosis, provide diagnostic approaches for each category of disease, 
and provide important outcome data in each of these groups of disease.  This study observed that 
no clear diagnostic test exists for specific clinical presentations.  Current standard practice 
utilizes CSF parameters such as WBC, protein, and glucose to guide diagnosis.  While CSF 
analysis of patients in this cohort was consistent with prior studies, there was significant overlap 
in the CSF parameters between diagnostic categories which implies that routine use of basic CSF 
parameters to guide diagnostic testing may result in missed diagnosis or inappropriate testing.  
There was also large heterogeneity in diagnostic testing ordered for patients with the same final 
diagnosis.  This inconsistency may result in delayed or missed diagnoses as well. 
Previous studies have focused on studying single diseases which cause 
neuroinflammation rather than studying neuroinflammation as a cohort.  One recent study 
evaluated categories of CNS disease in patients with neuroinflammation in a large cohort of 
patients with known infection and other causes.91  The study described characteristics of CSF 
pleocytosis in different categories of neuroinflammation which agree with our findings, but the 
study did not evaluate diagnostic approaches in these cases.  Additionally, clinical symptoms at 
presentation were non-specific for infection type.  Our data provide a picture of comprehensive 
132 
diagnostic approaches for patients with neuroinflammation and provide data on the usefulness of 
specific testing in these cases.  
Thus, studying the neuroinflammation cohort as a whole and defining broad diagnostic 
categories is a novel approach to standardizing the diagnostic strategy for clinicians who are 
challenged with evaluating patients by initial clinical presentation and laboratory measures with 
significant overlap. 
Key Finding #3:  Advancements in Immunology Applied to Diagnostic Technology 
Evaluating the immune response at presentation may be key in improving diagnostic 
strategies.  Once we established patient categories in the retrospective review, we initiated a 
prospective pilot study to determine the feasibility of evaluating immune markers between 
diagnostic categories as a possible diagnostic approach in patients with a CSF pleocytosis.   
Clinicians have used CSF parameters and cell type analysis for biomarkers of disease for 
almost 70 years.  Use of the basic immune phenotyping tests in the CSF as biomarkers has not 
changed over this time despite rapid advancement of multiplexed immune assays.  We expected 
that using modern immune phenotyping and multiplex assays, we would be able to rapidly group 
patients into diagnostic categories to narrow the differential diagnosis for the patients, focus 
diagnostic testing, decrease time to diagnosis, decrease time to treatment initiation, and improve 
patient outcomes.   
Although previous studies have found significant differences in the cytokine status of the 
CSF of the patients with bacterial and viral meningitis, malignancies, and neurodegenerative 
disorders,100-104 there have been no previous studies describing immune differential patterns in 
patients that present with a CSF pleocytosis.  Our data extends the literature by measuring the 
immune response in a neuroinflammation cohort grouped into larger diagnostic categories.  A 
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difference in the immune response between these categories will greatly focus the diagnostic 
strategy upon presentation with CSF pleyocytosis. 
We found that the growth factor VEG-f was significantly upregulated in the CSF of 
patients presenting with CSF pleocytosis due to a malignancy when compared to other causes of 
CSF pleocytosis.  We also found that specific categories of disease in the CSF exhibit trends 
toward differences in T cell subsets in the pilot study.   
Higher levels of Th17 and PD1- cytotoxic T cells and lower levels of B cells may be an 
indicator of malignancy.  Lower levels of PD1+ cytotoxic T cells may be an indicator of 
autoimmune/inflammation and higher levels of neutrophils may be an indicator of infection.   
Our data also suggests that CSF panels of cytokines and growth factors may function as 
biomarkers in the CSF.  We found that VEG-f may be a relevant biomarker for metastases 
involving the CNS since it was significantly elevated in the malignancy group compared to all 
other groups.  IL-16 was significantly higher in the bacterial infection group compared to any 
other group and may be a relevant biomarker for bacterial infection in the CNS.  IFN-γ was 
significantly higher in the viral infection group and may be a relevant biomarker for viral 
infection in the CNS.   
Patterns were observed in proportion of neutrophils, PD1- cytotoxic T cells, PD1+ 
cytotoxic T cells, Th17 cells, and B cells between diagnostic categories in this study.  
Additionally, data from this study suggest that VEGF may be a relevant biomarker for 
malignancy involving the CNS.  IL-16 and IFN-γ may be relevant biomarkers for bacterial and 
viral infections in the CNS, respectively.   
A higher proportion of neutrophils was seen in the infection group compared to other 
groups, although the difference was not statistically significant.  Neutrophils are important 
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components of the innate cell-mediated immune response during bacterial infections of the CNS, 
which may explain the higher proportion of neutrophils observed in this group.105  CD8+ 
cytotoxic T lymphocytes are the main effector cell involved in clearing virus from the CNS.106  
However, we observed a higher proportion of PD1-cytotoxic T cells in the malignancy group 
compared to the other groups, although not statistically significant.  The contribution of different 
immune cells to the pathogenicity of CNS autoimmune diseases remains under intense debate; 
however, two major arms of CD4+ T lymphocytes are understood to mediate these diseases.  
These two cell types are characterized by the production of IFNγ (“Th1” type) or IL-17 (“Th17” 
type).107-113  The proportion of Th17 cells was not elevated in the autoimmune/inflammatory 
group in this study which was not expected.  B cells were higher in the 
autoimmune/inflammatory group compared to the malignancy group, but not compared to the 
infection group.  Many cancers inhibit T cell responses by upregulating the ligands for CTLA-4 
or PD-1, which are expressed on T cells and result in downregulation of T cell responses when 
triggered.114,115  A slightly increased proportion of PD1+ cytotoxic T cells were observed in the 
malignancy group compared to the autoimmune/inflammatory group, but the proportion was the 
same in the infection group.  Although there were no statistically significant differences observed 
in the immune cell subtypes measured by flow cytometry, these observed patterns warrant 
further exploration. 
In this study, the VEGF levels in the malignancy group were significantly higher 
compared to other diagnostic categories, suggesting this may be an appropriate biomarker to aid 
in the diagnosis of malignancies in the CNS.  Although patients with Alzheimer’s disease were 
not studied in this cohort, patients with autoimmune/inflammatory disorders had lower levels of 
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VEGF, which warrants further investigation given previous claims that VEGF may be 
neuroprotective.   
IL-16 expression was significantly higher in the bacterial infection group compared to 
other diagnostic categories, which is consistent with previous reports.117   
IFN-γ was significantly increased in the viral infection group compared to other 
diagnostic categories.  One previous study reported elevated IFN-γ in relapsing multiple 
sclerosis.118  Another study reported that CSF IFN-γ did not distinguish between viral and 
bacterial meningitis although levels were increased in patients with CNS infections (n = 45).119  
However, in this study, there was a difference in the average IFN-γ in patients with viral 
infection and bacterial infection.   
Taken together, these data show that immune-based biomarkers can be defined in the 
CSF and can differentiate between categories of diseases that cause CSF pleocytosis. 
Strengths and Limitations 
The strengths of the retrospective cohort study include the longitudinal, unbiased 
selection and analysis of a cohort of patients at a large tertiary care center with a large catchment 
area in the Rocky Mountain region.  The breadth of data collected allow for a complete analysis 
of infections in the CNS and related outcomes.   
The major strength of the pilot study was the prospective, consecutive, unbiased selection 
and analysis of a cohort of patients at a large tertiary care center with a large catchment area in 
the Rocky Mountain region.   
Limitations to the retrospective cohort study include a retrospective, single-center deign, 
thus only existing data for patients could be collected and overall numbers analyzed were 
limited.  All patients did not have the same routine tests performed for comparison and there 
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were no samples to test in the event of an unclear diagnosis.  The amount of red blood cells in 
the CSF sample was not included in the dataset; thus, CSF WBC count was not corrected for 
blood contaminated samples.  Additionally, data for erythrocytes sedimentation rate and C-
reactive protein was not collected, which may be important diagnostic tests in the case of CSF 
pleocytosis. 
Also, the data may include referral bias of complex cases since more routine care of CNS 
infections may occur in the community without referral, while more complex cases in the 
community often get referred early to the study site.  Specifically, the data may be biased toward 
more complex disease and some more common community-acquired cases like enterovirus CNS 
infection may be underrepresented in this cohort.  There are also regional differences in the 
presentation of cases like WNV, Lyme disease, or endemic mycosis that may limit the 
generalizable nature of the diagnostic patters found in this cohort.  Thus, considerations should 
be made about leading causes of disease at each institution because the causes of CSF 
pleocytosis may vary by region. 
Limitations of the pilot study include low sample size and low cell viability.  Cell 
viability was an average of <45% in all groups for CSF flow cytometry sample.  The low cell 
viability was due to the use of CSF left over from routine clinical testing which resulted in 
samples that were prepare up to 3-4 days after collection from the patient.   
Additionally, the autoimmune and inflammatory disorders were studied together due to 
low sample availability, although we expect the immune response may be different between 
diagnoses in these categories.  Further, residual CSF was not available for all patients that 
presented to UCH with CSF pleocytosis because there was no remaining sample, or the 
remaining sample was not saved by laboratory personnel due to logistical constraints. 
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Future Research 
The goals of our clinical studies were to define the clinical characteristics, laboratory 
data, and outcomes of patients within diagnostic categories of CNS disease and define the 
neuroinflammatory responses that may differentiate diagnostic categories of CNS disease.  This 
research highlights the challenge to diagnosing patient with neuroinflammation and provides 
useful information about limitations to current testing strategies.  The high frequency of patients 
with neuroinflammation of unknown etiology confirms the urgency to improve current testing 
strategies.  The demonstration that immune-based biomarkers can be defined in the CSF and can 
differentiate between categories of diseases that cause CSF pleocytosis suggest a pathway to 
better diagnose patients with neuroinflammation. 
Opportunity for Improvement to Current Diagnostic Strategies 
Clinicians evaluate patients with neurologic syndrome and CSF pleocytosis and then 
recommend diagnostic testing based on clinical features; thus, it is important to understand the 
underlying causes and outcomes of these patients as a group as opposed to only studying single 
etiologies, all of which present with inflammation in the CNS.  Although patients with 
neuroinflammation present the same or similar clinically, underlying immunology is functionally 
different.  Specifically, grouping infrequent diagnoses into larger categories of disease such as 
viral infection, bacterial infection, autoimmune disorders, inflammatory disorders, and 
malignancy, it is possible to define the immunology and genetics of inflammation, develop 
diagnostics, and target evaluations to improve the diagnostic strategies for this patient 
population. 
Flow cytometric immunophenotyping and other multiplexed assays can capture multiple 
biomarkers to measure multiple immune processes contributing to neuroinflammation in a single 
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CSF sample.  This multiplexed design is important because multiple biomarkers are likely 
needed to improve diagnostic strategies for patients with neuroinflammation since adding more 
disease-specific test methods to the list of options for clinicians has not demonstrated 
improvement in patients with disease of unknown etiology.  Additionally, no single biomarker 
out of the 41 evaluated in this research informed the diagnostic category for all CSF samples 
tested. 
Considerations should be made about biomarkers in the CSF which may ‘diagnose’ 
patients into diagnostic categories.  Future studies should focus on VEG-f, IFN-γ, and IL-16.  
Larger, prospective studies should also focus on maintaining cell viability to explore patterns 
observed in proportion of neutrophils, PD1- cytotoxic T cells, PD1+ cytotoxic T cells, Th17 
cells, and B cells between diagnostic categories in this study in this study.  Further, Th17 
observation were inconsistent with previous literature.  We observed a low proportion of Th17 in 
the autoimmune/inflammatory group.  Thus, we recommend further evaluation of total CD4 T 
cells, subgroups of Th17 cells, and T regulatory cells.  It may also be useful to look at Th17+ 
cells compared to Th17- cells to provide more robust information about CD4 T cells present in 
the CSF.   
Future research including multiplex diagnostic panels, novel biomarkers, and more 
standardization of the diagnostic pathway is urgently needed to improve diagnosis and treatment 
of specific causes of neuroinflammation.  These studies should be designed prospectively with 
larger numbers.  When we applied the bootstrap replacement method to our data, we saw 
significance between average proportions of neutrophils, PD1 cytotoxic T cells, PD1+ cytotoxic 
T cells, Th17 cells, and B cells between diagnostic categories suggesting that larger numbers are 
important for detecting a difference in the immune patterns for these patients given the high 
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variability due to the broad causes of neuroinflammation.  Careful attention to sample integrity is 
critical to maintain cell viability when evaluating biomarkers measured by flow cytometry.  We 
recommend processing samples within 2-3 hours after sample collection by LP and avoiding use 
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Neuroinflammation may arise from a variety of factors including infection, 
autoimmunity, trauma, degenerative processes, toxins, and in some cases factors of unknown 
origin.1  It occurs when peripheral immune cells cross the blood brain barrier stimulating an 
immune response.2  Morbidity and mortality varies greatly depending on the cause of 
neuroinflammation.  Quickly ruling in or ruling out infectious causes of neuroinflammation may 
reduce time to treatment and will certainly reduce overuse of antimicrobials.  Inflammation of 
the brain is called encephalitis, which may or may not be caused by infection.  Bacteria, viruses, 
fungi, and parasites can all cause meningitis and enchephalitis.  The case-fatality rate for 
bacterial meningitis can be as high as 70% without treatment.3  Antimicrobial therapy provides 
the best outcomes with rapid initiation of treatment.4  Streptococcus pneumoniae, Streptococcus 
agalactiae (Group B Streptococcus), Neisseria meningitidis, Haemophilus influenzae, 
Escherichia coli (particularly the K1 serotype), and Listeria monocytogenes are the most 
common pathogens which cause acute bacterial meningitis infections, accounting for over 80% 
of infections.5  Cryptococcal meningitis is a common fungal cause of meningitis and has a high 
mortality rate.6  Immunosuppressive factors such as human immunodeficiency virus (HIV) 
infection is associated with higher pretest probability of cryptococcal meningitis.6  Viruses are 
the major cause of aseptic meningitis, which is more common but less severe than bacterial 
meningitis.  A variety of pathogens cause encephalitis, though non-infectious inflammatory 
processes can also cause encephalitis and the etiology is unknown in approximately 60% of 
encephalitis cases.7  Clinical symptoms are non-specific for meningitis and encephalitis (ME) 
which may include fever, headach, neck stiffness, altered consciousness, seizures and focal 
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neurological findings.  These non-specific symptoms often overlap with symptoms specific for 
the pathogen causing the infection.5 In a large study of bacterial meningitis of pediatric patient, 
only 7% of cases were positive by blood culture alone.8  Not only are there a large number of 
possible infectious causes of ME, approximately 10% of suspected cases are determined to have 
a noninfectious cause which adds to the complexity in the diagnostic pathway.5  Using a 
combination of cerebral spinal fluid (CSF) direct staining, culture, and antigen detection, the 
majority of cases of meningitis are accurately diagnosed.9,10  Cellular and chemistry parameters 
are routinely tested with CSF when ME is suspected, but this testing is non-specific.11  If 
bacterial meningitis is suspected, bacterial culture is performed which takes 2-5 days and may 
demonstrate poor sensitivity, particularly if antibiotics have been administered, sterile techniques 
were lacking, or the pathogen does not grown in conventional culture.5  For non-bacterial ME, 
the clinician must order the correct test to identify if a pathogen if present.  Given the lack of 
targeted testing, which increases the risk of delayed diagnosis and treatment, paired with the 
potential severity of neuroinflammation, more comprehensive and rapid diagnostics as well as 
better understanding clinical predictors for various causes of neuroinflammation may improve 
clinical outcomes in patients.  This study will evaluate clinical and laboratory parameters in the 
neuroinflammation population by the primary cause of neuroinflammation as well as evaluate 
diagnosis, treatment, and outcomes in this population. 
CHAPTER II 
RATIONALE FOR THE CURRENT STUDY 
Understanding clinical and laboratory measures and outcomes of patients presenting with 
neuroinflammation is critical for improving patient outcomes.  Additionally, identifying the 
proportion and outcomes for patients presenting with neuroinflammation of unknown origin may 
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be useful to improve the diagnostic pathway.  The diagnostic pathway for neuroinfections is 
highly susceptible to human error due to the need for clinicians to order specific tests for 
suspected causative pathogens and autoimmune disorders.  It is expected that patients with 
neuroinflammation of unknown origin have worse outcomes, which supports the hypothesis that 
rapid diagnosis of the primary cause of neuroinflammation improves outcomes.  Further, the time 
to treatment may be reduced in patients presenting with neuroinflammation if they are promptly 
tested for common pathogens and autoimmune disorders associated with neuroinfection.   
CHAPTER III 
OBJECTIVE 
The objective of this study is to evaluate a cohort of patients who presented with 




1. Proportion of participants diagnosed with infection, autoimmune, malignancy, inflammatory 
disorder, and unknown etiology 
Secondary Endpoints 
1. Case Fatality Rate (CFR) in participants diagnosed with infection, autoimmune, malignancy, 
inflammatory disorder, and unknown and overall CFR 
2. CSF laboratory parameters including leukocyte count and differential, glucose, and protein 
between participants diagnosed with infection, autoimmune, and unknown  
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3. Time to diagnosis and treatment in participants diagnosed with infection, autoimmune, 
malignancy, inflammatory disorder, and unknown and overall time to diagnosis and 
treatment 
4. Time in hospital in participants diagnosed with infection, autoimmune, malignancy, 
inflammatory disorder and unknown  
5. Neurologic deficit at discharge in participants diagnosed with infection, autoimmune, 
malignancy, inflammatory disorder, and unknown  
6. Explore clinical and laboratory parameters between infection (bacterial, viral, and parasite), 
autoimmune, malignancy, inflammatory disorder, and unknown neuroinflammation etiology 
including the following: 
• Symptoms such as constitutional, headaches, altered mental status, respiratory 
abnormalities, and fever  
• Medical history such as smoking, lung disease, diabetes mellitus, malignancy, 
sarcoidosis, cirrhosis, HIV infection, solid organ transplant, use of calcineurin 
inhibitors or steroids and prednisone dose  
• Current HIV infection and associated information including time since diagnosis, 
history of HIV antiretroviral drug resistance, antiretroviral therapy, CD4 count, 
and viral load  
• History of transplant (type and time since transplant)  
• Laboratory results including complete cell count, comprehensive metabolic panel, 
renal function, lumbar puncture opening pressure, serum cryptococcal antigen, 
CSF cryptococcal antigen, CSF culture, blood culture, CSF cell count, CSF 






This is a retrospective chart review study in a cohort of patients who presented to 
University of Colorado Hospital (UCH) with neuroinflammation.  De-identified data will be 
extracted from a patient log and from patient charts for this study.  Data were collected for 
patients who present with neuroinflammation on July 1, 2015 through June 30, 2016 and entered 
into a patient log by a neuroinfectious disease fellow for education purposes.  This patient log 
only contains neuroinflammation patients; therefore, all patients will meet enrollment criteria for 
this study.  Additional patients who were suspected of neuroinflammation during this time period 
will be included inthis study.  Patients not included on the patient log will be identified through 
the UCH microbiology laboratory as CSF samples received and cultured during this time period.  
The patient list will be provided by the UCH microbiology laboratory to the research team and 
data will be extracted from patient charts.  The infectious disease patient log and patients for 
whom CSF was tested in the UCH microbiology laboratory will be considered a comprehensive 
list of patients who presented to UCH from July 1, 2015 through June 30, 2016.  Identifiable data 
will not be used. 
Study Duration 
This is a retrospective chart review study and will not require contact with or time 







Patients who presented with neuroinflammation to the UCH from July 1, 2015 through 
June 30, 2016 and were included in the patient log.  Patients at UCH from July 1, 2015 through 
June 30, 2016 who had CSF fluid cultures submitted to the UCH microbiology laboratory and 
had evidence of a white blood cell (WBC) count in the CSF of >5. 
Exclusion Criteria 
Any patients with CSF submitted to the UCH microbiology laboratory following 
ventricular shunt placement or other neurological procedure within 3 months of the specimen 
collection. 
Informed Consent/Assent Process 
Informed consent will be waived as this is a retrospective chart review study. 
CHAPTER VII 
STUDY PROCEDURES 
Data Collection Procedures 
The PhD student will lead efforts in extracting data from the neuroinflammation patient 
log with oversight by the Investigator.  De-identified data will be entered into a spreadsheet to be 




POTENTIAL STUDY RISKS 
Privacy 
Loss of confidentiality is not a risk of this study.  Personal health information including 
any identifiable data will not be used as part of this study.   
Risk-Benefit Assessment 
There are no direct risks or benefits to study participants with data in the patient log or 
additional neuroinflammation participants with CSF samples tested at the UCH microbiology 
lab.  There is a potential future benefit to patients with neuroinflammation by evaluating the aims 
of this study. 
CHAPTER IX 
STATISTICAL PLAN 
This section summarizes the statistical methods that will be used in the analysis of the 
clinical data from this study. 
Participant Demographics and Baseline Characteristics 
All demographic and baseline characteristics will be presented by diagnosis 
(autoimmune, neuroinfection, unknown).   
Demographic and baseline participant characteristics that are available in the patient log 
will be summarized using descriptive statistics.   
Medical history and baseline signs and symptoms will be summarized by diagnosis. 
Participant Grouping by Diagnosis 
The number of participants will be summarized by diagnosis (infection, autoimmune, or 
unknown).   
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Primary diagnosis, treatment, and outcome will be listed. 
Primary and Secondary Endpoint Analyses 
Primary Endpoint 
The primary endpoint is proportion of participants diagnosed with infection, autoimmune, 
malignancy, inflammatory disorder, or unkown etiology. 
Proportions will be presented by primary cause of neuroinflammation.  The denominator 
will be the total number of participants.  No formal hypothesis testing for the primary endpoint is 
planned, given the intent of this investigation is to quantify estimates for several parameters by 
diagnosis.     
Secondary Endpoints 
There are 7 secondary endpoints of interest in this study (Section 4.2).     
Descriptive statistics for each diagnosis (autoimmune, infection, malignancy, 
inflammatory disorder, and unknown) will be presented for the secondary endpoints.  No formal 
hypothesis testing for the secondary endpoints is planned, given the intent of this investigation is 
to quantify estimates for several parameters by diagnosis, given the intent of this investigation is 
to quantify estimates for several parameters by diagnosis. 
Proportions in respect to diagnoses will be reported the follow way:  Number of 
participants with diagnosis (eg, infection, autoimmne, malignancy, inflammatory disorder, or 





Investigator Responsibilities  
Roles and responsibilities of Key Study Personnel 
• PI and Faculty Mentor:  overall responsibility over the study 
• Clinical Science PhD Student/PI:  procedures with the chart review, maintain study records, 
enter data into a spreadsheet 
Institutional Review Board 
The Colorado Multiple Institutional Review Board (COMIRB) approved the CIP before 
the patient log is assessed and information was extracted in this retrospective chart review study. 
Informed Consent  
Informed consent will be waived as this is a retrospective chart review study. 
Record Retention 
The Investigator will maintain all records pertaining to this study for 2 years after the 
study is complete.   
Recording and Collecting of Data 
The Investigator will maintain complete, accurate, legible, and easily retrievable data 
which shall also be secured on a password protected computer in order to prevent loss of data. 
Source data is all information, original records of clinical findings, observations, or other 
activities in the participant medical charts or patient logs necessary for the research aims of the 
clinical study.  Source data are contained in patient log.   
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All required data for this study will be recorded from the patient log into a password 
protected spreadsheet for analysis.  The spreadsheet is the primary data collection instrument for 
the study.  No identifiable data will be recorded in the spreadsheet. 
Investigator Responsibilities 
Compliance 
The study will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, United States CFR, ISO14155/2011 and any regional or 
national regulations, as appropriate.  The study will not begin until the required approvals from 
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Patients that present to medical care with inflammation in the central nervous system 
(CNS) face several barriers to obtaining a diagnosis and receiving successful treatment for their 
underlying disease.  1) Regardless of the underlying cause of neuroinflammation, the clinical 
presentations have significant overlap which means that there is no clear diagnostic test to send 
based on specific clinical presentations.  2) The causes of neuroinflammation are numerous and 
even in the best studies evaluating underlying causes of neuroinflammation, no underlying 
etiology is found in as many as 40-60% of patients.  3) There is no established clinical or 
diagnostic pathway for patients presenting with inflammation of the CNS. Given these factors, 
patients often experience delays in diagnosis and treatment for many treatable causes of 
neuroinflammation or receive no diagnosis at all.  The overarching goal of the proposed clinical 
studies is to begin a process to define clinical diagnostic pathways for patients with 
neuroinflammation that can improve the percentage of patients that receive a timely diagnosis, 
improve time to appropriate treatment, and eventually improve outcomes for these potentially 
devastating diseases. 
Since causes of neuroinflammation are very heterogeneous, prior studies that have 
evaluated a single etiology of neuroinflammation have failed to identify improved diagnostic or 
treatment approaches due to small numbers.  We propose that to improve the diagnosis, 
treatment and outcomes in this group of patients, patients with neuroinflammation must be 
studied as a group with novel diagnositic panels or arrays so that improved diagnostic and 
treatment algorhithms can be developed. 
Inflammation in the CNS, or neuroinflammation, may arise from a variety of factors 
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including infection, autoimmunity, trauma, degenerative processes, toxins, malignancy, and in 
some cases factors of unknown origin.1  Neuroinflammation is due to peripheral immune cells 
that cross the blood-brain barrier and stimulate an immune response.2  The blood-brain barrier 
regulates entry of molecules into the brain.3  Biological interactions can increase the ability of a 
molecule, such as a pathogen or a drug, to cross the blood-brain barrier and enter the 
cerebrospinal fluid (CSF).4   
Several underlying etiologies can initiate neuroinflammation.  Regardless of the 
heterogeneous presentation, neuroinflammation can only present clinically as a couple of defined 
syndromes.  If a patient has inflammation of the brain parenchyma, then the patient is said to 
have encephalitis which is typically characterized by altered mental status and/or significant 
focal neurologic deficits.  Inflammation of the membranes lining the brain (meninges) and spinal 
cord is called meningitis.  Bacteria, viruses, fungi, and parasites can all cause meningitis and 
encephalitis (ME) but non-infectious causes can cause these same presentations as well.  At 
times, the clinical presentation can be mixed resulting in a clinical presentation of 
meningoencephalitis or enchaphalomyelitis (inflammation of the brain and spinal cord) and often 
indicate a diffuse process of CNS inflammation and/or CNS infection.5  Morbidity and mortality 
varies greatly depending on the cause of CNS inflammation.  Several studies have shown that 
rapidly evaluating patients with neuroinflammation can reduce time to treatment, reduce overuse 
of antimicrobials, and improve outcomes.    
A diagnostic pathway includes a comprehensive evaluation of clinical and laboratory 
signs and symptoms with which a patient presents and the routine testing strategy to diagnose 
patients.  For patients with suspected ME or neuroinflammation, the diagnostic pathway is broad 
and routine testing is not well standardized between facilities and clinicians.  Clinical symptoms 
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are non-specific for ME, which may include fever, headache, meningismus, AMS, seizures, and 
FND, and these symptoms are nonspecific for the diverse group of infectious and noninfectious 
causes of CNS neuroinflammation.6  Overlap may also exist in CSF findings with early bacterial 
meningitis, partially treated bacterial meningitis, viral meningitis, viral encephalitis and many 
non-infectious causes of neuroinflammation.  In addition to the large number of infectious causes 
of ME, approximately 20% of suspected neuroinflammation cases are due to a noninfectious 
cause which adds to the complexity in the diagnostic pathway.6  Thus, new diagnostic pathways 
and approaches to deal with this complex and deadly clinical syndrome are urgently needed. 
Given the complexity of this syndrome, the diagnostic pathway for inflammation in the 
CNS is susceptible to human-factor variability due to the need for clinicians to order specific 
tests for suspected causative pathogens and autoimmune or non-infectious diseases.  It is 
expected that patients with CNS inflammation of unknown origin have worse outcomes, which 
supports the hypothesis that rapid diagnosis of the primary cause of CNS inflammation improves 
outcomes.  Unfortunately, the etiology of encephalitis remains unknown in 32%-75% of cases.7-
10  Time to treatment and proportion of patients with unknown etiology may be reduced in 
patients presenting with CNS inflammation (fever, headache, meningism, AMS, seizures, FND, 
and CSF white blood cell [WBC] count >5 cells/mm3) with improved testing strategies in this 
population.  Rapid diagnosis and timely treatment is critical for improving morbidity and 
mortality.11.  Research aimed at quickly narrowing the suspected etiology into diagnostic 
categories is needed; such studies may improve the time to diagnosis and minimize diagnostic 




RATIONALE FOR THE CURRENT STUDY 
Identifying the etiologic cause of neuroinflammation is frequently difficult and 
improvement to the diagnostic pathway is critical to improve clinical outcomes. 
There is a need for diagnostic pathways that rapidly provide a diagnosis in an unbiased 
manner and improve outcomes for patients presenting with neuroinflammation.  Specifically, 
research including multiplex diagnostic panels, novel biomarkers, and more standardization of 
the diagnostic pathway is urgently needed to improve diagnosis and treatment of specific causes 
of neuroinflammation.  No studies to date have described the immune phenotypic subsets of 
WBCs in the CSF overall for the neuroinflammation population.  Further, no studies have 
investigated neuroinflammation in terms of pre specified diagnostic categories to facilitate more 
efficient diagnostic testing in this population.  Research aimed at quickly narrowing the 
suspected etiology into diagnostic categories is needed; such studies may improve the time to 
diagnosis and minimize diagnostic burden.  This research aims to partly fulfil that gap. 
To guide the identification of biomarkers which may impact clinical outcomes, we 
anticipate it may be useful to group patients into pre-specified diagnostic categories that include 
diseases that are most clinically similar.  Categories are pre-specified in this research as viral 
infection, bacterial infection, autoimmune/inflammatory, or malignancy.  This approach to 
diagnose this broad population may guide clinicians to order the most appropriate confirmatory 
diagnostic tests and reduce time to diagnosis.  In turn, immunophenotyping of CSF may improve 
patient outcomes, decrease inaccurate and presumptive treatment, and decrease the healthcare 
burden imposed by neuroinflammation.  Further evaluation of clinical impact of 





The overarching goal of the proposed clinical study is to address the a barrier to obtaining 
a diagnosis for neuroinflammation by beginning a process to define clinical diagnostic pathways 
for patients.  Such pathways may improve the percentage of patients that receive a timely 
diagnosis, improve time to appropriate treatment, and eventually, improve outcomes for these 
potentially devastating diseases. 
Evaluation of biomarker panels which may predict diagnostic categories (viral infection, 





1. Leukocyte profile by diagnostic category (bacterial infection, viral infection, malignancy, 
autoimmune, inflammatory) in terms of proportions of 5 cell types (neutrophils, PD1- 
cytotoxic T cells, PD1+ cytotoxic T cells, Th17 cells, and B cells) between the categories.   
Secondary Endpoints 
1. Establish the leukocyte profile that best characterizes each diagnostic category 
2. Explore additional inflammatory cytokines using immunoassays 
3. Clinical and laboratory parameters by diagnostic category 
4. Explore the leukocyte profile of samples with a presumed diagnosis/unconfirmed etiology 






This is a pilot study in a cohort of patients who presented to UCH with 
neuroinflammation.  This pilot study will utilize banked CSF specimens left over from routine 
clinical testing.  The purpose of the pilot study is to evaluate immunophenotyping by flow 
cytometry to facilitate improvement in the diagnostic pathway for identifying etiologic causes of 
neuroinflammation.   
This study will be conducted in a neuroinflammation cohort to describe the immune differential 
patterns of immune cell subtypes for confirmed etiologic causes of neuroinflammation.  
Diagnoses will be classified as bacterial infection, viral infection, autoimmune, inflammatory 
disorder, or malignancy based on confirmatory diagnostic tests from routine clinical testing. 
Using CSF specimens left over from routine clinical testing is most feasible to evaluate 
the flow cytometry panel in this pilot study.  Residual CSF specimens left over from routine tests 
with a CSF WBC count >5 cells/mm3 will be selected for this pilot study.  The research team 
will identify specimens that meet selection criteria.  The patient identification number on the 
samples will be provided to the research team and used to extract routine test results from patient 
charts; however, no identifiable information will be entered into the study spreadsheet.  De-
identified data will be collected from respective patient charts and entered into a spreadsheet to 
be used for primary and secondary endpoint analyses.  The list of patient identification numbers 
will not be linked to the study identification number and will be destroyed once information from 




This piolot study will not require contact with or time commitment from the study 




Adult patients (> 18 years old) who have residual CSF samples left over from routine 
testing at UCH and had a WBC count in the CSF of >5 cells/mm3. 
Exclusion Criteria 
Any patients with ventricular shunt placement or other neurological procedure within 3 
months of the specimen collection. 
Informed Consent/Assent Process 
Informed consent will be waived for this pilot study.  This research would be difficult to 
carry out without consent waiver because CSF specimens used for this research are left over 
from routine clinical testing and participants have likely been discharged from the hospital at the 
time of testing the specimens.  Thus, it would be nearly impossible to obtain consent for use of 
the banked specimens. 
This research involves no more than minimal risk to the study participants (see Section 8 
below).  This waiver will not affect the rights or welfare of study participants.  This research will 
not require contact or time commitment from participants and the research team will not interact 
directly with the patients, because the CSF specimens are left over from routine testing and the 
CSF specimines are banked.  The patient identification number on the CSF specimens will only 
be used by the study team to confirm eligibility criteria, collect data from patient charts, and to 
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match results from the diagnostic testing for study endpoints.  The patient identification numbers 
will not be linked to the study identification number and will be destroyed once information from 
the patient chart is entered into the study spreadsheet.  In this way the study will be deidentified.  
Test results from this study will not be recorded in patient charts, will not be used for diagnostic 
purposes, and will not be released to treating physicians.   
CHPATER VII 
STUDY PROCEDURES 
Specimen Collection and Testing Procedures 
The PhD student will lead efforts in extracting data from patient charts and entering the 
test results into the study spreadsheet with oversight by the Faculty Mentor.  De-identified data 
including results from routine clinical tests will be entered into the spreadsheet to be used for 
primary and secondary endpoint analyses.  Residual CSF specimens left over from routine tests 
with a CSF WBC count >5 cells/mm3 will be selected for this pilot study.  The research team will 
identify specimens that meet selection criteria. 
Residual CSF specimens will be thawed to room temperature and will be tested on a 
novel flow cytometry assay. Testing will be performed by Infectious Disease research lab.  The 
data will be de-identified and entered into the research spreadsheet. 
Diagnostic test results from the flow cytometry panel and immunoassays will not be 
recorded in patient charts, used for diagnostic purposes, or released to treating physicians. 
Additional Data Collection Procedures 
The patient identification number on the samples will be provided to the research team 
and used to extract routine test results from patient charts; however, no identifiable information 
will be entered into the study spreadsheet.  De-identified data will be collected from respective 
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patient charts and entered into a spreadsheet to be used for primary and secondary endpoint 
analyses.  Clinical and laboratory data including routine test results will be collected from patient 
charts.   
The list of patient identification numbers will not be linked to the study identification 
number and will be destroyed once information from the patient chart and test results are entered 
into the study spreadsheet.   
CHAPTER VIII 
POTENTIAL STUDY RISKS 
Privacy 
This research involves minimal risk.  Loss of confidentiality is a minor risk of this study.  
Efforts will be made to minimize this risk to study participants. 
Personal health information including any identifiable data will not be entered into the 
study spreadsheet as part of this study.  Patient identifiers will be used to extract routine test 
results from patient charts.  Residual CSF samples left over from clinical tests will be tranfered 
and stored frozen by the research team.  However, the list of patient identification numbers will 
not be linked to the study identification number at any time, will not be entered into the study 
spreadsheet, and will be destroyed once information from the patient chart is entered into the 
study spreadsheet. 
Risk-Benefit Assessment 
There is a small risk of loss of confidentiality for participants in this study.  There are no 
direct benefits to study participants in this study.  Over 51% of patients over 1-year at UCH had 
neuroinflammation of unknown etiology and the average time to diagnosis for patients with CNS 
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infection was greater than 16 days, thus there is a potential future benefit to patients with 
neuroinflammation by evaluating the aims of this study. 
CHAPTER IX 
STATISTICAL PLAN 
This section summarizes the statistical methods that will be used in the analyses of the 
clinical and laboratory data from this study. 
Sample Size Rationale 
This is a descriptive study utilizing residual CSF samples left over from routine clinical 
testing.  All samples available through the clinical laboratory that meet enrollment criteria will be 
included in this pilot study.  Up to 100 CSF samples will be tested in this study. 
Participant Demographics and Baseline Characteristics 
All demographic and baseline characteristics will be presented.  
Demographic and baseline participant characteristics will be summarized using 
descriptive statistics.   
Medical history and baseline signs and symptoms will be summarized. 
Primary and Secondary Endpoint Analyses 
Primary Endpoint 
For the primary analysis, difference in proportions of each of the 5 immune cell subtypes 
between 5 diagnostic categories will be analyzed using ANOVA.  This will be 5 separate test/5 
separate graphs with the 1 cell type on the y-axis and 5 diagnostic categories on the x-axis.  We 
will test for normal distribution of the data and will use Bonferroni correction for multiple testing 





Descriptive statistics and t-tests, as appropriate, will be presented for clinical and 
laboratory parameters by diagnostic category including CSF WBC, glucose, protein; 
comorbidities; neurologic deficit using NIH stroke scale; immune status.  We will use chi-square 
to evaluate the impact on proportion of patients with unknown etiology with the use of the 
biomarker panel explored in this study.  A correction will be used to adjust the p-value for 
multiple comparisons, if necessary.   
The frequency of infection in patients with significant co-morbidities (eg, HIV) will be 
described and additional analyses will evaluate co-morbidities in terms of their effect on disease 
etiology and immune cell subtypes.  
CHPATER X 
STUDY MANAGEMENT 
Investigator Responsibilities  
Roles and responsibilities of Key Study Personnel 
• PI and Faculty Mentor:  overall responsibility over the study 
• Clinical Science PhD Student/PI:  screen specimens for enrollment criteria, procedures with 
the chart review, receive test results from the infectious disease laboratory, maintain study 
records, enter data into a spreadsheet 




Institutional Review Board 
The Colorado Multiple Institutional Review Board (COMIRB) will review and approve 
the CIP before the research team receives any study data or screens any specimens for enrollment 
criteria. 
Informed Consent  
Informed consent will be waived (see Section 6.3 above). 
Record Retention 
The Investigator will maintain all records pertaining to this study for 2 years after the 
study is complete.   
Recording and Collecting of Data 
The Investigator will maintain complete, accurate, legible, and easily retrievable data 
which shall also be secured on a password protected computer in order to prevent loss of data. 
Source data is all information, original records of clinical findings, observations, or other 
activities in the participant medical charts or results from the microbiology laboratory necessary 
for the research aims of the clinical study.  Source data are contained in patient charts and on a 
spreadsheet created by the Infectious Disease research laboratory.   
All required data for this study will be recorded from the patient charts and study results 
list into a password protected spreadsheet for analysis.  The spreadsheet is the primary data 
collection instrument for the study.  No identifiable data will be recorded in the spreadsheet. 
Compliance 
The study will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, United States CFR, ISO14155/2011 and any regional or 
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national regulations, as appropriate.  The study will not begin until the required approvals from 
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